Randomized, Crossover Study of the Pharmacodynamic Activity of P-321 Ophthalmic Solution Compared to Placebo in Subjects With Dry Eye Disease Characterized by Low Tear Volume
Phase: PHASE2
Conditions: Dry Eye Disease
Sponsor: Parion Sciences

Parion Sciences, Inc.  
CONFIDENTIAL 
Page 1 
Clinical Study Report: P-321-201 
P-321 (SHP659) Ophthalmic Solution 
07 September 2017 
 
Appendix 2 
Protocol and Protocol Amendments 
The protocol V1.0 was not circulated to regulatory authorities or ethics committee, and thus is 
not included here. 
Protocol Version 3.0 dated February 7, 2017 
Protocol Version 2.0 dated April 22, 2016 
 

PARION 
SCIENCES 
Clinical Protocol P-321-201 
Project Number 
Compound Number/ Name 
Protocol Number 
Protocol Title 
Sponsor 
Medical Monitor 
Authors 
Issue Date 
Sponsor Signature and Date 
P-1003-1101 
P-321 Ophthalmic Solution 
P-321-201 
Randomized, Crossover Study of the 
Pharmacodynamic Activity of P-321 Ophthalmic 
Solution Compared to Placebo in Subjects with Dry 
Eye Disease Characterized by Low Tear Volume 
Parion Sciences, Inc. 
2800 Meridian Parkway 
Suite 195 
Durham, NC 27713 
Gary N. Foulks, M.D. 
3103 Joy Place 
Wilmington, NC 28409 
Jose L. Boyer, Ph.D. 
Anita Woodring, MS, RAC 
Version 3.0: 07 February 2017 
Version 2.0: 22 April 2016 
Original Version 1.0: OS February 2016 
The information in this document is confidential and is provided to you as an investigator or consultant for review 
by you, your staff, and the applicable Institutional Review Board/Independent Ethics Committee. Your acceptance 
of this document constitutes agreement that you will not disclose the information contained herein to others without 
written authorization rrom Parion Sciences. 

Parion Sciences, Inc. 
 
P-321 Ophthalmic Solution 
Protocol P-321-201 Version 3.0 
CONFIDENTIAL 
Page 3 
 
Summary of Changes to the Protocol 
The previous version of this protocol (Version 2.0, 22 April 2016) was amended to create the 
current version (Version 3.0, 07 February 2017).   
Key changes in the current version of the protocol are summarized below.  
Change  
Affected Sections  
The following changes were made to the study inclusion criteria;  
 
Added clarification that a history of dry eye disease must be in 
both eyes.  
 
Changed the requirement for average tear meniscus height, as 
assessed by UHR-OCT, from less than 175 µm to 210 µm or 
less.  This requirement is now in one eye instead of both eyes.  
 
Removed Schirmer’s test > 1 mm and < 10 mm as an inclusion 
criteria.  
 
Added Xiidra® to the list of prohibited medications.  
Section 1.0, 5.1 and 7.4.2 
The following changes were made to the study exclusion criteria: 
 
Added clarification that external blepharoplasty, not resulting in 
exposure or abnormal blinking, will be allowed.  
 
Added that scleral lenses are not allowed.  
Section 1.0. 5.2 and 7.4.2 
Updated study design schematic. 
Section 1.0 and 4.1 
The requirement to meet the Schirmer’s test range at Visit 2 and Visit 3 
was removed.  
Sections 5.3, 6.2, and 6.3 
Definition of “study eye” was added.  
Section 5.4 
Clarified that informed consent must be obtained before initiating study 
procedures.  
Section 6.1, Appendix I/Table 1 
 
Section 8.0 
Removed phosphorus from the required serum chemistry tests.  
Appendix XIII 
 
Typographical and administrative changes were also made to improve the clarity of the 
document.  
 

Parion Sciences, Inc. 
 
P-321 Ophthalmic Solution 
Protocol P-321-201 Version 3.0 
CONFIDENTIAL 
Page 4 
 
1 PROTOCOL SYNOPSIS 
Name of Sponsor: 
Parion Sciences, Inc. 
Study Medication: 
0.017% P-321 Ophthalmic Solution and based on 
data review potentially 0.01%, 0.017% or 0.05% 
Ophthalmic Solution 
Protocol Number: 
P-321-201 
Phase: 
2a 
Indication: 
Treatment of dry eye disease 
Title of the Study: 
Randomized, Crossover Study of the Pharmacodynamic Activity of P-321 Ophthalmic Solution Compared to 
Placebo in Subjects with Dry Eye Disease Characterized by Low Tear Volume  
Investigators: 
Principal Investigator: Victor Perez, MD; Sub-Investigator:  Jianhua Wang, MD, PhD 
Study Center: 
Ocular Surface Center, Bascom Palmer Eye Institute, University of Miami Health System 
Study period (FPFV – LPLV): 
Approximately 6 months 
 
Objectives: 
Primary objective 
• 
The primary objective of this trial is to assess changes in tear volume by the non-invasive techniques Ultra 
High Resolution Optical Coherence Tomography (UHR-OCT) following the administration of P-321 
Ophthalmic Solution or Placebo in subjects with tear deficient dry eye disease.   
Secondary objective 
• 
assess changes in lower tear meniscus height by Keratograph 5M  
• 
compare lower tear meniscus height measurements between UHR-OCT and Keratograph 5M 
• 
assess the duration of action of P-321 Ophthalmic Solution 
• 
compare the pharmacodynamic activity of different strengths of P-321 in subjects with tear-deficient dry eye 
• 
monitor safety and tolerability of P-321 Ophthalmic Solution 
 

Parion Sciences, Inc. 
 
P-321 Ophthalmic Solution 
Protocol P-321-201 Version 3.0 
CONFIDENTIAL 
Page 5 
 
Study Design: 
 
This is a single-center, randomized, cross-over placebo controlled study to evaluate the changes in tear volume by 
P-321 Ophthalmic Solution or Placebo.  The study will enroll  subjects with tear deficient dry eye disease to 
receive sequentially two treatments: P-321 Ophthalmic Solution (Treatment A) and Placebo (Treatment B).  
Subjects will be randomly assigned to receive treatment sequence AB or BA.  The study will consist of two 
Phases: In each Phase, subjects will be treated with a different strength of P-321 Ophthalmic Solution under the 
same study design.Phase 1 will evaluate 0.017% P-321 Ophthalmic Solution and Phase 2 will evaluate either 
0.05%, additional subjects at 0.017% or 0.01% P-321 Ophthalmic Solution as determined by the Data Review 
Group.  
Approximately twenty-four eligible subjects will complete the study with approximately 8 subjects participating 
in Phase 1 and the remainder of the 24 subjects participating in the phase 2.  Decisions on the dose to be used to 
phase 2 will be made following unmasked data review from subjects in Phase 1.  The Principal Investigator, 
Medical Monitor and Parion Sciences representatives not involved in the day to day conduct of the study will 
review unmasked data as part of the Data Review Group, which will decide the dose to be used in Phase 2  of the 
study.  The treatment assignments will remain masked to subjects in the study, the clinical monitor, and other site 
and Parion Sciences personnel involved in the conduct of the study and not involved in the Data Review 
Group.  Additional unmasked reviews of subject data may occur during the study to make recommendations on 
further dose adjustments and for planning purposes.  These reviews will follow the procedures outlined above. 
The study will consist of three study visits: a Screening Visit (Visit 1), and two treatment visits (Visit 2 and Visit 
3).  The duration of the study may be up to 23 days. The pharmacodynamic measures of tear volume will be 
assessed at each visit by two non-invasive methods, UHR-OCT and Keratograph 5M.  Dry eye symptom 
questionnaires will be applied at each visit prior to other assessments. At Visit 1, tear volume will be assessed at 
three timepoints over 1 hour with measurements taken approximately 30 minutes apart. Tear volume 
measurements will be followed by other tests that involve contact with the ocular surface (tear osmolarity, tear 
break up time (TBUT), meibography and meibomian gland assessments, corneal and conjunctival staining, and 
Schirmer’s test).  At Visits 2 and 3, tear volume will be assessed serially over 6 hours at pre-dose, and post dose 
at 15 minutes, 30 minutes, 1 hour, 2 hours, 4 hours, and 6 hours.  Safety assessments include adverse events 
(AEs), biomicroscopy and external eye examination and an assessment of comfort after taking the medication in-
clinic. 

Parion Sciences, Inc. 
 
P-321 Ophthalmic Solution 
Protocol P-321-201 Version 3.0 
CONFIDENTIAL 
Page 6 
 
Subject Population:  
This study will complete approximately 24 subjects with dry eye disease with documented low tear volume as 
measured by non-invasive UHR-OCT.   Approximately 8 will participate in Phase 1 and the remainder of the 24 
subjects participate in the Phase 2.   
Male and female subjects 18-80 years of age who provide written informed consent and have a history of dry eye 
signs and symptoms of mild to moderate severity in both eyes supported by a previous clinical diagnosis may 
enter the study.  Subjects must have decreased lower tear meniscus height (LTMH) in both eyes assessed by 
UHR-OCT of not more than 210 µm, normal lid anatomy, have been stable on their current medication regimen 
for at least 28 days and remain on this regimen for the duration of the study.  Additionally, while in the clinic on 
visit days and for at least 6 hours after dosing with study medication, subjects must be able to withhold ocular 
topical medications (including artificial tears, topical steroids, Restasis® and Xiidra®), and if contact lens wearers, 
must be able to withhold wearing contact lenses.  To qualify for the study, subjects must not have an identifiable 
or suspected dry eye caused by pharmacologic, post-traumatic, or post-surgical condition; have undergone 
refractive eye surgery (e.g., LASIK) in either eye during the past 12 months; uncomplicated cataract surgery in 
either eye during the past 3 months; previous eyelid surgery in either eye (e.g., blepharoplasty, ptosis repair. 
External blepharoplasty not resulting in exposure or abnormal blinking will be allowed) and or botulinum toxin 
(Botox™ or equivalent) injection in the periocular area within 3 months prior to enrollment.  The subject must 
not have lid irregularities or deformities, or severe corneal surface irregularities, a history of glaucoma or 
intraocular pressure > 25 mmHg at the Screening Visit (Visit 1) or a history of elevated IOP within the past year, 
a systemic, multi-organ disease requiring active medical or surgical treatment. Additionally, subjects with any 
significant illness that, in the opinion of the Principal Investigator (PI), could interfere with the study parameters 
will also be excluded. Other exclusions include:  subjects who have punctal plugs, punctal occlusion, scleral 
lenses, or history of nasolacrimal duct obstruction, Stevens-Johnson syndrome, ocular cicatricial pemphigoid, or 
other ocular cicatrizing disorders, past or present exposure keratopathy, neurotrophic keratopathy, lagophthalmos, 
or trichiasis.  Use of oral and nasal antihistamines, oral or topical secretagogues such as pilocarpine and Evoxac, 
or Topical anti-glaucoma medications during the study and for 14 days prior to Visit 1 is prohibited. 
Number of Subjects: 
Approximately 24 subjects with tear deficient dry eye 
disease  
Number of Centers: 
1 
Test Product and Doses: 
P-321 Ophthalmic Solution and Placebo with dosage 
strengths of P-321 Opthalmic Solution of 0.017% in 
Phase 1 and 0.05%, 0.01% or 0.017% in Phase 2 
Route of Administration: 
Ocular instillation, one drop per eye  
Duration of Treatment: 
Subjects will receive a single dose of P-321 Ophthalmic Solution or Placebo in both eyes in random treatment 
order, one treatment on Visit 2 and the other treatment on Visit 3.    
Criteria for Evaluation: 
Background characteristics will be evaluated to better characterize subjects at entry.  These parameters include: 
demographics, visual acuity, intraocular pressure, dry eye symptoms upon entry, medical history, concomitant 
medication use, tear osmolarity, tear break up time, meibography and meibomian gland assessment, corneal and 
conjunctival staining, and Schirmer’s test. 
 
Pharmacodynamics 
Detailed measurements of tear volume before and after dose administration will be obtained using non-invasive 
methods, UHR-OCT (tear volume and tear meniscus height) and Keratograph 5M (tear meniscus height) imaging 
of the ocular surface. 
 
Safety  
Ocular safety measures include: Adverse events (AEs), biomicroscopy and external eye examination and an 
assessment of comfort after taking the medication.  

Parion Sciences, Inc. 
 
P-321 Ophthalmic Solution 
Protocol P-321-201 Version 3.0 
CONFIDENTIAL 
Page 7 
 
Statistical Analysis: 
Sample Size 
A sample size of approximately 24 subjects is proposed for this study. For a two-period, two-treatment, two-
sequence crossover design (2x2x2), this study size when all subjects treated with P-321 are analyzed, will provide 
98% power to detect a LTMH difference vs placebo of 60 μm at 1 hour or a power of 99% if the average increase 
in LTMH over the six hours is 60 μm (assuming within-subject SD of 71). In this study it is expected that the study 
medication will reach its peak effect at 1 hour post dose and that the effect diminishes at 4 and 6 hours post dose 
(to values still above pre-dose values).  
 
Disposition, Demographic, and Background Characteristics 
Subject disposition, demographic, and background characteristics will be summarized using descriptive statistics.  
Baseline homogeneity with respect to demographic and background characteristics will be assessed via an overall 
F-test from analysis of variance (ANOVA).  For categorical variables, treatment differences will be assessed using 
the chi-square test or Cochran Mantel Haenszel (CMH) test with modified ridit scores for ordered categorical 
variables. 
 
Pharmacodynamic Analysis 
Treatment group differences for tear volume assessments will be conducted via comparisons of tear meniscus 
height, and if applicable, tear meniscus volume (TMV).  These parameters will be compared between each dose of 
P-321 Ophthalmic Solution and Placebo using a t-test for study eyes, and for all eligible eyes.  Analysis of 
covariance (ANCOVA) models will be used to adjust for the baseline TMH and TMV for study eyes. For all 
eligible eyes, a generalized estimation equations (GEE) will also be used to account for the correlation between 
eyes.  For the GEE analysis, an exchangeable correlation matrix will be assumed.   
 
Safety 
All safety analyses will be included for all subjects who were randomized and received at least one dose of study 
medication.   
 
The incidence of AEs will be tabulated by treatment group, by treatment sequence, by severity, and by relationship 
to study medication.   
 
 

Parion Sciences, Inc. 
 
P-321 Ophthalmic Solution 
Protocol P-321-201 Version 3.0 
CONFIDENTIAL 
Page 8 
 
TABLE OF CONTENTS 
SUMMARY OF CHANGES TO THE PROTOCOL ........................................... 3 
1 
PROTOCOL SYNOPSIS .............................................................................. 4 
2 
BACKGROUND INFORMATION ........................................................... 13 
2.1 
Description of Study Medication ...................................................................................... 13 
2.2 
Non-Clinical Studies for P-321 Ophthalmic Solution ...................................................... 14 
2.2.1  Pharmacology ....................................................................................................................14 
2.2.2  Absorption, Distribution, Metabolism, and Excretion .......................................................15 
2.2.3  Toxicology .........................................................................................................................16 
2.3 
Clinical Experience with P-321 Ophthalmic Solution ...................................................... 17 
2.4 
Justification for Route of Administration and Dose Selection ......................................... 17 
2.5 
GCP Compliance .............................................................................................................. 17 
2.6 
Population to be Studied ................................................................................................... 18 
3 
TRIAL OBJECTIVES AND PURPOSE ................................................... 19 
4 
INVESTIGATIONAL PLAN ..................................................................... 20 
4.1 
Overall Study Design ........................................................................................................ 20 
4.2 
Endpoints .......................................................................................................................... 21 
4.2.1  Primary Endpoint ...............................................................................................................21 
4.2.2  Secondary Endpoints .........................................................................................................21 
4.2.3  Safety and Tolerability Endpoints .....................................................................................22 
4.3 
Duration of Participation................................................................................................... 22 
5 
SELECTION AND WITHDRAWAL OF SUBJECTS ............................ 23 
5.1 
Subject Inclusion Criteria ................................................................................................. 23 
5.2 
Subject Exclusion Criteria ................................................................................................ 23 
5.3 
Randomization Criteria ..................................................................................................... 24 
5.4 
Study Eye .......................................................................................................................... 25 
5.5 
Subject Withdrawal Criteria and Stopping Rules ............................................................. 25 
6 
PROCEDURES ............................................................................................ 26 
6.1 
Visit 1: Screening (3 to 9 days prior to Visit 2 – Randomization) ................................... 26 
6.2 
Visit 2:  First Treatment Visit (3 -9 days after Visit 1) ..................................................... 27 
6.3 
Visit 3:  Second Treatment Visit (7-14 days after Visit 2) ............................................... 27 

Parion Sciences, Inc. 
 
P-321 Ophthalmic Solution 
Protocol P-321-201 Version 3.0 
CONFIDENTIAL 
Page 9 
 
6.4 
Early Termination Visit .................................................................................................... 28 
6.5 
Selecting Dosage Strength in Phase 2 ............................................................................... 29 
6.6 
Potential Toxicity Management ........................................................................................ 29 
6.7 
Collection of Data ............................................................................................................. 30 
7 
TREATMENT OF SUBJECTS .................................................................. 31 
7.1 
Treatment Administration ................................................................................................. 31 
7.2 
Trial Treatments ................................................................................................................ 31 
7.3 
Methods to Minimize Bias ................................................................................................ 31 
7.4 
Concomitant Medications ................................................................................................. 32 
7.4.1  Medications Permitted .......................................................................................................32 
7.4.2  Medications Not Permitted ................................................................................................32 
7.5 
Treatment Compliance ...................................................................................................... 33 
7.6 
Drug Accountability.......................................................................................................... 33 
7.7 
Maintenance of Randomization and Procedure for Breaking the Code ........................... 33 
8 
STATISTICS ................................................................................................ 35 
8.1 
Statistical Methods ............................................................................................................ 35 
8.1.1  Subject Disposition, Demographic and Background Characteristics ................................35 
8.1.2  Pharmacodynamic parameters ...........................................................................................35 
8.1.3  Analysis of Efficacy ...........................................................................................................35 
8.1.4  Analysis of Safety ..............................................................................................................35 
8.1.5  Interim Reviews of Data ....................................................................................................36 
8.2 
Sample Size Estimation .................................................................................................... 36 
8.3 
Level of Significance ........................................................................................................ 36 
8.4 
Criteria for Termination of an Individual Subject ............................................................ 36 
8.5 
Criteria for Termination of the Trial ................................................................................. 37 
8.6 
Procedure for Accounting for Missing, Unused, or Spurious Data .................................. 37 
8.7 
Procedure for Reporting Deviations from the Statistical Plan .......................................... 37 
8.8 
Subjects to be Included in the Analysis ............................................................................ 37 
9 
ASSESSMENT OF PHARMACODYNAMICS ....................................... 38 
10 
ASSESSMENT OF SAFETY ..................................................................... 39 
10.1 
Safety Parameters .............................................................................................................. 39 
10.2 
Procedures for Adverse Events Reporting ........................................................................ 39 

Parion Sciences, Inc. 
 
P-321 Ophthalmic Solution 
Protocol P-321-201 Version 3.0 
CONFIDENTIAL 
Page 10 
 
10.3 
Serious Adverse Event Reporting ..................................................................................... 39 
10.4 
Procedures for Reporting Pregnancy ................................................................................ 40 
11 
DIRECT ACCESS TO SOURCE DATA AND DOCUMENTS ............. 41 
12 
QUALITY CONTROL AND QUALITY ASSURANCE ........................ 42 
13 
ETHICS ........................................................................................................ 43 
13.1 
Institutional Review Board ............................................................................................... 43 
13.2 
Informed Consent Requirements ...................................................................................... 43 
13.3 
Data Handling and Record Keeping ................................................................................. 44 
13.4 
Data Quality Control and Reporting ................................................................................. 44 
13.5 
Records Retention ............................................................................................................. 44 
13.6 
Publication Policy ............................................................................................................. 44 
14 
REFERENCES ............................................................................................ 45 
APPENDIX I: SCHEDULE OF VISITS AND PROCEDURES. ...................... 47 
APPENDIX II: ADVERSE EVENT REPORTING ........................................... 49 
APPENDIX III: VISUAL ACUITY ASSESSMENT ......................................... 52 
APPENDIX IV: BIOMICROSCOPY/EXTERNAL EYE EXAMINATION .. 53 
APPENDIX V: FLUORESCEIN TEAR BREAK-UP TIME (TBUT) ............. 55 
APPENDIX VI: FLUORESCEIN CORNEAL STAINING .............................. 56 
APPENDIX VII: LISSAMINE GREEN CONJUNCTIVAL STAINING ....... 57 
APPENDIX VIII: INSTILLATION OF MEDICATION .................................. 58 
APPENDIX IX: DRY EYE SYMPTOM QUESTIONNAIRES ........................ 59 
APPENDIX X: TEAR VOLUME ASSESSMENTS: ......................................... 63 
APPENDIX XI: POST INSTILLATION QUESTIONNAIRES ....................... 71 
APPENDIX XII:  MEIBOGRAPHY ASSESSMENT ........................................ 72 
APPENDIX XIII:  SERUM CHEMISTRY AND HEMATOLOGY 
ANALYTES ............................................................................................ 73 
APPENDIX XIV:  DOSE SELECTION FOR PHASE 2 AND DATA 
REVIEW DURING STUDY .................................................................. 74 

Parion Sciences, Inc. 
 
P-321 Ophthalmic Solution 
Protocol P-321-201 Version 3.0 
CONFIDENTIAL 
Page 11 
 
ABBREVIATIONS 
AE 
Adverse event 
ANCOVA 
Analysis of covariance 
AUC 
Area under the curve analysis 
BID 
Two times daily 
C 
Celsius 
CMH 
Cochran Mantel Haenszel (test) 
CRF 
Case report form 
ECG 
Electrocardiogram 
ENaC 
Epithelial sodium channel 
F 
Fahrenheit 
FDA 
Food and Drug Administration 
GEE 
Generalized estimation equations 
GLP 
Good Laboratory Practices 
ICH 
International Conference on Harmonization  
IOP 
Intraocular pressure 
IRB 
Institutional Review Board 
Isc 
Short-circuit current 
IV 
Intravenous 
LTMH 
Lower tear meniscus height 
LTMV 
Lower tear meniscus volume 
NOAEL 
No-observed-adverse-effect level 
OSDI 
Ocular symptom disease index 
PD 
Potential difference 
PI 
Principal investigator 
QID 
Four times daily 
SAE 
Serious adverse event 
SANDE 
Symptom Assessment in Dry Eye questionnaire 
SPEED 
Standard Patient Evaluation of Eye Dryness questionnaire 
SS 
Sjögren’s syndrome 
TBUT 
Tear break-up time 
TMH 
Tear meniscus height 
TTMV 
Total tear meniscus volume calculated as UTMV + LTMV 

Parion Sciences, Inc. 
 
P-321 Ophthalmic Solution 
Protocol P-321-201 Version 3.0 
CONFIDENTIAL 
Page 12 
 
UHR-OCT 
Ultra high resolution optical coherence tomography 
UTMH 
Upper tear meniscus height 
UTMV 
Upper tear meniscus volume 

Parion Sciences, Inc. 
 
P-321 Ophthalmic Solution 
Protocol P-321-201 Version 3.0 
CONFIDENTIAL 
Page 13 
 
2 BACKGROUND INFORMATION 
2.1 Description of Study Medication 
Parion Sciences, Inc. is developing P-321 Ophthalmic Solution for the treatment of subjects with 
dry eye disease.  P-321 is a novel potent inhibitor of the epithelial sodium channel (ENaC) and a 
structural analog of amiloride with unique pharmacokinetic (PK) and pharmacodynamic 
characteristics designed for ocular topical administration, metabolic stability and limited 
systemic exposure. The formulation being studied is a sterile non-preserved aqueous solution of 
P-321.   
ENaC is a transmembrane sodium channel important in the regulation of epithelial sodium 
absorption that is present in the eye and other tissues such as lung, kidney, colon, and sweat 
glands.  ENaC has been extensively characterized in the lung where it plays a major role in the 
regulation of the composition of the airway surface liquid and is tightly linked to the 
maintenance of airway surface hydration and mucocilliary clearance (Barker, 1998).  The 
absorption of sodium from the epithelial surface liquid via ENaC osmotically entrains water into 
the epithelium, decreasing the level of hydration of the mucosal surface.   
The dynamics of the ocular tear film are maintained through an integrated system known as the 
lacrimal functional unit that consists of the ocular surface epithelium (cornea and conjunctiva), 
the lacrimal glands, the meibomian glands, and their neural and immunological components 
(Stern, 2004).  
ENaC is a key ion channel in this process, mediating the absorption of sodium (and hence water) 
from the tear fluid through the ocular surface epithelium (cornea and conjunctiva) where ENaC 
is expressed (Levin, 2006; Thelin, 2012; Krueger. 2012; Yu, 2012a; Yu, 2012b).  Therefore, 
ENaC provides an absorptive pathway for tear fluid loss, which regulates the composition and 
volume of tears under non-stimulated or “basal” conditions.  The inhibition of ENaC with highly 
potent, small molecule channel blockers represents a unique ocular hydration strategy, working 
by preventing the absorption of tear fluid and thereby maintaining the protective and lubricating 
actions of tears on the ocular surface. 
 

Parion Sciences, Inc. 
 
P-321 Ophthalmic Solution 
Protocol P-321-201 Version 3.0 
CONFIDENTIAL 
Page 14 
 
2.2   Non‐Clinical Studies for P‐321 Ophthalmic Solution 
2.2.1   Pharmacology 
In vitro studies: 
The inhibitory effect of P-321 on ENaC was studied in human and canine primary cultures of 
bronchial epithelial cells.  Apical administration of P-321 produced a concentration-dependent 
inhibition of ENaC-mediated short-circuit currents (Isc) with a potency of 3.247 ± 1.231 nM 
(n=12) and 1.901 ± 0.7543 nM (n=3) for canine and human airway epithelial cells, respectively. 
Primary cultures of human conjunctival epithelia grown on a permeable support at an air-liquid 
interface were used to assess the effect of P-321 on the absorption of fluid by the conjunctiva.  
Addition of fluid to the apical surface of these cells resulted in rapid absorption of fluid into the 
tissue.  The presence of P-321 on the apical surface inhibited the “tear” fluid absorption of the 
conjunctiva, suggesting that ENaC-mediated sodium absorption plays an important role on fluid 
absorption and tear dynamics. 
Among the unique characteristics built in the design of P-321 are the low systemic exposure 
following administration on the ocular surface, and the retention of the drug on the ocular surface 
to increase the duration of action.  The penetration of P-321 into the corneal epithelium was 
measured by confocal microscopy imaging, taking advantage of the intrinsic fluorescence of 
P-321.  Ex vivo imaging of mouse corneas treated with P-321 or amiloride indicated that in 
corneas treated with P-321, the drug remained associated with the mucosal surface of the cornea, 
whereas under identical conditions, amiloride had fully penetrated the epithelium, the stroma, 
and the endothelium, suggesting that P-321 is selectively retained by the epithelium of the ocular 
surface. 
In vivo Studies 
The effect of P-321 on the activity of ENaC in the ocular surface was studied in C57BL/6 mice 
by in vivo measurements of the transepithelial potential difference (PD) driven by sodium 
movement through ENaC.  Topical ocular instillation of P-321 produced a concentration-
dependent inhibition of the ocular PD measurements with a potency of 57.2 nM, (95% 
Confidence Interval: 35.2 to 93.0 nM).  These studies are consistent with in vitro results obtained 
in airway cells and suggest that P-321 is a potent inhibitor of the ocular ENaC-mediated 
epithelial sodium transport in vivo. 
The ability of P-321 to increase tear volume was studied in the ExLac dry eye animal model in 
rats in which the main lacrimal glands have been surgically removed (Fujihara, 2001).  ExLac 
rats exhibit approximately 50 to 60% reduction in the basal tear volume compared to normal 
animals.  A single ocular instillation of P-321 produced a concentration-dependent increase of 
tear volume that reached tear volumes similar to those observed in normal animals and at 
maximally effective concentrations.  The increase in tear levels was maintained for several hours 
following a single administration of P-321.   
The effect of repeat dosing of P-321 on tear volume was also studied in the ExLac rat animal 
model.   

Parion Sciences, Inc. 
 
P-321 Ophthalmic Solution 
Protocol P-321-201 Version 3.0 
CONFIDENTIAL 
Page 15 
 
Animals were treated with repeated administrations of 0.001% P-321 or vehicle control for five 
consecutive days at two dosing frequencies, twice daily (BID) and four times daily (QID).  
Animals treated with vehicle control showed no significant changes in tear volume throughout 
the five days of dosing. In contrast, in the group of animals treated with P-321 administered BID 
or QID, a gradual increase in tear volume was observed on each day of treatment reaching by the 
fifth day of treatment a steady state level similar to the tear volume of normal rats. On the first 
day of treatment, the animals receiving P-321 QID had a larger increase in tear volume than the 
animals treated BID, however, both groups had similar levels of tear volume by the end of 
treatment on Day 5.  These results show that a maximum effect on tear volume can be achieved 
with low concentrations of P-321 (0.001%) when administered either BID or QID over five 
consecutive days. 
In vivo pharmacology studies have shown that epithelial sodium channel inhibitors, including P-
321 have a stimulatory effect on tear volume in an animal model of dry eye disease (Thelin, 
2012).   
These in vivo and in vitro pharmacological actions together with the PK properties of P-321 
provide a strong scientific rationale for the use of P-321 Ophthalmic Solution for the treatment of 
diseases of impaired ocular hydration such as dry eye.  
2.2.2 Absorption, Distribution, Metabolism, and Excretion 
The absorption, distribution, metabolism, and excretion profile of P-321 was characterized in 
in vitro and in vivo studies.  P-321 was not metabolized in plasma from different species (rat, 
rabbit, dog and human) or by incubation with rat and dog hepatocytes.   
Oral administration of P-321 to rats did not produce measurable plasma drug concentrations, 
suggesting that P-321 is not orally available.   
The PK and systemic clearance of P-321 was characterized in rats following intravenous (IV) 
administration.  P-321 displayed biphasic elimination from plasma with a long terminal half-life 
and a high volume of distribution.  The PK of P-321 in plasma showed no difference among sex, 
and no accumulation was observed after multiple days of IV administration. 
The renal elimination of P-321 and its potential for inhibition of ENaC in the kidney was studied 
in rats treated with P-321 by topical ocular administration or by IV infusion.  The amount of 
P-321 recovered in urine over 24 hours following IV and ocular administration accounted for 
only a small fraction of the total dose administered corresponding to 0.57-1.3% and 0.19%, 
respectively.  Ocular administration of P-321 Ophthalmic Solution in dogs given four times per 
day over multiple days also indicated that very low amounts of P-321 were excreted in the urine 
and these concentrations of drug were not associated with changes in urine electrolyte excretion, 
the most sensitive measurement of the effect of ENaC blockers in the kidney.  
The ocular distribution and PK following topical ocular administration of P-321 was assessed in 
Dutch Belted rabbits following a single dose of 0.1% P-321 Ophthalmic Solution or during QID 
administration for 14 days. The ocular distribution of P-321 was limited only to the external 
surface of the eye. P-321 had a long terminal half-life in tears of approximately 24 hours.  
Sustained drug levels were also observed in the palpebral and bulbar conjunctiva and eyelids for 
up to 48 hours following a single administration.  After multiple days of QID dosing, P-321 

Parion Sciences, Inc. 
 
P-321 Ophthalmic Solution 
Protocol P-321-201 Version 3.0 
CONFIDENTIAL 
Page 16 
 
concentrations in these tissues, increased relative to the levels observed following a single 
administration, and reached a steady-state level after approximately 5 days of dosing.  P-321 had 
minimal or no penetration into internal regions of the eye such as the retina and aqueous humor, 
or the main lacrimal glands.  Furthermore, the systemic exposure of P-321 following ocular 
instillation was low, as evidenced by low or non-detectable drug levels in the plasma following a 
single dose or during 14 days of QID administration. 
The toxicokinetics of P-321 were estimated in Good Laboratory Practices (GLP) studies 
conducted in rabbits and dogs following ocular administration four times per day for 28 days.  
The systemic exposure of P-321 in rabbits was low with only the highest dose tested 
(0.5% P-321, QID) exhibiting quantifiable plasma drug levels.  P-321 was rapidly absorbed 
following ocular administration and rapidly cleared from plasma, with mean t1/2 values ranging 
from 0.183 to 0.254 hours on Days 1 and 28, respectively.  No accumulation was observed over 
28 days of dosing based on plasma drug concentrations. Note, the nominal ocular dose that 
produced systemic exposure in rabbits is 120-fold larger than the initial dose to be given to the 
subjects in this study, and 40-fold larger than the high dose planned for this study (0.05%).  The 
systemic exposure in dogs was also low, and only observed with the highest dose tested (0.05% 
QID) on Day 28.  P-321 was rapidly absorbed following ocular administration and rapidly 
cleared from plasma, with mean t1/2 values ranging from 2.28 to 2.68 hours. Note, the nominal 
ocular dose that produced systemic exposure in dogs is 12-fold larger than the initial dose to be 
given to the subjects in this study, and 4-fold larger than the high dose planned for this study 
(0.05%).   
In summary, P-321 is metabolically stable.  Following IV administration P-321 is rapidly cleared 
primarily via non-renal mechanisms, and is not orally available.  The ocular tissue distribution of 
P-321 following ocular instillation is essentially limited to its site of action on the ocular surface 
(tears, palpebral conjunctiva, bulbar conjunctiva, and cornea) with no penetration to internal 
structures of the eye (aqueous humor, retina) or the main lacrimal glands.  Topical ocular 
administration of P-321 Ophthalmic Solution at pharmacologically active concentrations results 
in minimal to no systemic exposure and also failed to produce any renal effect.  Furthermore, in 
subjects with dry eye disease treated with 0.01% P-321 BID for 28 days, we were not able to 
detect any drug present in plasma or urine from these subjects.    
2.2.3 Toxicology  
Multiple toxicology studies have been conducted using P-321Ophthalmic Solution.  Systemic 
administration of P-321 via IV, oral and ocular routes of administration, in both acute and repeat-
dose nonclinical studies, demonstrated that P-321 Ophthalmic Solution at pharmacologically 
active concentrations is well tolerated.  Extensive ocular toxicology studies for up to 28 days of 
administration at higher frequencies than those used in this study have been conducted in rabbits 
and dogs, with the dog being the most sensitive species.  The primary finding associated with 
ocular administration of P-321 was a dose-dependent increase of ocular irritation, described as 
minimal or slight, that reversed upon discontinuation of treatment.  No significant effects of 
P-321 Ophthalmic Solution were observed at any dose level for both species on 
electroretinograms, corneal thickness, and corneal endothelial cell density.  For the dose limiting 
factor of ocular irritation, the no-observed-adverse-effect levels (NOAEL) of 0.8 mg/eye/day in 
rabbits and 0.024 mg/eye/day in dogs exceeds the human doses planned for of this study. The 
NOAEL of 0.05 mg/kg/day in rats administered P-321 IV exceeds the potential exposure from 

Parion Sciences, Inc. 
 
P-321 Ophthalmic Solution 
Protocol P-321-201 Version 3.0 
CONFIDENTIAL 
Page 17 
 
the proposed initial ocular dose of 2.2661x10-4 mg/kg/day (assuming bilateral dosing of 0.017% 
P-321, QD with a 40 µl drop size in a 60 kg person) by 225-fold on a Human Equivalent Dose 
basis. For the high dose planned in this study, the dose of 6.666x10-4 mg/Kg/day (assuming 
bilateral dose of 0.05% P-321 QD in a 60 Kg person, the systemic safety margin is 75-fold on a 
Human Equivalent Dose basis. 
No systemic effects at any dose level in dogs or rabbits were observed following ocular 
administration of P-321 Ophthalmic Solution. 
In a battery of genotoxicity studies, P-321 did not cause mutations in the Ames or mouse 
lymphoma assay in vitro with or without S9 metabolic activation.  Additionally, the compound 
was negative in a rat micronucleus study.  Thus, P-321 can be considered to be non-mutagenic 
and non-clastogenic, with no evidence of disruption of the mitotic apparatus.   
2.3 Clinical Experience with P‐321 Ophthalmic Solution 
There has been one study completed with P-321 Ophthalmic Solution in which 40 subjects with 
mild to moderate dry eye disease were treated with P-321 Ophthalmic Solution.  In this study, P-
321 Ophthalmic Solution was well-tolerated at concentrations of 0.0005%, 0.0015%, 0.005% 
instilled twice daily for up to 15 days and 0.01% instilled twice daily for up to 28 days.  There 
were no clinically relevant adverse drug-related, dose-related or time of treatment-related effects 
on any safety measure.  No serious adverse events (SAEs) were reported.  No evidence of 
systemic exposure of P-321 was observed.  
Although this study was not powered for effects on efficacy measurements, improvements in the 
frequency and severity of symptoms of dry eye disease that approached statistical significance 
compared with placebo were observed.  In addition, consistent with the proposed mechanism of 
action of P-321, the treatment difference relative to placebo favored P-321 for the measurements 
of tear meniscus height (TMH) observed in this study.   
2.4 Justification for Route of Administration and Dose Selection 
P-321 Ophthalmic Solution is expected to exert its biological activity through direct interaction 
with ENaC on the corneal and conjunctival surface of the eye.  Since the intended route of 
administration for P-321 is topical ocular, this route of administration will be used in this study.  
The dose planned for this study was selected based upon results of the first clinical study and 
preclinical safety studies.   
This study is a single day crossover comparing P-321 Ophthalmic Solution and Placebo on the 
pharmacodynamic measure, tear volume.  During Phase 1, a single dose of 0.017% will be 
administered and during Phase 2 and based on the recommendation of the Data Review Group, a 
single dose of either 0.05%, 0.017% or 0.01% will be administered.  These doses on a single 
instillation frequency and are covered by the safety profile obtained in the most sensitive species 
(dog) with safety margins that range from 6-fold to 1.2-fold.  
2.5 GCP Compliance 
This clinical trial will be conducted in compliance with the protocol, International Conference on 
Harmonization (ICH) Good Clinical Practice guidelines, and other applicable regulatory 
requirements. 

Parion Sciences, Inc. 
 
P-321 Ophthalmic Solution 
Protocol P-321-201 Version 3.0 
CONFIDENTIAL 
Page 18 
 
2.6 Population to be Studied 
Dry eye disease is a multifactorial debilitating disease of the ocular surface characterized by 
ocular signs of corneal and conjunctival impairment and damage of the protective epithelial 
surface, as well as, decreased tear volume, decreased tear break-up time, and symptoms of 
discomfort that can range from mild to severe such as, burning, pain, stinging, itching, swelling, 
foreign body sensation, photophobia, and ocular fatigue.  Frequent instillation of artificial tears is 
currently the most commonly used treatment for mild to moderate dry eye signs and symptoms.   
According to recent prevalence estimates, dry eye disease can affect up to 20 million people in 
the US, with a disproportionate number of women and elderly being afflicted.  However, with 
the spread use of digital technologies in recent years, increased incidence of dry eye in younger 
adults is being observed.  There is a heterogeneous collection of diseases with many shared 
characteristics that can precipitate dry eye disease.  Dry eye disease is one of the hallmarks of the 
Sjögren's syndrome (SS); however, they represent only a fraction of subjects who experience dry 
eye symptoms.  Dry eye is also observed in approximately 40 to 60% of subjects who have 
undergone hematopoietic stem cell transplantation and develop graft versus host disease (Saboo, 
2015).  One core abnormality of the disease is the decrease in tear volume that can be originated 
by a deficiency of tear secretion or composition which in turn triggers the loss of volume and 
compromises the protective barrier of the ocular film.  Additionally, dry eye symptoms can be 
the side effect of many commonly used medications such as anticholinergics, antidepressants, 
and environmental factors such as air conditioning and focusing on video displays for prolonged 
periods of time.  These symptoms of dry eye can vary from mild to severe and in the most severe 
cases, can result in significant vision impairment and permanent damage of the ocular surface.  
In this study, subjects with tear deficient dry eye disease will be recruited for participation. 
Approximately 24 subjects with tear deficient dry eye disease documented by low tear volume as 
measured by UHR-OCT will be completed in this single-center, randomized,  cross-over, 
placebo controlled study to evaluate the changes in tear volume by P-321 Ophthalmic Solution or 
Placebo.  The study consists of two Phases.  Approximately 8 subjects participating in Phase 1 
will receive 0.017% P-321 Ophthalmic Solution or Placebo, and the remainder of the 24 subjects 
participating in Phase 2 will receive either 0.05%, 0.017% or 0.01%.  The decision on the dose 
administered in Phase 2 will be made following unmasked data review from subjects in Phase 1.  
In each Phase, subjects will receive sequentially two treatments: P-321 Ophthalmic Solution 
(Treatment A) and Placebo (Treatment B).  Subjects will be randomly assigned to receive 
treatment sequence AB or BA, with each subject in Phase 1 and Phase 2 being treated with P-321 
Ophthalmic Solution and placebo  The Principal Investigator, Medical Monitor and Parion 
Sciences representatives not involved in the day to day conduct of the study will review 
unmasked data as part of the Data Review Group, which will decide the dose to be used in Phase 
2 of the study.  The treatment assignments will remain masked to subjects in the study, the 
clinical monitor, and other site and Parion Sciences personnel involved in the conduct of the 
study and not involved in the Data Review Group.  Additional unmasked reviews of subject data 
may occur during the study to make recommendations on further dose adjustments and for 
planning purposes.  These reviews will follow the procedures outlined above. 
 

Parion Sciences, Inc. 
 
P-321 Ophthalmic Solution 
Protocol P-321-201 Version 3.0 
CONFIDENTIAL 
Page 19 
 
3 TRIAL OBJECTIVES AND PURPOSE 
The primary objective of this trial is to assess changes in tear volume by the non-invasive 
techniques Ultra High Resolution Optical Coherence Tomography (UHR-OCT) following the 
administration of P-321 Ophthalmic Solution or Placebo in subjects with tear deficient dry eye 
disease.   
The secondary objectives are to: 
 assess changes in lower tear meniscus height by Keratograph 5M  
 compare lower tear meniscus height measurements between UHR-OCT and Keratograph 
5M 
 assess the duration of action of P-321 Ophthalmic Solution 
 compare the pharmacodynamic activity of different strengths of P-321 in subjects with 
tear-deficient dry eye 
 monitor safety and tolerability of P-321 Ophthalmic Solution 

Parion Sciences, Inc. 
 
P-321 Ophthalmic Solution 
Protocol P-321-201 Version 3.0 
CONFIDENTIAL 
Page 20 
 
4 INVESTIGATIONAL PLAN 
4.1 Overall Study Design 
This is a single-center, randomized,  cross-over, placebo-controlled, Phase 2a trial designed to 
evaluate the pharmacodynamic effects of tear volume of P-321 Ophthalmic Solution in tear-
deficient dry eye subjects.  Approximately 24 eligible subjects will complete the study which 
consists of two Phases: Approximately 8 subjects participating in Phase 1 will receive 0.017% P-
321 ophthalmic Solution and Placebo, and the remainder of the 24 subjects participating in Phase 
2 will receive either 0.05%, 0.017% or 0.01% P-321 and placebo.  The decision on the dose 
administered in Phase 2 will be made following unmasked data review from subjects in Phase 1.  
In each Phase, subjects will receive sequentially two treatments: P-321 Ophthalmic Solution 
(Treatment A) and Placebo (Treatment B).  Subjects will be randomly assigned to receive 
treatment sequence AB or BA, in a 1:1 ratio.  
The pharmacodynamic measures of tear volume will be assessed by two methods: UHR-OCT 
and Keratograph 5M.  Optical coherence tomography (OCT) has been used to image the anterior 
segment of the eye including tears on the ocular surface. The method is non-invasive and non-
contact which is suitable for imaging the tear meniscus around both upper and lower lids. The 
system at Bascom Palmer Eye Institute is a custom made OCT system (UHR-OCT) with an ultra-
high resolution (3 µm). Many previous studies have been done using UHR-OCT and its clinical 
application has been well documented. With the wide scan of the UHR-OCT, cross-sectional 
images of the tear menisci can be imaged and tear meniscus volume can be calculated.  The 
Keratograph 5M is a corneal topographer with a built in camera optimized for external imaging. 
The Keratograph 5M has a feature that enables the non-invasive assessment of the tear meniscus 
height of the inferior eyelid from high resolution images obtained under infrared light.  With the 
use of a built-in measurement tool the height of the tear meniscus is obtained. 
The study will consist of three study visits: a Screening Visit (Visit 1), and two treatment visits 
(Visit 2 and Visit 3).  The duration of the study may be up to 23 days. 
At Visit 1, three tear volume measurements will be conducted over 1 hour with measurements 
taken approximately 30 minutes apart (initial timepoint, and at 30 and 60 minutes later) and prior 
to any invasive ocular assessments.  The average of these three measurements will be obtained 
and used as baseline tear volume and meniscus height and to determine the eligibility of the 
subject to participate in the study.   
At Visits 2 and 3, tear volume will be assessed serially over 6 hours: Before administration of 
assigned study medication (time =  0, pretreatment),  and at 15 minutes, 30 minutes, 1 hour, 2 
hours, 4 hours and 6 hours after study medication administration.  Subjects will be asked to 
arrive to the clinic for Visit 2 and Visit 3 between 8:00AM and 11:00AM and at approximately 
the same time as Visit 1.   
Safety assessments including adverse events (AEs), biomicroscopy and external eye examination 
and an assessment of comfort immediately after taking the medication will be conducted 
following each in-clinic dose.  Changes in medical conditions and medication, abbreviated 
physical exam changes and vital signs will be recorded periodically throughout the study. A post 

Parion Sciences, Inc. 
 
P-321 Ophthalmic Solution 
Protocol P-321-201 Version 3.0 
CONFIDENTIAL 
Page 21 
 
instillation dry eye symptom assessment will be conducted at Visits 2 and 3 immediately prior to 
the 2 hour post dose time point.  
Subjects may be asked to stop or withhold certain medications, and on visit days and for at least 
6 hours after dosing with study medication, withhold certain medications and not wear contact 
lenses on visit days.  After the assessments of  Visit 3 are completed, the subject will be 
discharged from the study. 
A detailed schedule of the time and events for the study is provided in Appendix I. 
A schematic of the study design is shown in Figure 1. 
Figure 1: P-321-201 Study Schematic 
 
 
4.2 Endpoints 
4.2.1 Primary Endpoint 
The primary endpoint for this study is the change in measurements of tear volume over time as 
measured by the UHR-OCT following the administration of P-321 Ophthalmic Solution and 
Placebo in subjects with tear deficient dry eye disease.   
4.2.2  Secondary Endpoints 
The secondary endpoints are to: 
 assess changes in lower tear meniscus height by Keratograph 5M  
 compare lower tear meniscus height measurements between UHR-OCT and Keratograph 
5M 

Parion Sciences, Inc. 
 
P-321 Ophthalmic Solution 
Protocol P-321-201 Version 3.0 
CONFIDENTIAL 
Page 22 
 
 assess the duration of action of P-321 Ophthalmic Solution 
 compare the pharmacodynamic activity of different strengths of P-321 in subjects with 
tear-deficient dry eye 
 monitor safety and tolerability of P-321 Ophthalmic Solution 
4.2.3 Safety and Tolerability Endpoints 
Safety endpoints include: AEs, biomicroscopy and external eye examination and comfort 
assessment (after each in-clinic dose).   
4.3 Duration of Participation 
The study will consist of three study visits: A Screening Visit (Visit 1), and two Treatment Visits 
(Visit 2 and Visit 3).  The duration of the study may be up to 23 days. The start of each visit will 
take place between 8:00AM and 11:00 AM and at approximately the same time as Visit 1. 
Visit 1 is expected to last approximately 2 hours and Visits 2 and 3 are expected to last 
approximately 7 hours.  
 

Parion Sciences, Inc. 
 
P-321 Ophthalmic Solution 
Protocol P-321-201 Version 3.0 
CONFIDENTIAL 
Page 23 
 
5 SELECTION AND WITHDRAWAL OF SUBJECTS 
5.1 Subject Inclusion Criteria  
Subjects must meet the following criteria at Screening to be enrolled in the study: 
1. Provide written informed consent 
2. Male or female subjects aged 18 to 80 years 
3. Are willing and able to follow instructions and can be present for the required study visits 
for the duration of the study 
4. Have a history of predominantly tear-deficient dry eye of mild to moderate severity, in both 
eyes, supported by a previous clinical diagnosis  
5. Subjects must have in at least one eye an average tear meniscus height (TMH) of the lower 
eye lid of 210 µm or less as assessed by UHR-OCT 
6. Have normal lid anatomy 
7. Female subjects of child bearing potential must have a negative serum pregnancy test at 
Screening and agree to use a medically acceptable form of birth control (e.g., intrauterine 
device, birth control pill, patch or subcutaneous implant, condoms, diaphragm, or 
abstinence) throughout the duration of the study.  Females who are breast feeding an infant 
are not eligible to participate in the study. 
8. Subjects must: 
a. Remain on current medications for the duration of the study 
b. Be on the current medication regimen at least during the past 28 days 
c. Be able to withhold ocular topical medications, including artificial tears, topical 
steroids, Restasis, Xiidra®, autologous serum, and lid wipes and scrubs on visit 
days while in the clinic, and for at least 6 hours after dosing with study 
medication 
d. If they are contact lens wearers, be able to withhold wearing contact lenses on 
visit days, while in the clinic, and for at least 6 hours after dosing  
5.2 Subject Exclusion Criteria  
Subjects who meet any of the following criteria at Screening or during the study will be excluded 
from the study. 
1. Have an identifiable or suspected dry eye caused by pharmacologic, post-traumatic, or post-
surgical condition 
2. Have undergone refractive eye surgery (e.g., LASIK) in either eye during the past 12 months  
3. Have undergone uncomplicated cataract surgery in either eye during the past 3 months  
4. Have undergone previous eyelid surgery in either eye (e.g., blepharoplasty, ptosis repair).  
External blepharoplasty, not resuting in exposure or abnormal blinking, will be allowed.  
5. Have lid irregularities or deformities  
6. Have severe corneal surface irregularities  

Parion Sciences, Inc. 
 
P-321 Ophthalmic Solution 
Protocol P-321-201 Version 3.0 
CONFIDENTIAL 
Page 24 
 
7. Have undergone botulinum toxin (Botox™ or equivalent) injection in the periocular area 
within 3 months prior to Visit 1  
8. Have a history of glaucoma or IOP > 25 mmHg at the Screening Visit (Visit 1) or a history 
of elevated IOP within the past year 
9. Subjects that have a systemic, multi-organ disease (with the exception of subjects with SS or 
GVHD) requiring active medical or surgical treatment are excluded, except if the following 
conditions are met: 
a. the condition is chronic (> 1 years' duration), stable, of mild severity and 
adequately controlled 
b. the condition does not or is unlikely to have ocular manifestations 
c. the condition is one of the following: 
i. essential hypertension 
ii. coronary artery disease 
iii. Type II diabetes mellitus without diabetic retinopathy 
iv. thyroid dysfunction without thyroid eye disease 
v. non-morbid obesity 
vi. remote history of cancer (> 5 years from diagnosis) 
10. Have punctal plugs, punctal occlusion, or history of nasolacrimal duct obstruction or wear 
scleral lenses, 
11. Stevens-Johnson syndrome, ocular cicatricial pemphigoid, or other ocular cicatrizing 
disorders 
12. Past or present exposure keratopathy, neurotrophic keratopathy, lagophthalmos, or trichiasis 
13. Subjects taking the following medications within 14 days of Visit 1 or during the study are 
excluded 
a. Oral, nasal and ocular antihistamines 
b. Oral or topical secretagogues such as pilocarpine and Evoxac 
c. Topical anti-glaucoma medications 
14. History of allergies to any of the components of the study medication 
15. Are pregnant or breast feeding an infant.  
16. Have any significant illness that, in the opinion of the Principal Investigator (PI), could 
interfere with the study parameters 
17. Use of any investigational product or device within 28 days prior to the Screening Visit or 
during the study 
18. Are unable in the opinion of the PI to comply fully with the study requirements or to 
complete the study 
5.3 Randomization Criteria 
At Visit 2 (First Treatment Visit) and Visit 3 (Second Treatment Visit), an eligible subject must: 
1. 
Continue to meet all clinical inclusion/exclusion criteria as defined in Section 5.1 and 
Section 5.2, with the exception of the inclusion criteria #5 (UHR-OCT measurement) 
.   

Parion Sciences, Inc. 
 
P-321 Ophthalmic Solution 
Protocol P-321-201 Version 3.0 
CONFIDENTIAL 
Page 25 
 
A log will be maintained at the sites for those subjects that do not meet eligibility criteria. 
Minimally this log will include the subject’s age, sex and race and the reason that they were not 
eligible.  Screen failure data will not be collected in the clinical database.   
5.4 Study Eye 
The  Study eye will be the eye that meets entry criteria as defined in Section 5.1, Section 5.2, and 
Section 5.3.  If both eyes meet entry criteria, the study eye will be the eye with the lower average 
TMH by OCT.  If both eyes have the same average TMH, then the qualifying sStudy eye will be 
the right eye.  
5.5 Subject Withdrawal Criteria and Stopping Rules 
Treatment may be discontinued and the subject withdrawn at any time during the study at the 
discretion of the investigator, Medical Monitor or Parion Sciences for any reason including but 
not limited to occurrence of an AE which precludes subsequent participation, withdrawal of 
Informed Consent, or requirement of an ocular surgery or intervention.  Also in the event that a 
woman becomes pregnant while participating on the study, she will be withdrawn from the 
study.  In the event that discontinuation of treatment is necessary, the investigator will make 
every attempt to complete all subsequent safety assessments and the Early Termination Visit.  
The reason for premature discontinuation should be entered onto the paper case report form 
(CRF).  Subjects who withdraw from the study will be replaced.   
Additionally, the trial or parts of the trial may be discontinued by Parion Sciences, Inc. or at the 
recommendation of the Investigator or Medical Monitor after consultation with Parion.  This 
may be based on a significant number of AEs of a similar nature that warrant such action or at 
the request of Parion Sciences, Inc.   

Parion Sciences, Inc. 
 
P-321 Ophthalmic Solution 
Protocol P-321-201 Version 3.0 
CONFIDENTIAL 
Page 26 
 
6 PROCEDURES 
The procedures performed for this study are listed below.  The times indicated in the following 
sections and Appendices are based on the visit starting in the AM with each visit starting at a 
consistent timeframe relative to Visit 1.   
6.1 Visit 1: Screening (3 to 9 days prior to Visit 2 – Randomization)  
The subject should initiate screening procedures within 14 days of signing the ICF.  Prior to 
conducting study procedures, informed consent will be obtained. 
The following procedures will be completed at Visit 1 which will start between 8:00AM and 
11:00AM: 
 Review eligbility criteria 
 Review of the medical history  
 Review concomitant medication history in the past 28 days  
 Administer ocular symptom questionnaires (SPEED, OSDI, and SANDE Part 1 only) 
before other procedures 
 Biomicroscopy and external eye examination 
 Visual acuity  
 Abbreviated physical exam (including respiratory, cardiovascular, musculoskeletal, 
gastrointestinal, dermatological) 
 Vital signs (pulse, blood pressure, temperature and respiration rate) and height and 
weight 
 Conduct pretreatment measurements in both eyes by UHR-OCT and Keratograph 5M 
three times in one hour (at 0 minutes, 30 ± 10 minutes and 60 ± 20 minutes).   NOTE: 
throughout the study, UHR-OCT will be conducted first, immediately followed by 
Keratograph 5M. 
 Tear osmolarity 
 TBUT 
 Assessment of meibomian glands 
 Corneal staining 
 Conjunctival staining 
 Schirmer’s test   
 IOP  
 Collect blood for hematology, chemistry and pregnancy tests 
 
Monitoring of adverse events will begin from the time the Informed consent is signed 
 
Eligible subjects will be instructed to return to the clinic between 3 and 9 days for the first 
treatment (Visit 2, First Treatment Visit) with the visit occurring in the AM, at approximately 
the same time of day as Visit 1.  Subjects will be reminded not to use ocular medications or 
wear contact lenses on the day of Visit 2. 
 

Parion Sciences, Inc. 
 
P-321 Ophthalmic Solution 
Protocol P-321-201 Version 3.0 
CONFIDENTIAL 
Page 27 
 
6.2 Visit 2:  First Treatment Visit (3 ‐9 days after Visit 1) 
The following procedures will be completed at Visit 2 which will take place between 8:00AM 
and 11:00 AM and at approximately the same time as Visit 1: 
 Subjects will be asked to remain on site through this visit and limit use of devices with 
video display screens. 
 Confirm continued eligibility through review of inclusion and exclusion criteria as 
outlined in Sections 5.1 and 5.2 of the protocol with the exception of the inclusion 
criteria #5 (UHR-OCT dry eye).  
 Review of concomitant medications and medical changes since last visit 
 Administer symptom questionnaires (SPEED, OSDI, and SANDE Part 1 and Part 2) 
before other procedures and before dosing 
 Assess adverse events since the last visit and during this visit 
 Collect vital signs (pulse, blood pressure, temperature and respiration rate) pre-treatment 
 Conduct pretreatment  measurements in both eyes by UHR-OCT and Keratograph 5M  
(at approximately the same time as conducted at Visit 1) immediately prior the 
administration of study medication.  UHR-OCT will be conducted first, immediately 
followed by Keratograph 5M. 
 Subjects will be assigned a treatment number at this visit. 
 Administer one drop of assigned study medication in each eye immediately after the 
pretreatment assessment (the drug administration will be conducted by the PI or clinical 
site personnel). NOTE:  Remove study medication from refrigerator at least 15 minutes 
prior to administration.   
 At approximately 5 minutes after drug administration, administer drop instillation 
comfort assessment  
 Repeat assessments by UHR-OCT and Keratograph 5M post dose at 15 ± 5 minutes, 30 
± 10 minutes minutes, 1 hour ± 20 minutes, 2 hours ± 30 minutes, 4 hours ± 30 minutes, 
and 6 hours ± 30 minutes. 
 Immediately prior to the 2 hour time point for tear volume measurement, a post 
instillation dry eye symptom assessment will be completed 
 After the 6-hour tear volume assessment, conduct a biomicroscopy and external 
examination  
 At the end of the visit, the subject will be instructed to return to the clinic between 7 and 
14 days for the second treatment (Visit 3, Second Treatment Visit) with the visit 
occurring in the AM, at approximately the same time of day as Visit 1 and Visit 2 
 The subjects will be instructed to maintain the same medications and study restrictions 
between visits to continue being eligible to remain in the study. Subjects will be 
reminded not to use ocular medications or wear contact lenses on the day of Visit 3 
 
6.3 Visit 3:  Second Treatment Visit (7‐14 days after Visit 2) 
 Subjects will be asked to remain on site through this visit and limit use of devices with 
video display screens. 

Parion Sciences, Inc. 
 
P-321 Ophthalmic Solution 
Protocol P-321-201 Version 3.0 
CONFIDENTIAL 
Page 28 
 
 Confirm continued eligibility through review of inclusion and exclusion criteria as 
outlined in Sections 5.1 and 5.2 of the protocol with the exception of the inclusion 
criteria #5 (UHR-OCT dry eye).   
 Review of concomitant medications and medical changes since last visit 
 Administer symptom questionnaires (SPEED, OSDI, and SANDE Part 1 and Part 2) 
before other procedures and before dosing   
 Assess adverse events since the last visit and during this visit 
 Collect vital signs pre-treatment (pulse, blood pressure, temperature and respiration rate) 
 Conduct pretreatment measurements in both eyes by UHR-OCT and Keratograph 5M in 
the AM (at approximately the same time as conducted at Visit 1) immediately prior the 
administration of study medication.  NOTE: throughout the study, UHR-OCT will be 
conducted first, immediately followed by Keratograph 5M. 
 Administer one drop of assigned study medication in each eye immediately after the 
pretreatment assessment (the drug administration will be conducted by the PI or clinical 
site personnel). NOTE:   Remove study medication from refrigerator at least 15 minutes 
prior to administration.   
 At approximately 5 minutes after drug administration, administer drop instillation 
comfort assessment 
 Repeat assessments by UHR-OCT and Keratograph 5M post dose at 15 ± 5 minutes, 30 
± 10 minutes minutes, 1 hour ± 20 minutes, 2 hours ± 30 minutes, 4 hours ± 30 minutes, 
and 6 hours ± 30 minutes. 
 Immediately prior to the 2 hour time point for tear volume measurement, a post 
instillation dry eye symptoms assessment will be completed 
 After the 6-hour tear volume assessment, conduct a biomicroscopy and external eye 
examination 
 At this point, the subject will be discharged from the study. 
 Subjects may resume previously used ocular medications when discharged from the 
study. 
 
6.4 Early Termination Visit 
The following assessments will be performed at the Early Termination Visit for randomized 
subjects who are withdrawn from the study prematurely:  
 
 Assess adverse events since the last visit and during this visit 
 Assess concomitant medications and medical changes since last visit  
 Collect vital signs (pulse, blood pressure, temperature and respiration rate) and height 
and weight 
 Conduct an abbreviated physical examination (including respiratory, cardiovascular, 
musculoskeletal, gastrointestinal, and dermatological) 
 Conduct a biomicroscopy and external eye examination 
 
   

Parion Sciences, Inc. 
 
P-321 Ophthalmic Solution 
Protocol P-321-201 Version 3.0 
CONFIDENTIAL 
Page 29 
 
6.5 Selecting Dosage Strength in Phase 2 
The decision of dose strength for P-321 Opthalmic Solution in Phase 2 of the study will be the 
responsibility of the Data Review Group constituted by the Prinicipal Investigator (or a designee 
not directly involved in the conduct of the study), the Medical Monitor and representatives of 
Parion Sciences.  Decision on the dose level to be given in Phase 2 will be made based on 
unmasked review of the study data from the first 8 subjects by the review committee.  Data to be 
considered will include safety and efficacy measures.  A detailed criterion for Dose selection for 
Phase 2 is described in Appendix XIV and outlined below. 
The dose level may be increased to 0.05% in Phase 2 in the event that: 
1) No cases of serious, suspected related, unexpected events are noted in Phase 1 OR 
2) No cases of serious ocular safety events are noted in Phase 1 
3) Lack of evidence that P-321 produced an increase in tear volume based on OCT and/or 
Keratograph 5M, or evidence that additional improvements in tear volume (or the 
duration of effect) may be obtained with a higher dose. 
The dose level may be decreased to 0.01% in Phase 2 in the event that: 
1) No cases of serious, suspected related, unexpected events are noted in Phase 1  
2) No cases of serious ocular safety events are noted in Phase 1  
3) There is evidence of a significant increase in tear volume and the duration of effect based 
on OCT and/or Keratograph 5M 
 
The dose level may remain at 0.017% (the same as in Phase 1) in the event: 
1) No cases of serious, suspected related, unexpected events are noted in Phase 1  
2) No cases of serious ocular safety events are noted in Phase 1  
3) There is not compelling data to either increase or decrease the strength for Phase 2.  
 
The Data Review Group will make a recommendation to Parion Sciences to increase the dose, 
decrease the dose or maintain the dose.  
Additional unmasked reviews of subject data may occur throughout the study to make 
recommendations on further dose adjustments and for planning purposes.  These reviews will 
follow the procedures outlined above. 
6.6 Potential Toxicity Management 
All preclinical evidence indicates that systemic exposure of P-321 via ocular topical 
administration is none or negligible at concentrations up to 10-fold higher than the concentration 
planned in this study (the estimated systemic safety margins for the doses anticipated in this 
study range from 75- to 375-fold).  However, since P-321 is an ENaC inhibitor, a previous 
potential safety signal of concern following the administration of P-321, was drug-induced 
hyperkalemia.  This possibility was carefully investigated in Study P-321-101.  No changes in 
plasma or serum potassium were noted in this study in subjects administered 0.01% P-321 
Ophthalmic Solution BID for up to 28 days.  

Parion Sciences, Inc. 
 
P-321 Ophthalmic Solution 
Protocol P-321-201 Version 3.0 
CONFIDENTIAL 
Page 30 
 
No concerns for systemic toxicity in this single-dose administration study are based on the lack 
of safety findings from the P-321-101 study when treatment with P-321 was administered BID 
for up to 28 days.  In addition, in the same study, the pharmacokinetic results demonstrated a 
lack of systemic availability of 0.01% P-321 Ophthalmic Solution given twice daily for 28 days.  
In this study, treatment with P-321 Ophthalmic Solution at doses up to 0.05% will be given only 
once to each participating subject.  Thus, no post dose monitoring of serum potassium is planned 
for this trial. 
Any additional questions regarding toxicity management should be managed by appropriate 
medical professional at the clinical site and directed to Parion Sciences Medical Monitor. 
6.7 Collection of Data 
Source documentation for data collected in the study will be maintained at the investigative site.  
In cases where no source documents will be used (i.e., data will be recorded directly onto the 
CRF without first being recorded on another document, such as the subject symptom 
questionnaires, for which data will be recorded directly on the CRF pages by the subject), the 
original data will be included in the CRF and this will be noted in the investigator files. 

Parion Sciences, Inc. 
 
P-321 Ophthalmic Solution 
Protocol P-321-201 Version 3.0 
CONFIDENTIAL 
Page 31 
 
7 TREATMENT OF SUBJECTS 
7.1 Treatment Administration 
Study medication will be administered by the PI or clinical site personnel at Visits 2 and 3.  At 
Visit 2, eligible subjects will be randomized (1:1 ratio) to receive one of two treatment 
sequences: P-321 Ophthalmic Solution at Visit 2, and Placebo at Visit 3, or Placebo at Visit 2 
and P-321 at Visit 3.  The order of the treatment is randomized, neither the subjects nor site 
personnel will know which treatment the subject receives at which visit.  Assessments will be 
conducted before and at the indicated times after study medication administration in the 
indicated order in Section 6.   
7.2 Trial Treatments 
Subjects will receive P-321 Opthalmic Solution or Placebo in random order at Visit 2 and 3.  The 
study treatment order will be determined by the assignment of the randomization code.  P-321 
Ophthalmic Solution and Placebo.   
P-321 Ophthalmic Solution is a sterile, aqueous, non-preserved solution of approximately pH 5, 
and tonicity of approximately 290 mOsm/kg.  Placebo solution has identical composition without 
the active ingredient.  Both solutions are packaged in low density, polyethylene dropper bottles.  
Each bottle of study medication will contain sufficient volume of ophthalmic solution for the 
intended dosing (1 drop in each eye).  Only one drop should be instilled in each eye.   
For Phase 1, one pouch of study medication will be used at each clinical visit, the label on the 
pouch will indicate the visit number at which the drug will be administered (Visit 2 or Visit 3).  
The labels on the kit and the pouches will minimally contain the following information:  Study 
ID, kit number, storage temperature, and “Caution: New Drug – Limited by Federal Law to 
Investigational use”.  The study medications will be stored at approximately 2-8C in a secure 
area with limited access to study personnel. 
For Phase 2, the dose selected of P-321 Ophthalmic Solution and Placebo will be provided by a 
compounding pharmacy in individual vials similar to those of the Phase 1 study, based on a 
randomization code.  No medication kits will be prepared for Phase 2.  The pharmacy will be 
unmasked to distribute according to the randomization scheme.  The study medications will be 
stored at approximately 2-8C in a secure area with limited access to study personnel and should 
be labeled and “Caution: New Drug – Limited by Federal Law to Investigational use”.  
Pharmacy records should include Study ID, randomization number, visit number, date, and 
subject identifiers. 
The medication will be administered by the PI or clinical site personnel at each of Visit 2 and 
Visit 3.  There will be no study medication administered at an Early Termination Visit. 
7.3 Methods to Minimize Bias 
To minimize bias, the treatment regimen will be randomized and masked.  The randomization 
code will be generated by an independent designee of Parion Sciences, Inc. who is not involved 
in the day-to-day conduct of the clinical study.  The randomization code will be provided to the 
designee of Parion Sciences, Inc. who is responsible for the manufacture, packaging and labeling 

Parion Sciences, Inc. 
 
P-321 Ophthalmic Solution 
Protocol P-321-201 Version 3.0 
CONFIDENTIAL 
Page 32 
 
of the clinical supplies; further the randomization code will be maintained in a secure location 
separate from the clinical study site personnel.   
The Medical Monitor and Principal Investigator and members of the Parion team not involved in 
the conduct of the study will be unmasked as part of the Data Review Group for decision making 
on the strength of P-321 Opthalmic Solution to be used in Phase 2 of the study.  The treatment 
assignments will remain masked to subjects in the study, the clinical monitor, and other site and 
Parion Sciences personnel involved in the conduct of the study and not involved in the Data 
Review Group.  Additional unmasked reviews of subject data may occur throughout the study to 
make recommendations on further dose adjustments and for planning purposes.  These reviews 
will follow the procedures outlined in Section 6.5. 
7.4 Concomitant Medications 
7.4.1 Medications Permitted 
All medications including prescription, over-the-counter, and natural remedies, that the subject 
has taken within 28 days prior to Visit 1 or during the study will be recorded in the CRF and in 
the subjects’ source documents.  The name of the drug, dose, route of administration, duration of 
treatment (including start and stop dates), frequency, and indication will be recorded for each 
medication.  The use of fluorescein and lissamine green do not need to be recorded on the 
concomitant medications page.   
Subjects should use medications consistently throughout the study and for 28 days prior to Visit 
1 with the exceptions outlined in Section 7.4.2.   
7.4.2 Medications Not Permitted 
Use of the following products on visit days, while in the clinic, and for at least 6 hours after 
dosing will not be allowed (use of these all other times during the study is permitted): 
 Topical ocular medications including artificial tears, topical steroids, Restasis®, Xiidra®, 
autologous serum, and lid wipes and scrubs. 
 Contact lens wear 
Use of the following medications during the study will NOT be allowed within 14 days of Visit 1 
or during the study: 
 Oral, nasal and ocular antihistamines 
 Oral or topical secretagogues such as pilocarpine or Evoxac 
 Topical anti-glaucoma medications 
 
Use of the following medications during the study or within 28 days prior to Visit 1 will NOT be 
allowed: 
 Investigational product or device 
Use of the following medications during the study or within 3 months prior to Visit 1 will NOT 
be allowed: 

Parion Sciences, Inc. 
 
P-321 Ophthalmic Solution 
Protocol P-321-201 Version 3.0 
CONFIDENTIAL 
Page 33 
 
 Botulinum toxin (Botox® or equivalent) injection in the periocular region 
7.5 Treatment Compliance 
Because this is a single day crossover, with study medication administered by the PI or clinical 
site personnel, treatment compliance will not be calculated.  Time of administration of study 
medication and kit number will be captured in the CRF. 
7.6 Drug Accountability 
Study medication accountability will occur during monitoring visits by Parion Sciences, Inc, or 
its designee.  Accountability will be ascertained by performing reconciliation between numbers 
of Kits/bottles of study medication received on site/compounded for distribution, number of 
bottles dispensed to subjects according to the protocol-specified dosing regimen, and the 
remaining unused study medication at the time of reconciliation.   
Clinical trial materials and bulk supplies will be shipped to the investigational site/pharmacy 
under sealed conditions.  Study medication shipment records will be verified by comparing 
actual quantity of drug received against the shipment inventory sheet accompanying the drug 
received at the site.  Accurate records of receipt and disposition of the study medications (e.g., 
dates, quantity, subject number, dose dispensed, returned, etc.) must be maintained by the 
investigator or his/her designee.  Study medication will be stored at the site in an area free of 
environmental extremes, at controlled temperatures between 2 – 8°C (36 - 46°F).  This area 
should be limited and have controlled access.   
At the end of the study, all study materials, including unused study medication bottles and bulk 
supplies will be returned to Parion Sciences, Inc. (or its designee) for disposal.  The study 
monitor or designee should verify drug accountability at routine monitoring visits.   
7.7 Maintenance of Randomization and Procedure for Breaking the Code 
The treatment assignments will be masked to the investigator, medical monitor, study site 
personnel, subjects in the study and those involved in the conduct of the study. 
Only in the case of a medical emergency, or occurrence of a suspected related, unexpected, SAE, 
may the randomization code be unmasked and made available to the investigator, medical 
monitor, subject, and/or other personnel involved in the monitoring or conduct of this study.  In 
the absence of medical need, the randomization code will not be available to the above personnel 
until after the study is completed and the database is locked.  
The Data Review Group will review unmasked data.  The Medical Monitor and Principal 
Investigator (or designee) and members of the Parion team not involved in the conduct of the 
study will be unmasked as part of the Data Review Group for decision making on the strength of 
P-321 Opthalmic Solution to be used in Phase 2 of the study.  The treatment assignments will 
remain masked to subjects in the study, the clinical monitor, and other site and Parion Sciences 
personnel involved in the conduct of the study and not involved in the Data Review 
Group.  Additional unmasked reviews of subject data may occur throughout the study to make 
recommendations on further dose adjustments and for planning purposes.  These reviews will 
follow the procedures outlined in Section 6.5. 

Parion Sciences, Inc. 
 
P-321 Ophthalmic Solution 
Protocol P-321-201 Version 3.0 
CONFIDENTIAL 
Page 34 
 
For Phase 1, a a randomization list will be generated and the kits will be labeled in a masked 
fashion.  The randomization assignments will be kept in a secure area at Parion Sciences, Inc. or 
designee.  For Phase 2, a randomization list will be provided to the pharmacy and the pharmacy 
will distribute the assigned drug according to the randomization schedule with subjects 
remaining masked.  
In case of a medical need, the investigator will treat the subject as needed regardless of 
randomized treatment.  Since there is no specific antidote to P-321 Ophthalmic Solution, 
immediate emergency unmasking is not necessary.  If the investigator feels it is necessary to 
unmask a subject’s treatment assignment after an emergency situation, the investigator must call 
the medical monitor and notify Parion Sciences, Inc.  The treatment assignment will be revealed 
on a subject-by-subject basis, leaving the masking of the remaining subjects intact. 

Parion Sciences, Inc. 
 
P-321 Ophthalmic Solution 
Protocol P-321-201 Version 3.0 
CONFIDENTIAL 
Page 35 
 
8 STATISTICS 
8.1 Statistical Methods 
8.1.1 Subject Disposition, Demographic and Background Characteristics 
Subject disposition, demographic, and background characteristics will be summarized by using 
descriptive statistics.  Baseline homogeneity with respect to demographic and background 
characteristics will be assessed via an overall F-test from analysis of variance (ANOVA).  For 
categorical variables, treatment differences will be assessed using the chi-square test or Cochran 
Mantel Haenszel (CMH) test with modified ridit scores for ordered categorical variables. 
Background characteristics include:  demographics, tear volume measurements by UHR-OCT 
and Keratograph 5M, visual acuity,  symptoms upon entry, medical history, concomitant 
medication use, tear osmolarity, tear break up time, meibomian gland assessments, corneal and 
conjunctival staining, Schirmer and IOP. 
8.1.2 Pharmacodynamic parameters 
UHR-OCT will assess the following parameters in both eyes: UTMH, LTMH, UTMV, LTMV, 
and TTMV (UTMV + LTMV).  Treatment group differences for tear volume assessments will be 
conducted via comparisons of tear meniscus height, and if applicable, tear meniscus volume 
(TMV).  These parameters will be compared between each dose of P-321 Ophthalmic Solution 
and Placebo using a t-test for study eyes, and for all eligible eyes.  Analysis of covariance 
(ANCOVA) models will be used to adjust for the baseline TMH and TMV for study eyes. For all 
eligible eyes, a generalized estimation equations (GEE) will also be used to account for the 
correlation between eyes.  For the GEE analysis, an exchangeable correlation matrix will be 
assumedArea under the curve (AUC) analysis will also be performed as an exploratory analysis 
to compare OCT assessments and  Keratograph 5M LTMH for Placebo vs each dose of P-321.  
  
8.1.3 Analysis of Efficacy 
This is a pharmacodynamic and tolerability study of a single administration of P-321 Ophthalmic 
Solution or Placebo, and therefore, no primary or secondary efficacy endpoints will be formally 
assessed.  
8.1.4 Analysis of Safety 
All safety data collected on or after the date that study medication was first dispensed up through 
the date of the final post dose assessment will be summarized. 
The objective of the statistical analysis of the safety parameters is to investigate the data for any 
effects of study medication on clinical tolerability.  All such parameters will be summarized by 
treatment group and time point as indicated below. Because this study, is a cross over design 
and, at the cross over treatment, the subjects may no longer be treatment naive, analysis will 
check for sequence/period effects.  If sequence/period effects are detected, the analysis of safety 
will use just the first period results.  Provided that no sequence/period effects are seen, analysis 
will use the most-recent treatment received as the treatment group. 

Parion Sciences, Inc. 
 
P-321 Ophthalmic Solution 
Protocol P-321-201 Version 3.0 
CONFIDENTIAL 
Page 36 
 
In the absence of any predefined hypotheses, the general strategy of the safety analysis will be to 
examine the data summaries for any trends amongst the treatment groups.  No formal hypothesis 
testing will be carried out.  
The incidence of AEs will be tabulated by treatment group overall, by treatment sequence, by 
severity, and relationship to study medication.   
Change from baseline values (or shifts from baseline, if more appropriate) will be presented for 
other safety measures for the visits at which they are assessed. 
8.1.5 Interim Reviews of Data  
A Data Review Group will review unmasked data when approximately 8 subjects have 
completed Phase 1.  The Data Review Group will include the Prinicpal Investigator (or 
designee), the Medical Monitor and representative of Parion Sciences not involved in the 
conduct of the study.  Other study site personnel, subjects in the study and those involved in the 
conduct of the study will remain masked.  Additional unmasked reviews of subject data may 
occur throughout the study to make recommendations on further dose adjustments and for 
planning purposes.  These reviews will follow the procedures outlined in Section 6.5. 
8.2 Sample Size Estimation 
An initial sample size of approximately 24 subjects is proposed for this study. The study design 
includes OCT measurements at time 0 (pretreatment) and post dose at 15 minutes, 30 minutes, 1 
hour, 2 hours, 4 hours and 6 hours. Shen et al. (Shen, 2009) reported that among the measures of 
tear volume and tear film thickness obtainable through OCT, the most sensitive and specific 
measure of dry eye is the low tear meniscus height (LTMH). Power estimations for a two-period, 
two-treatment, two-sequence crossover design (2x2x2),this study size when all subjects treated 
with P-321are analyzed, will provide 98% power to detect a difference of 60 μm at 1 hour or a 
power of 99% if the average increase in LTMH over the six hours is 60 μm (assuming within-
subject SD of 71). In this study it is expected that the drug will reach its peak effect at 1 hour 
post dose and that the effect diminishes at hours 4 and 6 (to values still above pre-dose values).   
 
8.3 Level of Significance 
Each hypothesis will be tested at a significance level of 0.05.   
8.4 Criteria for Termination of an Individual Subject 
An individual subject may be terminated from the trial for any reason including, but not limited 
to the following: 
 Subject withdrawing consent to continue in the trial  
 Occurrence of an AE which precludes subsequent participation  
 Requirement of an ocular surgery or intervention that is exclusionary for the trial 
 Physician discretion based on the ability of the subject to continue schedule or treatment 
regimens according to protocol, or for the safety of the subject  
 In the event that a woman becomes pregnant while participating on the study, she will be 
withdrawn from the study 

Parion Sciences, Inc. 
 
P-321 Ophthalmic Solution 
Protocol P-321-201 Version 3.0 
CONFIDENTIAL 
Page 37 
 
8.5 Criteria for Termination of the Trial 
The trial may be discontinued by Parion Sciences, Inc. or at the recommendation of the principal 
investigator after consultation with Parion.  This may be based on a significant number of AEs of 
a similar nature that warrant such action, or at the request of Parion Sciences, Inc.  Should this be 
necessary, both parties will arrange discontinuation procedures and notify the appropriate 
regulatory authority(ies) and Institutional Review Board (IRB). In terminating the study, Parion 
Sciences and the investigator will assure that adequate consideration is given to the protection of 
the subjects’ interests.   
8.6 Procedure for Accounting for Missing, Unused, or Spurious Data 
All analyses will be based on observed data only.  No attempts will be made to impute or 
estimate missing data. 
8.7 Procedure for Reporting Deviations from the Statistical Plan 
Any deviations from the statistical plan will be described and a justification given in the final 
clinical report. 
8.8 Subjects to be Included in the Analysis 
All safety analyses will include all subjects who were randomized and received at least one dose 
of study medication.   

Parion Sciences, Inc. 
 
P-321 Ophthalmic Solution 
Protocol P-321-201 Version 3.0 
CONFIDENTIAL 
Page 38 
 
9 ASSESSMENT OF PHARMACODYNAMICS 
Detailed measurements of tear volume before and after dose administration will be obtained 
using UHR-OCT (tear volume and tear meniscus height) and Keratograph 5M (tear meniscus 
height).  Procedures for these measurements are located in Appendix X. 

Parion Sciences, Inc. 
 
P-321 Ophthalmic Solution 
Protocol P-321-201 Version 3.0 
CONFIDENTIAL 
Page 39 
 
10 ASSESSMENT OF SAFETY 
10.1 Safety Parameters 
Subject safety will be evaluated by a medical professional during the study.  Tolerance of study 
medication as well as general subject well-being will be assessed.  Subjects may be discontinued 
from the study at any time by the investigator if this action is considered in the subject's best 
interest. 
Post dose safety parameters are measured as described in Appendix I and include: 
 Assessment of adverse events (Appendix II) 
 Biomicroscopy and external eye examination (Appendix IV) 
 Assessment of comfort in taking the medication will be conducted (Appendix XI) 
10.2 Procedures for Adverse Events Reporting  
An AE is any untoward medical occurrence in a subject or clinical investigation subject 
administered a pharmaceutical product, which does not necessarily have to have a causal 
relationship with this treatment.  AEs will be documented upon signing the informed consent.  A 
treatment emergent AE (TEAE) is an AE that either commenced following initiation of study 
treatment or was present prior to study treatment but increased in frequency or severity following 
initiation of study treatment.   
A non-serious AE is any AE that does not meet the definitions for SAEs as described in 
Section 10.3.   
AEs that occur prior to subject randomization at Visit 2 will be documented in source 
documents. TEAEs will be monitored throughout the study and will be recorded on the CRF with 
the date and time of onset, date and time of resolution, intensity, seriousness, causality 
(relationship to study medication), treatment required and the outcome.   
If an AE occurs, the investigator will institute support and/or treatment as deemed appropriate.  
If a non-serious AE is unresolved at the time of the last visit, a reasonable effort will be made to 
follow up until the AE is resolved or stabilized, the subject is lost to follow-up, or there is some 
other resolution of the event.   
To elicit AEs simple questions with minimal connotations should be used as the initial questions 
at all evaluation points during the trial.  For example: 
 How have you felt since your last assessment? 
 Have you had any health problems since your last assessment? 
10.3 Serious Adverse Event Reporting 
An SAE is any untoward medical occurrence occurring on this trial that results in any of the 
following outcomes: 
 Death  

Parion Sciences, Inc. 
 
P-321 Ophthalmic Solution 
Protocol P-321-201 Version 3.0 
CONFIDENTIAL 
Page 40 
 
 A life-threatening adverse drug experience (i.e., the subject is at immediate risk of death 
at the time of the event)  
 In-patient hospitalization or prolongation of existing hospitalization  
 A persistent or significant incapacity or substantial disruption of the ability to conduct 
normal life functions 
 
A congenital anomaly/birth defect   
 
Important medical events that may not result in death, be life-threatening, or require 
hospitalization may be considered serious when, based upon appropriate medical 
judgment, they may jeopardize the subject and may require medical or surgical 
intervention to prevent one of the outcomes listed in this definition 
The Investigator or other study personnel must immediately inform Parion Sciences or designee 
by phone or email of any AE considered serious or otherwise significant, as described above.  In 
addition, a completed SAE report form must be submitted to Parion within 24 hours of 
initial awareness of the event. 
 
SAE Reporting 
Dedicated Safety Email Address:   safety@parion.com 
 
It is the responsibility of the investigator or their designee to report any event of this nature to 
Parion Sciences, Inc. within 24 hours of the event being brought to the investigator’s or their 
staffs' attention.  It is also the responsibility of the investigator to report all SAEs to their IRB 
according to their requirements and provide a copy of this notification to Parion Sciences.  The 
investigator should make every attempt to follow all SAEs to resolution. 
Information to submit when reporting an SAE to Parion Sciences, Inc. is located in Appendix II. 
10.4 Procedures for Reporting Pregnancy 
Any subject found to be pregnant at any time during the study will be withdrawn from the study 
immediately.  Any pregnancy outcome that meets the criteria for an SAE will be reported as an 
SAE.  All pregnancies will be reported to Parion Sciences within 24 hours of the event being 
brought to the investigator’s or their staffs' attention.  It is also the responsibility of the 
investigator to report all pregnanciess to their IRB according to their requirements and provide a 
copy of this notification to Parion Sciences.  The investigator should make every attempt to 
follow all pregnancies to resolution (i.e., birth or voluntary or spontaneous termination of the 
pregnancy).   
 

Parion Sciences, Inc. 
 
P-321 Ophthalmic Solution 
Protocol P-321-201 Version 3.0 
CONFIDENTIAL 
Page 41 
 
11 DIRECT ACCESS TO SOURCE DATA and DOCUMENTS 
The principal investigator will permit trial-related monitoring, audits, IRB review, and regulatory 
inspection(s) by providing direct access to source data and documents.   

Parion Sciences, Inc. 
 
P-321 Ophthalmic Solution 
Protocol P-321-201 Version 3.0 
CONFIDENTIAL 
Page 42 
 
12 QUALITY CONTROL AND QUALITY ASSURANCE 
The progress of the study will be monitored by on-site, written, e-mail and telephone 
communications between personnel at the study center and Parion Sciences, Inc. (or designated 
monitor).  The investigator will allow Parion Sciences, Inc. clinical monitors, designees, 
auditors, and regulatory authorities to inspect all CRFs; subject records (source documents), 
signed informed consent forms; records of study medication receipt, storage, and dispensation; 
and regulatory files related to this study. 
At the time of database lock, the clinical database will be audited in order to ensure accuracy of 
all data as well as to provide an estimated error rate for the final, locked database.  The results of 
the audit will be provided in the final study report.  The audit will involve a comparison of CRF 
values with values from data listings generated from the clinical database.  Values of all 
variables will be confirmed for the five randomly selected subjects.  If the database fails to meet 
an accuracy rate of 99.5% (less than 1 error / 200 fields), a second set of 5 subjects will be 
selected, If a combined sample fails to meet an accuracy rate of 99.5%, the remainder of the 
database will be rechecked or take other action taken agreed with by Parion. 

Parion Sciences, Inc. 
 
P-321 Ophthalmic Solution 
Protocol P-321-201 Version 3.0 
CONFIDENTIAL 
Page 43 
 
13 ETHICS 
This protocol is written in accordance with the principles established by the 18th World Medical 
Assembly General Assembly (Helsinki, 1964) and amendments and clarifications adopted by 
subsequent General Assemblies.  The investigator will make sure that the study described in this 
protocol is conducted in full conformance with those principles, the protocol, current FDA 
regulations, ICH Good Clinical Practices (GCP) guidelines, Good Laboratory Practices (GLP) 
guidelines, local ethical and regulatory requirements, including the Federal Food, Drug and 
Cosmetic Act, U.S. applicable Code of Federal Regulations (CFR) (title 21), any Ethics 
Committee (EC) requirements relative to clinical studies.  As required by the US FDA, the study 
drug may not be shipped to any participating investigator until the requisite study documentation 
has been submitted to the IND. 
13.1 Institutional Review Board 
The EC/IRB must be a properly constituted board or committee operating in accordance with 21 
CFR Part 56, “Institutional Review Boards.”  This protocol, any protocol amendments and the 
associated informed consent forms and translations must be submitted to the EC/IRB for review 
and approved before the enrollment of any subject into the trial. 
All subject recruitment materials and advertising information, including translated versions of 
these documents, must be submitted to Parion or its designee and to the EC/IRB for review and 
approval prior to implementation.  EC/IRB approval of any protocol amendments must be 
received before any of the changes outlined in the amendments are put into effect, except when 
the amendment has been enacted to eliminate a potential hazard to study subjects.  In such cases, 
the chair of the EC/IRB should be notified immediately and the amendment forwarded to the 
EC/IRB for review and approval. 
In addition, the Clinical Investigator Brochure should be submitted to the IRB.   
Written IRB approval must adequately identify the materials approved.  Copies of all approved 
materials, all correspondence with the IRB, and written approval from the IRB must be made 
available to Parion Sciences, Inc. (or designated monitor) prior to shipment of study medication 
and the start of subject enrollment into the study. 
SAEs will be reported to the IRB by the principal investigator as required by the IRB.   
13.2 Informed Consent Requirements 
Written informed consent will be obtained from each subject prior to any study related 
procedures being performed.  A copy of the signed and dated consent document will be given to 
each subject.  The original signed and dated informed consent document must be maintained in 
the study files at the investigative site and be available for Parion Sciences, Inc. or designee, and 
regulatory authorities for review. 
Each informed consent form will contain contact information with a telephone number the 
subject should contact if they have medical concerns 24-hours a day.   

Parion Sciences, Inc. 
 
P-321 Ophthalmic Solution 
Protocol P-321-201 Version 3.0 
CONFIDENTIAL 
Page 44 
 
13.3 Data Handling and Record Keeping 
All procedures for the handling and analysis of data will be conducted using good clinical 
practices meeting ICH and U.S. Food and Drug Administration (FDA) guidelines for the 
handling and analysis of data for clinical trials. 
13.4 Data Quality Control and Reporting 
After data have been entered into the study database, a system of computerized data validation 
checks and manual data reviews will be implemented and applied to the database.  Query reports 
pertaining to data omissions and discrepancies will be forwarded to the clinical investigator and 
monitor(s) for resolution.  The study database will be updated in accordance with the resolved 
query reports.  All changes to the study database will be documented. 
CRFs will be provided by Parion Sciences, Inc.  All data relating to the trial must be recorded in 
the CRFs.  The Investigator must verify that all data entries in the CRFs are accurate and 
complete. The CRF must be signed and dated by the Investigator upon subject withdrawal or 
completion of the study. 
During monitoring visits, CRFs will be reviewed by study monitor(s) for completeness, 
accuracy, and legibility. CRFs will be compared with the source documents to ensure that there 
are no discrepancies. All CRF entries, corrections, and alterations must be made by an 
Investigator or his/her designee. Corrections must be made in such a way that the original entry 
is not obliterated. Correction fluid must NOT be used. The correct data must be inserted, dated 
and initialed by the Investigator or his/her designee. The study monitor is not allowed to make 
entries on the CRF pages. 
The original CRF page will be retrieved by the monitor and returned to Parion Sciences, Inc. 
after complete review of the case.  A copy must be maintained by the Investigator.  If 
documented corrections to a CRF are needed after removal of the original CRF copy from the 
center, a Data Correction Form (DCF) will be used. The Investigator or a staff member must 
verify, sign, and date each DCF. 
A log will be maintained at the sites for those subjects that do not meet eligibility criteria. 
Minimally this log will include the subject’s age, sex and race and the reason that they were not 
eligible.  Screen failure data will not be collected in the clinical database.   
13.5 Records Retention 
The study center will retain all records related to the study in compliance with ICH Good 
Clinical Practices Guidelines. 
13.6 Publication Policy 
The institution and investigators participating in this trial shall have no rights to publish, disclose 
or present the results of this study without prior written consent of Parion Sciences, Inc. 

Parion Sciences, Inc. 
 
P-321 Ophthalmic Solution 
Protocol P-321-201 Version 3.0 
CONFIDENTIAL 
Page 45 
 
14 REFERENCES 
Arita R, Itoh K, Inoue K, Amano S. Noncontact infrared meibography to document age-related 
changes of the Meibomian glands in a normal population. Ophthalmology. 2008;115:911–915. 
Barker, P. M., Nguyen, M. S., Gatzy, J. T., Grubb, B., Norman, H., Hummler, E., Koller, B. 
(1998). Role of gammaENaC subunit in lung liquid clearance and electrolyte balance in newborn 
mice. Insights into perinatal adaptation and pseudohypoaldosteronism. The Journal of Clinical 
Investigation, 102(8), 1634–40. doi:10.1172/JCI3971. 
Foulks G, Bron AJ. A clinical description of meibomian gland dysfunction. Ocul Surf. 
2003;1:107–126. 
Fujihara, T., Murakami, T., Fujita, H., Nakamura, M., Nakata, K. (2001). Improvement of 
corneal barrier function by the P2Y(2) agonist INS365 in a rat dry eye model. Investigative 
Ophthalmology & Visual Science, 42(1), 96–100. 
Korb D.R., Herman J.P., Greiner J.V., Scaffidi R.C., Finnemore V.M., Exford J.M., Blackie 
C.A., Douglass T. (2005) Lid Wiper Epitheliopathy and Dry Eye Symptoms.  Eye and Contact 
Lens, 31(1), 2-8. 
Krueger, B., Schlötzer-Schrehardt, U., Haerteis, S., Zenkel, M., Chankiewitz, V. E., Amann, K. 
U., Korbmacher, C. (2012). Four subunits (αβγδ) of the epithelial sodium channel (ENaC) are 
expressed in the human eye in various locations. Investigative Ophthalmology & Visual Science, 
53(2), 596–604. doi:10.1167/iovs.11-8581. 
Lemp, M. A. (1995). Report of the National Eye Institute/Industry workshop on Clinical Trials in 
Dry Eyes. The CLAO Journal : Official Publication of the Contact Lens Association of 
Ophthalmologists, Inc, 21(4), 221–32. 
Levin, M. H., Kim, J. K., Hu, J., & Verkman, A. S. (2006). Potential difference measurements of 
ocular surface Na+ absorption analyzed using an electrokinetic model. Investigative 
Ophthalmology & Visual Science, 47(1), 306–16. doi:10.1167/iovs.05-1082. 
Ngo W., Situ P., Keir N., Korb D., Blackie C., Simpson T., (2013). Psychometric Properties and 
Validation of the Standard Patient Evaluation of Eye Dryness Questionnaire. Cornea, (32):1204–
1210. 
Saboo, U., Amparo, F., Abud, T., Schaumberg, D., Dana, R., (2015). Vision-Related Quality of 
Life in Patients with Graft-versus-Host Disease. Ophthalmology, 122 (8), 1669-1674. 
Schaumberg, D. A., Gulati, A., Mathers, W. D., Clinch, T., Lemp, M. A., Nelson, J. D., Dana, R. 
(2007). Development and validation of a short global dry eye symptom index. The Ocular 
Surface, 5(1), 50–7. 

Parion Sciences, Inc. 
 
P-321 Ophthalmic Solution 
Protocol P-321-201 Version 3.0 
CONFIDENTIAL 
Page 46 
 
Schiffman R.M., Christianson M.D., Jacobsen G., Hirsch J.D., Reis B.L. (2000). Reliability and 
validity of the Ocular Surface Disease Index. Arch Ophthalmol., 118:615-621. 
 
Shen M., Li J., Wang J., Ma H., Cai C., Tao A., Yuan Y., Lu F (2009). Upper and lower tear 
menisci in the diagnosis of dry eye. Invest. Ophthalmol. Vis. Sci., 50:2722-2726 
Stern, M. E., Gao, J., Siemasko, K. F., Beuerman, R. W., & Pflugfelder, S. C. (2004). The role of 
the lacrimal functional unit in the pathophysiology of dry eye. Experimental Eye Research, 
78(3), 409–16. 
Thelin, W. R., Johnson, M. R., Hirsh, A. J., Kublin, C. L., & Zoukhri, D. (2012). Effect of 
topically applied epithelial sodium channel inhibitors on tear production in normal mice and in 
mice with induced aqueous tear deficiency. Journal of Ocular Pharmacology and Therapeutics : 
The Official Journal of the Association for Ocular Pharmacology and Therapeutics, 28(4), 433–
8. doi:10.1089/jop.2011.0157. 
Yu, D., Thelin, W. R., Randell, S. H., & Boucher, R. C. (2012a). Expression profiles of 
aquaporins in rat conjunctiva, cornea, lacrimal gland and Meibomian gland. Exp Eye Res. (103), 
22–32.  
Yu, D., Thelin, W. R., Rogers, T. D., Stutts, M. J., Randell, S. H., Grubb, B. R., & Boucher, R. 
C. (2012b). Regional differences in rat conjunctival ion transport activities. Am J Physiol Cell 
Physiol., 303(7), C767–780. 
 

Parion Sciences, Inc. 
 
P-321 
Protocol P-321-201 Version 3.0 
 
CONFIDENTIAL 
Page 47 
 
APPENDIX I: SCHEDULE OF VISITS AND PROCEDURES. 
Table 1 
Schedule of Visits and Procedures  
Event 
Visit 1 
Visit 2 
 
Visit 3 
ET 
Screening Visit 
First Treatment Visit 
(3 to 9 days after Visit 1) 
Wash-out  
(7 to 14 Days) 
Second Treatment Visit 
(7 to 14 days after Visit 2) 
Early Termination Visit 
Informed Consent 
Xa 
 
 
 
 
Eligibility Criteria Reviewed 
X 
X 
 
X 
 
Medical History/Changes 
X 
X 
 
X 
X 
Concomitant 
Medication/Changes  
Xb 
X 
 
X 
X 
Abbreviated Physical Exam 
X 
 
 
 
X 
Vital Signs 
X 
Xc 
 
Xc 
X 
Tear Osmolarity 
X 
 
 
 
 
Assessment of Meibomian 
Glandsd 
X 
 
 
 
 
Pregnancy Test 
X 
 
 
 
 
Serum Chemistry 
X 
 
 
 
 
Hematology 
X 
 
 
 
 
Dry Eye Symptomse 
X 
X 
 
X 
 
Study Medication 
Administration 
N/A 
One drop per eye in AMf 
 
One drop per eye in AMf 
 
UHR-OCT Assessmentsg 
Xg 
Xi 
 
Xi 
 
Keratograph 5M 
Xg 
Xi 
 
Xi 
 
Drop Instillation Comfort 
Assessmentj 
 
X 
 
X 
 

Parion Sciences, Inc. 
 
P-321 
Protocol P-321-201 Version 3.0 
 
CONFIDENTIAL 
Page 48 
 
Event 
Visit 1 
Visit 2 
 
Visit 3 
ET 
Screening Visit 
First Treatment Visit 
(3 to 9 days after Visit 1) 
Wash-out  
(7 to 14 Days) 
Second Treatment Visit 
(7 to 14 days after Visit 2) 
Early Termination Visit 
Post Instillation Dry Eye 
Symptoms Assessment  
 
Xk 
 
Xk 
 
Visual Acuity 
X 
 
 
 
 
Biomicroscopy and External 
Eye Examination 
X 
Xl 
 
Xl 
X 
Corneal Staining 
X 
 
 
 
 
Conjunctival Staining 
X 
 
 
 
 
TBUT 
X 
 
 
 
 
Intraocular Pressure  
X 
 
 
 
 
Schirmer’s Test 
X 
 
 
 
 
Adverse Event Monitoring 
X 
X 
 
X 
X 
a. 
Prior to conducting study procedures, informed consent will be obtained. 
b. 
Concomitant medications taken within 28 days of screening will be reviewed 
c. 
To be completed pre-treatment 
d. 
Meibomian gland assessment to include clinical exam and meibography 
e. 
Dry eye symptom questionnaires (OSDI, SPEED, and SANDE with SANDE part 1 at visit 1, 2 and 3 and Part 2 at Visit 2 and Visit 3 only) will be administered pre-
dose and before other procedures. 
f. 
Remove study medication from refrigerator at least 15 minutes before administration 
g. 
Measurementes include: UTMH, LTMH, UTMV, LTMV, and TTMV (UTMV + LTMV) 
h. 
To be measured three times in one hour (at 0 minutes, 30 minutes, and 60 minute interval) 
i. 
Timepoints: Pre dose and post dose at 15±5 minutes, 30±10 minutes, 1 hour±20 minutes, 2 hours±30 minutes, 4 hours±30 minutes, and 6 hours±30 minutes 
j. 
To be completed approximately 5 minutes after dosing 
k. 
To be completed immediately prior to the 2 hour post dose tear volume measurements 
l. 
To be completed after 6 hour tear volume assessment 
 
 

Parion Sciences, Inc. 
 
P-321 Ophthalmic Solution 
Protocol P-321-201 Version 3.0 
CONFIDENTIAL 
Page 49 
 
APPENDIX II: ADVERSE EVENT REPORTING 
Adverse Event Definitions 
Adverse Event (AE):  Any untoward medical occurrence in a subject or clinical investigation 
subject administered a pharmaceutical product; which does not necessarily have a causal 
relationship with this treatment.  
Treatment Emergent Adverse Event (TEAE): A treatment emergent AE (TEAE) is an AE that 
either commenced following initiation of study treatment or was present prior to study treatment 
but increased in frequency or severity following initiation of study treatment.   
A SERIOUS ADVERSE EVENT (SAE) is any adverse drug experience occurring at any dose 
that results in any of the following outcomes:  
 Death 
 A life-threatening adverse drug experience (i.e., the subject is at immediate risk of death 
at the time of the event) 
 In-patient hospitalization or prolongation of existing hospitalization 
 A persistent or significant incapacity or substantial disruption of the ability to conduct 
normal life functions 
 A congenital anomaly/birth defect 
 Important medical events that may not result in death, be life-threatening, or require 
hospitalization may be considered serious when, based upon appropriate medical 
judgment, they may jeopardize the subject and may require medical or surgical 
intervention to prevent one of the outcomes listed in this definition 
A NON-SERIOUS ADVERSE EVENT is any adverse event that does not meet the definitions 
for serious adverse events as described above.  
Adverse Event Classification 
Each Adverse Event will be classified as SERIOUS or NONSERIOUS using the definitions 
provided above. 
The INTENSITY of each Adverse Event will be classified as MILD, MODERATE, or 
SEVERE.   
The CAUSALITY of the Adverse Event will be classified as NOT RELATED to study 
medication, POSSIBLY RELATED to study medication, or RELATED to study 
medication defined as follows: 
Not related: 
An event that does not follow a reasonable temporal sequence from 
administration to the suspected drug, is not a known response pattern to 
the suspect drug or due wholly to the subject’s clinical state or other 
factors.  

Parion Sciences, Inc. 
 
P-321 Ophthalmic Solution 
Protocol P-321-201 Version 3.0 
CONFIDENTIAL 
Page 50 
 
Possibly related: 
An event that follows a reasonable temporal sequence form administration 
of the study medication, follows a known or expected response pattern to 
the suspected drug, but that could be explained by the subject’s clinical 
state or other factors. 
Related: 
An event that follows a distinct temporal sequence from administration of 
the study medication, follows a known or expected response pattern to the 
suspected drug, and cannot be explained by subject’s clinical state or other 
factors  
Serious Adverse Event Reporting 
The following information should be provided when an SAE is reported to Parion Sciences: 
1. Protocol Number 
2. Site ID 
3. Subject Initials 
4. Subject Number 
5. Subject Demographic information, including: 
a. Date of Birth 
b. Sex 
c. Race 
6. Start date of study medication administration 
7. Date of last dose of study product  
9. SAE information, including: 
a. SAE Term (diagnosis only; if known or serious signs/symptoms) 
b.  Description of SAE/narrative 
c. Date of onset 
d. Outcome 
e. Date of resolution or death 
f. Duration of SAE if less than 24 hours 
g. Relationship to study medication 
h.  Action taken with Study medication 
i. If ocular, which eye(s) were affected 
10. Criteria for classifying the event as serious, including whether the SAE resulted in any of 
the following:   
a. Death 

Parion Sciences, Inc. 
 
P-321 Ophthalmic Solution 
Protocol P-321-201 Version 3.0 
CONFIDENTIAL 
Page 51 
 
b. Life-threatening 
 
c. In-patient hospitalization or prolongation of existing hospitalization 
 
d. A persistent or significant incapacity or substantial disruption of the ability to conduct 
normal life functions 
 
e. Congenital anomaly/birth defect 
 
f. Important medical events that may not result in death, be life-threatening, or require 
hospitalization may be considered serious when, based upon appropriate medical 
judgment, they may jeopardize the subject and may require medical or surgical 
intervention to prevent one of the outcomes listed in this definition. Examples of such 
medical events include allergic bronchospasm requiring intensive treatment in an 
emergency room or at home, blood dyscrasias or convulsions that do not result in in-
patient hospitalization, or the development of drug dependency or drug abuse. 
11. Concomitant medications 
12. Relevant history 
13. Possible causes of SAE other than study medication 
14. Copy of the Adverse Event page from the Case Report Form if the subject has been 
randomized 
15. Signed copy of the SAE form  
 
 

Parion Sciences, Inc. 
 
P-321 Ophthalmic Solution 
Protocol P-321-201 Version 3.0 
CONFIDENTIAL 
Page 52 
 
APPENDIX III: VISUAL ACUITY ASSESSMENT 
Visual acuity will be measured by the M&S Technologies Smart System II (Park Ridge, IL).  
This is a  computer generated visual acuity test.  The Smart System II comprises a computer 
processor, using a flat LCD screen monitor, and an interactive keypad controller. The LCD 
screen monitor is wall-mounted and manufactured to M&S Technologies’ specifications, with 
high resolution and a 450:1 nominal contrast ratio.  The examiner uses the keypad to access 
directly each primary acuity test, specific optotypes, randomization options, and to increase or 
decrease the size of the optotype on demand.  The system allows the examiner to present random 
letter sequences to preclude subjects from memorizing the sequence to pass each line. The Smart 
System II can be calibrated for lane lengths of 6 to 22 feet. 
  
 

Parion Sciences, Inc. 
 
P-321 Ophthalmic Solution 
Protocol P-321-201 Version 3.0 
CONFIDENTIAL 
Page 53 
 
APPENDIX IV: BIOMICROSCOPY/EXTERNAL EYE EXAMINATION 
Slit lamp biomicroscopy will be performed and the observations will be graded as described 
below: 
Lashes 
 
0= Normal 
 
1= Abnormal 
 
Eyelid 
 
Erythema  
 0 = Normal, without any redness 
 
 
+1 = A low grade flushed reddish color 
 
 
+2 = Diffused redness encompassing the entire lid margin 
+3 = Deep diffused reddish color of lid margins and superior or inferior eyelid 
Edema 
 
 
    
0 = Normal, no swelling of the lid tissue 
 
 
+1 = Slight diffuse swelling above normal 
 
 
+2 = General swelling 
 
+3 = Swelling sufficient to close the lid 
 
Conjunctiva 
Erythema 
0 = Normal 
+1 = A flush, pink color predominantly confined to the palpebral or bulbar     
conjunctiva; slight localized injection 
+2 = More prominent red color of the palpebral or bulbar conjunctiva 
+3 = Marked redness of the palpebral or bulbar conjunctiva 
 
Edema 
  
 0 = Normal, no swelling of the conjunctiva 
+1 = Slight diffuse or regional swelling of the conjunctiva 
+2 = General swelling of the conjunctiva 
+3 = Extensive swelling of the conjunctiva 
 
Tear Film Debris 
 
 
  0 = None; absence of debris 
 
 
+1 = Mild; presence of debris in inferior tear meniscus 
+2 = Moderate; presence of debris in inferior tear meniscus and in tear film overlying 
 
cornea 
+3 = Severe; presence of debris in inferior tear meniscus and in tear film overlying 
cornea  
presence of mucus strands in inferior fornix or on bulbar conjunctiva 
+4 = Very Severe; presence of debris in inferior tear meniscus and in tear film overlying 
cornea;  
presence of numerous AND/OR adherent mucus strands in inferior fornix and on 
bulbar conjunctiva or filamentary keratitis 

Parion Sciences, Inc. 
 
P-321 Ophthalmic Solution 
Protocol P-321-201 Version 3.0 
CONFIDENTIAL 
Page 54 
 
 
 
Cornea 
Endothelial Changes 
 
 
  0 = Normal 
 
 
+1 = Slight pigment, keratoprecipitates, guttata 
 
 
+2 = Moderate pigment, keratoprecipitates, guttata 
 
 
+3 = Dense pigment, keratoprecipitates, guttata    
 
Edema 
    
0 = None, transparent and clear 
 
 
+1 = Mild, dull glassy appearance 
 
 
+2 = Moderate, dull glassy appearance of epithelium with large number of vacuoles 
 
+3 = Severe, epithelial bullae and/or stromal edema, localized or diffuse, with or without 
stromal striae.    
 
Anterior Chamber 
 
Cells 
 
 
  0 = No cells seen 
 
 
+1 = + cells 
 
 
+2 = ++ cells 
 
 
+3 = +++ cells 
 
 
+4 = ++++ cells, Hypopyon formation 
 
Flare 
 
 
  0 = No Tyndall effect 
+1 = Tyndall beam in the anterior chamber has a mild intensity 
 
+2 = Tyndall beam in the anterior chamber is of strong intensity 
+3 = Tyndall beam is very intense; the aqueous has a white, milky appearance 
 
 
Lens Pathology 
 
0 = Normal; no opacity in the lens 
1 = Abnormal; existing opacity in the lens; aphakic or pseudophakic eyes or other 
abnormal findings. 
 

Parion Sciences, Inc. 
 
P-321 Ophthalmic Solution 
Protocol P-321-201 Version 3.0 
CONFIDENTIAL 
Page 55 
 
APPENDIX V: FLUORESCEIN TEAR BREAK‐UP TIME (TBUT) 
Non-preserved fluorescein will be used to conduct this assessment.  When conducting all 
assessments room temperature and humidity should be relatively consistent throughout each visit 
and throughout the study. 
TBUT should be conducted as specified in Appendix I:  Schedule of Visits and Procedures. 
Fluorescein Tear Break-Up Time 
 Perform the examination with the slit lamp at 10X magnification and cobalt blue 
illumination. 
 Draw 5 L of 2% sodium fluorescein into the micropipette, allowing a drop to form. 
 Gently touch the drop at the tip of the delivery dropper to the lower palpebral conjunctiva 
of the right eye.   
 In order to thoroughly mix the fluorescein with the tear film, ask the subject to blink 
several times and move his/her eye around. 
 Using a stop watch, measure the time it takes for the appearance of the first dry spot after 
blinking. 
 Ask the subject to blink again and repeat the measurement of the time it takes for the 
appearance of the first dry spot after blinking.  Repeat this procedure once more for a 
total of three measurements.  
NOTE:  If this procedure is completed within two minutes, proceed to measure corneal staining 
in the same eye as described in Appendix VI without applying more fluorescein. 
 Repeat these steps for the left eye. 
 Using these three assessments calculate the mean time in seconds for each eye and record 
this time in the subject’s chart as well as the case report form. 
 
 
 

Parion Sciences, Inc. 
 
P-321 Ophthalmic Solution 
Protocol P-321-201 Version 3.0 
CONFIDENTIAL 
Page 56 
 
APPENDIX VI: FLUORESCEIN CORNEAL STAINING  
The cornea will be stained with non-preserved, 2% fluorescein as described by Lemp et al. 
(Lemp, 1995).  When conducting all assessments room temperature and humidity should be 
relatively consistent throughout each visit and throughout the study. 
Corneal Staining should be conducted as specified in Appendix I: Schedule of Visits and 
Procedures. 
Corneal Staining 
 Using a yellow barrier filter (Wratten or Tiffen #11 or #12) and the slit lamp with cobalt 
blue illumination, with a 3 mm slit width and 10X or 16X magnification. 
 Draw a 5 L drop of fluorescein in the right eye. 
 In order to thoroughly mix the fluorescein with the tear film, ask the subject to blink 
several times and move his/her eye around. 
 Wait two minutes. 
 Evaluate the cornea for staining referencing the diagram below.   
 Punctate staining is recorded using a standard grading system of 0-3 for each of the five 
areas shown below. 
 Repeat this procedure for the left eye. 
 

Parion Sciences, Inc. 
 
P-321 Ophthalmic Solution 
Protocol P-321-201 Version 3.0 
CONFIDENTIAL 
Page 57 
 
APPENDIX VII: LISSAMINE GREEN CONJUNCTIVAL STAINING 
The conjunctiva will be stained with non-preserved, 1% lissamine green as described by Lemp et 
al. (Lemp, 1995).  When conducting all assessments room temperature and humidity should be 
relatively consistent throughout each visit and throughout the study. 
Conjunctival Staining should be conducted as specified in Appendix I:  Schedule of Visits and 
Procedures. 
 Without flushing the eye from the previous assessment, instill a 20 l drop of lissamine 
green to the right eye using a micropipette, allowing a drop to form. 
 Gently touch the drop at the tip of the delivery dropper to the lower palpebral conjunctiva 
of the right eye.    
 In order to thoroughly coat the ocular surface with the lissamine, ask the subject to blink 
several times and move his/her eye around. 
 After 1 minute and before 4 minutes have elapsed, using white light of moderate 
intensity, grade the areas of the conjunctiva of the right eye with the 0-3 scale shown 
below. 
 Repeat this procedure for the left eye. 
 
 
 

Parion Sciences, Inc. 
 
P-321 Ophthalmic Solution 
Protocol P-321-201 Version 3.0 
CONFIDENTIAL 
Page 58 
 
APPENDIX VIII: INSTILLATION OF MEDICATION 
Study personnel will instill medication at Visit 2 (First Treatment Visit) and Visit 3 (Second 
Treatment Visit). 
Instilling the Medication 
 The study personnel will remove the study medication from the refrigerator at least 15 
minutes prior to planned administration. 
 The study personnel will record the kit number in the subject’s records and the Subject 
ID  number on the labels of the kit and vial pouches before proceeding with dosing the 
subject: 
 Confirm that the visit number on the pouch corresponds to the subject’s visit  
 Open the pouch  
 Instruct subject to slightly tilt his/her head back and look upward 
 The study personnel should gently squeeze the bottle allowing one drop to coat the ocular 
surface.  
 Repeat procedure for left eye using the same bottle. 
 The subject should gently close his or her eyes for a few seconds. 
 Use one pouch of assigned study medication for Visit 2 and one pouch for Visit 3.   
 The used bottle should be returned to its pouch and the pouch returned to its kit box. 
 After dose administration at Visit 2, return the kit containing one used, and one unused 
bottle to the refrigerator. 
 After dosing at Visit 3, return the bottle into the pouch and place the pouch in the kit box.  
At this time, the kit containing two used bottles can be stored at room temperature before 
returning to the sponsor for disposal. 

Parion Sciences, Inc. 
 
P-321 Ophthalmic Solution 
Protocol P-321-201 Version 3.0 
CONFIDENTIAL 
Page 59 
 
APPENDIX IX: DRY EYE SYMPTOM QUESTIONNAIRES 
The following subject reported outcomes measurements will be collected as noted in Appendix I: 
 SANDE 
 SPEED 
 OSDI 
 
SYMPTOM ASSESSMENT IN DRY EYE QUESTIONNAIRE (SANDE) (Schaumberg, 
2007) 
Part 1 (administer at Visits 1, 2, and 3) 
 
PLEASE COMPLETE THE FOLLOWING QUESTIONS REGARDING THE 
FREQUENCY AND SEVERITY OF YOUR DRY EYE SYMPTOMS 
1.   Frequency of symptoms:
Please place an ‘I’ on the line to indicate how often, on average, your eyes 
felt dry and/or irritated in the past day:
Rarely 
All the time
2.   Severity of symptoms: 
Please place an ‘I’ on the line to indicate how severe, on average, you feel your 
symptoms of dryness and /or irritation were in the past day:
Very Mild 
Very Severe

Parion Sciences, Inc. 
 
P-321 Ophthalmic Solution 
Protocol P-321-201 Version 3.0 
CONFIDENTIAL 
Page 60 
 
Part 2 (administer at only Visits 2 and 3) 
 
 
 
 
PLEASE COMPLETE THE FOLLOWING QUESTIONS REGARDING THE 
FREQUENCY AND SEVERITY OF YOUR DRY EYE SYMPTOMS 
1.   Frequency of symptoms:
Please place an ‘I’ on the line to indicate how often, on average, your eyes feel 
dry or irritated now compared to at your last visit
2.   Severity of symptoms: 
Please place an ‘I’ on the line to indicate how severe, on average, you feel 
your symptoms of dryness and irritation are now compared to at your last visit
Last Visit
Much less 
Frequent 
Much more 
frequent
Last Visit
Much more 
severe 
Much less 
severe 

Parion Sciences, Inc. 
 
P-321 Ophthalmic Solution 
Protocol P-321-201 Version 3.0 
CONFIDENTIAL 
Page 61 
 
SPEED QUESTIONNAIRE (Ngo, 2013 and Korb, 2005)   
 
 
1. Report the type of SYMPTOMS you experience and when they occur: 
 
 
At this Visit 
Within the 
past 72 hours 
Within past 3 
months
Symptoms 
Yes
No
Yes
No 
Yes 
No
Dryness 
 
Grittiness or Scratchiness 
 
Soreness or Irritation 
 
Burning or Watering
 
Fatigue 
 
 
 
 
2. Report the FREQUENCY of your symptoms using the rating list below: 
 
Symptoms 
0
1
2 
3
Dryness 
 
Grittiness or Scratchiness 
 
Soreness or Irritation 
 
Burning or Watering
 
Fatigue 
 
 
0 = Never 
1 = Sometimes 
2 = Often 
3 = Constant 
 
 
 
3. Report the FREQUENCY of your symptoms using the rating list below: 
Symptoms 
0
1
2
3 
4
Dryness 
 
 
Grittiness or Scratchiness 
 
 
Soreness or Irritation 
 
 
Burning or Watering
 
 
Fatigue 
 
 
 
0 = No problems 
1 =Tolerable; not perfect, but not uncomfortable 
2 = Uncomfortable; irritating, but does not interfere with my day 
3 = Bothersome; irritating and interferes with my day 
4 = Intolerable; unable to perform my daily tasks 
 
 
 

Parion Sciences, Inc. 
 
P-321 Ophthalmic Solution 
Protocol P-321-201 Version 3.0 
CONFIDENTIAL 
Page 62 
 
OCULAR SYMPTOM DISEASE INDEX (Schiffman, 2000) 
Ocular Surface Disease Index (OSDI) Questionnaire 
Please answer the questions by checking the box that best represents your answer 
 
HAVE YOU EXPERIENCED ANY OF THE FOLLOWING DURING THE LAST WEEK: 
 
 
HAVE PROBLEMS WITH YOUR EYES LIMITED YOU IN PERFORMING ANY OF THE 
FOLLOWING DURING THE LAST WEEK: 
 
 
HAVE YOUR EYES FELT UNCOMFORTABLE IN ANY OF THE FOLLOWING 
SITUATIONS DURING THE LAST WEEK: 
 
 
All of the 
time
Most of the 
time
Half of the 
time
Some of 
the time 
None of the 
time
1. Eyes that are sensitive to light? 
4 
3 
2 
1 
0 
2. Eyes that feel gritty? 
4 
3 
2 
1 
0 
3. Painful or sore eyes? 
4 
3 
2 
1 
0 
4. Blurred vision? 
4 
3 
2 
1 
0 
5. Poor vision? 
4 
3 
2 
1 
0 
 
All of the 
time 
Most of 
the time 
Half of the 
time 
Some of 
the time 
None of 
the time 
N/A 
6. Reading? 
4 
3 
2 
1 
0 
N/A 
7. Driving at night? 
4 
3 
2 
1 
0 
N/A 
8. Working with a computer 
or bank machine (ATM)? 
4 
3 
2 
1 
0 
N/A 
9. Watching TV? 
4 
3 
2 
1 
0 
N/A 
 
All of the 
time 
Most of 
the time 
Half of the 
time 
Some of 
the time 
None of 
the time 
N/A 
10. Windy conditions? 
4 
3 
2 
1 
0 
N/A 
11. Places or areas with low 
humidity (very dry)? 
4 
3 
2 
1 
0 
N/A 
12. Areas that are air 
conditioned? 
4 
3 
2 
1 
0 
N/A 
 

Parion Sciences, Inc. 
 
P-321 Ophthalmic Solution 
Protocol P-321-201 Version 3.0 
CONFIDENTIAL 
Page 63 
 
APPENDIX X: TEAR VOLUME ASSESSMENTS: 
Three assessments of tear volume are used in the study:  Ultra high resolution optical coherence 
tomography (UHR-OCT) measuring tear volume and tear meniscus height, lower tear meniscus 
height measured by Keratograph 5M, and Schirmer’s test.  The sections below briefly describe 
procedures for each. 
Tear meniscus imaged Ultra High Resolution Optical Coherence Tomography (UHR-OCT) 
The custom-built ultra-high resolution (3 microns axial resolution) spectral domain OCT can 
image a full 15mm width scan at up to 48 images per second.  The tear meniscus around the 
upper and lower eyelids can be  imaged and measured with the OCT, a unique capability. The 
OCT images obtained with this system show the tear menisci around both eyelids (Figure 1).   
Figure 1: Tear menisci imaged with UHR-OCT 
 
 
Figure 1: Upper and lower tear menisci imaged with ultra-high resolution optical coherence 
tomography. A custom built 3 µm resolution ultra-high resolution optical coherence tomography was 
used to image both upper and lower tear menisci. The boundaries of the tear meniscus were clearly 
visualized. The bars denote to 500 µm. 
 

Parion Sciences, Inc. 
 
P-321 Ophthalmic Solution 
Protocol P-321-201 Version 3.0 
CONFIDENTIAL 
Page 64 
 
OCT imaging 
Each subject will be asked to sit in front of a slit-lamp, on which an OCT probe is mounted. 
An internal fixation target will be provided to facilitate the subject to keep the eye on a 
straight forward direction. The central OCT beam as indicated as a green line on the OCT 
monitor is set to be on the corneal apex (Figure 1), which a specular reflection is normally 
detected. Immediately after eye opening, corneal images with the OCT will be recorded. A 
vertical OCT scan with a scan width of up to 13 mm will be used so that the entire cornea and 
both upper and lower eyelids will be imaged. The measurements will be acquired in one scan 
with 3 images in the same fashion. The first image will be processed for the measurement. If 
the first image is not good, the second or third image will be used.  The measurements of the 
image analyzed  will be collected in the CRF. 
 
Image process to yield the results.  
All meniscus variables of upper (A) and lower (B) tear menisci are measured with a custom 
software program with operator inputs (TDanalyer, ver. 1.0) (Figure 2). Touch points (pink 
dots) between two elements (eyelid, cornea, and tear meniscus) and a middle point (green dot) 
of the front edge of the tear meniscus are marked. After that, the software process the image, 
to yield the results. The three-point method is used to fit a circle to yield tear the meniscus 
height and area. Tear meniscus height and area of both upper and lower tear menisci will be 
used. In addition, the eye lid length will be photographied and measured to calculate tear 
meniscus volumes in both upper and lower tear menisci. 

Parion Sciences, Inc. 
 
P-321 Ophthalmic Solution 
Protocol P-321-201 Version 3.0 
CONFIDENTIAL 
Page 65 
 
Figure 2:  Measuring menisci variables with UHR-OCT 
 
 
 
Tear Meniscus Height measured by Keratograph 5M  
Evaluation of tear film volume will be assessed via tear meniscus height measurements using the 
Keratograph 5M.  High resolution images of the lower tear meniscus from both eyes are obtained 
under infrared light as indicated in the Keratograph 5M user manual.  Using integrated 
magnification and measurement tools, the tear meniscus height of the lower lid margin are 
estimated.  Detailed description of the operation of the instrument and software is described in 
Keratograph 5M user manual provided by Oculus.   
Instructions: 
 
 Turn on the computer.  After turning on the computer the operating system loads the 
Keratograph 5M program.  If necessary click on the Keratograph 5M icon  
. 
 Turn on the Keratograph 5M 
 
 
 Enter Subject information in the Patient Data Management Page. 

Parion Sciences, Inc. 
 
P-321 Ophthalmic Solution 
Protocol P-321-201 Version 3.0 
CONFIDENTIAL 
Page 66 
 
 
 
 In the "Patient" box on the top left, select [New]. The following screen will appear: 
 
 Enter the patient’s last name, first name, and date of birth and click [Save]. 
 Click [Keratograph] in the “Functions” box to transition from the Patient Data 
Management  to the Keratograph Overview. 
 In the “Examination” menu click [New] and the following screen will appear: 

Parion Sciences, Inc. 
 
P-321 Ophthalmic Solution 
Protocol P-321-201 Version 3.0 
CONFIDENTIAL 
Page 67 
 
 
 
 Activate the [Tear Meniscus Height] function button on the “TF Scan” Box on the left. 
 In the illumination box on the right-hand side of the screen, select [IR] lighting. 
 If necessary, adjust the camera for optimal focusing on the tear meniscus as seen on the 
example in the image below (i.e. at approximately the 6:00 position). 
 
 
 
 After a blink, focus the camera on the central part of the tear meniscus of the lower eyelid 
as indicated in the red circle above. 
 Click on the [Image] button to record the image. 
 The magnification changer and camera settings located at the right-hand side of the 
screen are set to optimal settings. No adjustments should be needed. 
 Confirm that the image is in focus at the central area of the eyelid (below the center of the 
iris), if not, repeat the image. 
Note: This procedure is repeated to obtain 3 quality images per eye 

Parion Sciences, Inc. 
 
P-321 Ophthalmic Solution 
Protocol P-321-201 Version 3.0 
CONFIDENTIAL 
Page 68 
 
 
Repeat the procedure for the other eye. 
 Select [Close] after the three images have been taken.  
 
Measurement of the Tear Meniscus Height (TMH) 
 
 From the three images from each eye obtained above, the tear meniscus height is 
measured with a software-integrated ruler.  The evaluations can be made at different 
magnification levels.  Select a higher magnification if necessary. 
 
If the TMH is not measured at the time the image is captured, select the patient and the 
assessment from the Patient Data Management Page by double clicking on the assessment on the 
right of the screen for the selected patient on the left. 
 
The following screen will be displayed: 
 
 
 
 
 Measure the tear meniscus height with the ruler option.  
 Select the following button  
from the left of the screen with the left mouse button. 

Parion Sciences, Inc. 
 
P-321 Ophthalmic Solution 
Protocol P-321-201 Version 3.0 
CONFIDENTIAL 
Page 69 
 
 The button will be highlighted in blue. 
 Click once with the left mouse button on the edge of the lower eyelid to position one of 
the edges of the measurement. 
 Move the cursor vertically from this edge to the upper tear meniscus margin and 
 click the left mouse button again. 
 
 The measurement length will appear on the image (in millimeters) as indicated below: 
 
 
 
 The system will display the real measurement regardless of the magnification used for the 
measurement. 
 If the selection of the tear meniscus height is not accurate, delete the measurement and 
repeat the procedure. 
 Record the distance of the TMH. 
 Repeat the procedure for the all three images of each eye. 
 Click [Close] and the image with the measurement will be saved in the patient file.  
 
 
Schirmer’s Test 
Schirmer’s strips will be supplied to the clinical site.  When conducting assessments room 
temperature and humidity should be relatively consistent throughout each visit and throughout 
the study.  
Schirmer’s Test without Anesthesia 
 While still in the plastic sheath, fold the notched end of the Schirmer at the apex of 
“v”.  Additionally, fold a partial second fold at the halfway point of the strip so that 
the strip does not lie directly in the subject’s line of sight. 
 Remove the right eye strip from the sheath. 

Parion Sciences, Inc. 
 
P-321 Ophthalmic Solution 
Protocol P-321-201 Version 3.0 
CONFIDENTIAL 
Page 70 
 
 Ask the subject to look up and gently draw the right lower lid in a downward and 
temporal direction.  
 Place the rounded end of the strip toward the temporal one-third of the lower eyelid.  
 Repeat this procedure in the left eye. 
 Darken slightly the room, and instruct the subject to relax and look at an object in the 
room while blinking normally or have subjects gently close eyes. 
 Strips are removed after five minutes. 
 After removing the strips, with a sharp pencil draw a horizontal line across the 
leading edge of moisture and a second horizontal line across the lowest point of 
moisture. 
 Using a ruler and/or the millimeters recorded on the strips, measure a point halfway 
between the two lines and record this as the amount of wetting. 
 
 
 

Parion Sciences, Inc. 
 
P-321 Ophthalmic Solution 
Protocol P-321-201 Version 3.0 
CONFIDENTIAL 
Page 71 
 
APPENDIX XI: POST INSTILLATION QUESTIONNAIRES 
DROP INSTILLATION COMFORT MEASUREMENT  
Evaluation of the comfort of the eye drop will be conducted approximately 5 minutes following 
initial dosing at Visits 2 and 3 for subjects.   
 
The subject will respond to the following question upon instillation of the study medication: 
 
“Did you experience any discomfort when the drop was placed in your eyes?" 
 
The response to the question will be graded using the following scale: 
 
1 = None 
2 – Mild 
3 = Moderate 
4 = Severe 
 
Note:  The drop instillation comfort response is NOT considered an AE regardless of severity 
unless it results in discontinuation of the subject from the study.  
If the subject experiences discomfort symptoms within 15 minutes after the drop instillation 
comfort assessment is completed, then the site should record these symptoms as AEs. 
 
POST INSTILLATION DRY EYE SYMPTOMS ASSESSMENT 
 
The subject will respond to the following question immediately prior to the 2 hour post dose tear 
volume measurements at Visits 2 and 3: 
Did you experience any change in your dry eye symptoms after instillation of the eye drop? 
 
-1 = Worsening 
 0 = No change 
+1 = Improvement 
 
 
 

Parion Sciences, Inc. 
 
P-321 Ophthalmic Solution 
Protocol P-321-201 Version 3.0 
CONFIDENTIAL 
Page 72 
 
APPENDIX XII:  MEIBOGRAPHY ASSESSMENT 
Meibomian gland evaluation will be conducted in both eyes using the clinical grading scores 
indicated below for plugging, character of secretions, and ease of expression (modified from 
Foulks, 2003). In addition, meibomian gland loss as determined by non-contact Meibography as 
described by Arita (Arita, 2008). 
 
Plugging  (nasal third of lower lid) 
0 no glands plugged 
1 1-2 glands plugged 
2 3- 4 glands plugged 
3 5 glands plugged 
 
Character of secretion 
0 clear 
1 turbid 
2 turbid with clumps or granular 
3 thick or paste-like 
 
Ease of expression 
0 easily expressed 
1 light pressure 
2 moderate pressure 
3 heavy pressure 
 
Noncontact meiboscopy (Arita et al2): Scored for LL and UL0  
no gland loss 
1 gland loss 33% of total area  
2 gland loss, 33%–67% of total area 
3 gland loss  >67% of total area 
 
Scores of upper and lower lid summed  
Scale range: 0 – 6 
 

Parion Sciences, Inc. 
 
P-321 Ophthalmic Solution 
Protocol P-321-201 Version 3.0 
CONFIDENTIAL 
Page 73 
 
APPENDIX XIII:  SERUM CHEMISTRY AND HEMATOLOGY ANALYTES 
 
Serum Chemistry Panel includes the following analytes: 
 
 Sodium 
 Potassium 
 BUN/Urea 
 Creatinine 
 Glucose 
 Calcium 
 Total Protein 
 Albumin 
 AST(SGOT) 
 ALT(SGPT) 
 Alkaline Phosphatase 
 
Hematology Panel includes: 
 WBC 
 Haemoglobin 
 Haematocrit 
 RBC 
 MCV 
 MCH 
 MCHC 
 RDW 
 Platelet Count 
 Differential (% and absolute) 
Serum pregnancy test in women of child bearing potential. 
 

Parion Sciences, Inc. 
 
P-321 Ophthalmic Solution 
Protocol P-321-201 Version 3.0 
CONFIDENTIAL 
Page 74 
 
APPENDIX XIV:  DOSE SELECTION FOR PHASE 2 AND DATA REVIEW 
DURING STUDY 
The decision on dosage strength to be used in Phase 2 will be the responsibility of the Data 
Review Group constituted by the Prinicipal Investigator (or designee), Medical Monitor and 
representative(s) of Parion Sciences not involved in the conduct of the study. The Data Review 
Group may request the participation of an independent statistician to assist in the assessment of 
the safety of the study medication and the dosage strength selection for Phase 2.  
The Data Review Group will review unmasked data in order to make a decision on the dose to be 
administered in Phase 2.  The Data Review Group will convene when approximately 8 subjects 
have completed the study,or earlier if needed.  The trial will continue enrolling during the time 
the review by the Data Review Group is being prepared and being held.  The Data Review Group 
will review the following to assist in making their recommendation for dose selection in Phase 2: 
 Adverse events 
 Biomicroscopy and external eye examination  
 Drop instillation comfort assessments 
 Abnormal alert laboratory results 
 Tear volume via OCT 
 Tear volume via Keratograph 5M 
Recommendations by the Data Review Group may include: 
1) The dose level may be increased to 0.05% in Phase 2 in the event that: 
a) No cases of serious, suspected related, unexpected events are noted in Phase 1 AND 
b) No cases of serious ocular safety events are noted in Phase 1 
c) Lack of evidence that P-321 produced an increase in tear volume based on OCT 
and/or Keratograph 5M, or evidence that additional improvements in tear volume (or 
the duration of effect) may be obtained with a higher dose 
2) The dose level may be decreased to 0.01% in Phase 2 in the event that: 
a) There is evidence of a significant increase in tear volume and duration of effect in 
Phase 1 based on OCT and/or Keratograph 5M 
b) No cases of serious, suspected related, unexpected events are noted in Phase 1  
c) No cases of serious ocular safety events are noted in Phase 1 
3) The dose level may remain at 0.017% (the same as in Phase 1) in the event that: 
a) There is no compelling data to either increase or decrease the strength for Phase 2.  
b) No cases of serious, suspected related, unexpected events are noted in Phase 1  
c) No cases of serious ocular safety events are noted in Phase 1 
4) Discontinue the study. 
5) Amend the protocol 
 
The Data Review Group will make a recommendation to the Parion Sciences following the 
meeting and review of data and via a written memo.  If additional data is required, the Data 
Review Group may request additional data for their review.  If the Data Review Group requires 

Parion Sciences, Inc. 
 
P-321 Ophthalmic Solution 
Protocol P-321-201 Version 3.0 
CONFIDENTIAL 
Page 75 
 
additional unmasked data in order to safeguard the safety of the study subjects, this data will be 
provided.   
 
The Data Review Group will make every effort to arrive to a decision by consensus. 
Upon receipt fo theData Review Group recommendation, Parion representatives will make a 
decision that is consistent with the safeguard of the interests of study subjects. 
Additional Data Reviews 
Additional unmasked reviews of subject data may occur throughout the study to make 
recommendations on further dose adjustments and for planning purposes.  These reviews will 
follow the procedures outlined above. 
Unmasking the study 
In the event of a medical emergency where breaking the mask of the study is being considered, 
the Principal Investigator may request unmasking by contacting the Medical Monitor and the 
Parion Representative.  If the Medical Monitor and Parion Representative grant the unmasking, 
the unmasking will be clearly documented with the date the code is broken indicated, who 
authorized the unmasking and other details regarding the unmasking.  A copy of this unmasking 
memo will be  provided to the sponsor for their records and a copy should remain in the source. 
 

PARI ON 
SCIE N CES 
Clinical Protocol P-321-201 
Project Number 
Compound Number/ Name 
Protocol Number 
Protocol Title 
Sponsor 
Medical Monitor 
Authors 
Issue Date 
Sponsor Signature and Date 
P-1003-1101 
P-321 Ophthalmic Solution 
P-321-201 
Randomized, Crossover Study of the 
Pharmacodynamic Activity of P-321 Ophthalmic 
Solution Compared to Placebo in Subjects with Dry 
Eye Disease Characterized by Low Tear Volume 
Parion Sciences, Inc. 
2800 Meridian Parkway 
Suite 195 
Durham, NC 27713 
Gary N. Foulks, M.D. 
3103 Joy Place 
Wilmington, NC 28409 
Jose L. Boyer, Ph.D. 
Anita Woodring, MS, RAC 
Version 2.0: 22 Apri12016 
Original Version 1.0: OS February 2016 
The information in this document is confidential and is provided to you as an investigator or consultant for review 
by you, your staff, and the applicable Institutional Review Board/Independent Ethics Committee. Your acceptance 
of this document constitutes agreement that you will not disclose the information contained herein to others without 
written authorization from Parion Sciences. 

Parion Sciences, Inc. 
Protocol P-321-201 Version 2.0 
Project Number 
Compound Number/ Name 
Protocol Number 
Protocol Title 
Sponsor 
Issue Date 
PARION SCIENCES, INC. 
Clinical Protocol P-321-201 
Investigator Signature Page 
P-1003-1101 
P-321 Ophthalmic Solution 
P-321-201 
P-321 Ophthalmic Solution 
Randomized, Crossover Study of the Pharmacodynamic 
Activity of P-321 Ophthalmic Solution Compared to 
Placebo in Subjects with Dry Eye Disease Characterized 
by Low Tear Volume 
Parion Sciences, Inc. 
2800 Meridian Parkway 
Suite 195 
Durham, NC 27713 
Version 2.0: 22 April 2016 
Original Version 1.0: 05 February 2016 
I have reviewed and understand this protocol and all amendments associated with it. I will 
administer the protocol in accordance with ICH, FDA, and local regulations and 
guidelines. I will keep the information provided to me within this protocol and by Parion 
Sciences, Inc. staff, their representatives, and designees confidential. 
Investigator Name (printed or typed): 
0) 
cq 
\oate 
CONFIDENTIAL 
Page 2 

Parion Sciences, Inc. 
 
P-321 Ophthalmic Solution 
Protocol P-321-201 Version 2.0 
CONFIDENTIAL 
Page 3 
 
1 PROTOCOL SYNOPSIS 
Name of Sponsor: 
Parion Sciences, Inc. 
Study Medication: 
0.017% P-321 Ophthalmic Solution and based on 
data review potentially 0.01%, 0.017% or 0.05% 
Ophthalmic Solution 
Protocol Number: 
P-321-201 
Phase: 
2a 
Indication: 
Treatment of dry eye disease 
Title of the Study: 
Randomized, Crossover Study of the Pharmacodynamic Activity of P-321 Ophthalmic Solution Compared to 
Placebo in Subjects with Dry Eye Disease Characterized by Low Tear Volume  
Investigators: 
Principal Investigator: Victor Perez, MD; Sub-Investigator:  Jianhua Wang, MD, PhD 
Study Center: 
Ocular Surface Center, Bascom Palmer Eye Institute, University of Miami Health System 
Study period (FPFV – LPLV): 
Approximately 6 months 
 
Objectives: 
Primary objective 
• 
The primary objective of this trial is to assess changes in tear volume by the non-invasive techniques Ultra 
High Resolution Optical Coherence Tomography (UHR-OCT) following the administration of P-321 
Ophthalmic Solution or Placebo in subjects with tear deficient dry eye disease.   
Secondary objective 
• 
assess changes in lower tear meniscus height by Keratograph 5M  
• 
compare lower tear meniscus height measurements between UHR-OCT and Keratograph 5M 
• 
assess the duration of action of P-321 Ophthalmic Solution 
• 
compare the pharmacodynamic activity of different strengths of P-321 in subjects with tear-deficient dry eye 
• 
monitor safety and tolerability of P-321 Ophthalmic Solution 
 

Parion Sciences, Inc. 
 
P-321 Ophthalmic Solution 
Protocol P-321-201 Version 2.0 
CONFIDENTIAL 
Page 4 
 
Study Design: 
 
 
 
This is a single-center, randomized, cross-over placebo controlled study to evaluate the changes in tear volume by 
P-321 Ophthalmic Solution or Placebo.  The study will enroll  subjects with tear deficient dry eye disease to 
receive sequentially two treatments: P-321 Ophthalmic Solution (Treatment A) and Placebo (Treatment B).  
Subjects will be randomly assigned to receive treatment sequence AB or BA.  The study will consist of two 
Phases: In each Phase, subjects will be treated with a different strength of P-321 Ophthalmic Solution under the 
same study design.Phase 1 will evaluate 0.017% P-321 Ophthalmic Solution and Phase 2 will evaluate either 
0.05%, additional subjects at 0.017% or 0.01% P-321 Ophthalmic Solution as determined by the Data Review 
Group.  
Approximately twenty-four eligible subjects will complete the study with approximately 8 subjects participating 
in Phase 1 and the remainder of the 24 subjects participating in the phase 2.  Decisions on the dose to be used to 
phase 2 will be made following unmasked data review from subjects in Phase 1.  The Principal Investigator, 
Medical Monitor and Parion Sciences representatives not involved in the day to day conduct of the study will 
review unmasked data as part of the Data Review Group, which will decide the dose to be used in Phase2 2 of the 
study.  The treatment assignments will remain masked to subjects in the study, the clinical monitor, and other site 
and Parion Sciences personnel involved in the conduct of the study and not involved in the Data Review 
Group.  Additional unmasked reviews of subject data may occur during the study to make recommendations on 
further dose adjustments and for planning purposes.  These reviews will follow the procedures outlined above. 
The study will consist of three study visits: a Screening Visit (Visit 1), and two treatment visits (Visit 2 and Visit 
3).  The duration of the study may be up to 23 days. The pharmacodynamic measures of tear volume will be 
assessed at each visit by two non-invasive methods, UHR-OCT and Keratograph 5M.  Dry eye symptom 
questionnaires will be applied at each visit prior to other assessments. At Visit 1, tear volume will be assessed at 
three timepoints over 1 hour with measurements taken approximately 30 minutes apart. Tear volume 
measurements will be followed by other tests that involve contact with the ocular surface (tear osmolarity, tear 
break up time (TBUT), meibography and meibomian gland assessments, corneal and conjunctival staining, 
Schirmer’s test).  At Visits 2 and 3, tear volume will be assessed serially over 6 hours at pre-dose, and post dose 
at 15 minutes, 30 minutes, 1 hour, 2 hours, 4 hours, and 6 hours.  Safety assessments include adverse events 

Parion Sciences, Inc. 
 
P-321 Ophthalmic Solution 
Protocol P-321-201 Version 2.0 
CONFIDENTIAL 
Page 5 
 
(AEs), biomicroscopy and external eye examination and an assessment of comfort after taking the medication in-
clinic. 
Subject Population:  
This study will complete approximately 24 subjects with dry eye disease with documented low tear volume as 
measured by non-invasive UHR-OCT.   Approximately 8 will participate in Phase 1 and the remainder of the 24 
subjects participate in the Phase 2.   
Male and female subjects 18-80 years of age who provide written informed consent and have a history of dry eye 
signs and symptoms of mild to moderate severity supported by a previous clinical diagnosis may enter the study.  
Subjects must have decreased lower tear meniscus height (LTMH) in both eyes assessed by UHR-OCT of not 
more than 175µm, Schirmer’s test >1mm and <10mm, normal lid anatomy, have been stable on their current 
medication regimen for at least 28 days and remain on this regimen for the duration of the study.  Additionally, 
while in the clinic on visit days and for at least 6 hours after dosing with study medication, subjects must be able 
to withhold ocular topical medications (including artificial tears, topical steroids, and Restasis) and if contact lens 
wearers, must be able to withhold wearing contact lenses.  To qualify for the study, subjects must not have an 
identifiable or suspected dry eye caused by pharmacologic, post-traumatic, or post-surgical condition; have 
undergone refractive eye surgery (e.g., LASIK) in either eye during the past 12 months; uncomplicated cataract 
surgery in either eye during the past 3 months; previous eyelid surgery in either eye (e.g., blepharoplasty, ptosis 
repair) and or botulinum toxin (Botox™ or equivalent) injection in the periocular area within 3 months prior to 
enrollment.  The subject must not have lid irregularities or deformities, or severe corneal surface irregularities, a 
history of glaucoma or intraocular pressure > 25 mmHg at the Screening Visit (Visit 1) or a history of elevated 
IOP within the past year, a systemic, multi-organ disease requiring active medical or surgical treatment. 
Additionally, subjects with any significant illness that, in the opinion of the Principal Investigator (PI), could 
interfere with the study parameters will also be excluded. Other exclusions include:  subjects who have punctal 
plugs, punctal occlusion, or history of nasolacrimal duct obstruction, Stevens-Johnson syndrome, ocular 
cicatricial pemphigoid, or other ocular cicatrizing disorders, past or present exposure keratopathy, neurotrophic 
keratopathy, lagophthalmos, or trichiasis.  Use of oral and nasal antihistamines, oral or topical secretagogues such 
as pilocarpine and Evoxac, or Topical anti-glaucoma medications during the study and for 14 days prior to Visit 1 
is prohibited. 
Number of Subjects: 
Approximately 24 subjects with tear deficient dry eye 
disease  
Number of Centers: 
1 
Test Product and Doses: 
P-321 Ophthalmic Solution and Placebo with dosage 
strengths of P-321 Opthalmic Solution of 0.017% in 
Phase 1 and 0.05%, 0.01% or 0.017% in Phase 2 
Route of Administration: 
Ocular instillation, one drop per eye  
Duration of Treatment: 
Subjects will receive a single dose of P-321 Ophthalmic Solution or Placebo in both eyes in random treatment 
order, one treatment on Visit 2 and the other treatment on Visit 3.    
Criteria for Evaluation: 
Background characteristics will be evaluated to better characterize subjects at entry.  These parameters include: 
demographics, visual acuity, intraocular pressure, dry eye symptoms upon entry, medical history, concomitant 
medication use, tear osmolarity, tear break up time, meibography and meibomian gland assessment, corneal and 
conjunctival staining, and Schirmer. 
 
Pharmacodynamics 
Detailed measurements of tear volume before and after dose administration will be obtained using non-invasive 
methods, UHR-OCT (tear volume and tear meniscus height) and Keratograph 5M (tear meniscus height) imaging 
of the ocular surface. 
 

Parion Sciences, Inc. 
 
P-321 Ophthalmic Solution 
Protocol P-321-201 Version 2.0 
CONFIDENTIAL 
Page 6 
 
Safety  
Ocular safety measures include: Adverse events (AEs), biomicroscopy and external eye examination and an 
assessment of comfort after taking the medication.  
Statistical Analysis: 
Sample Size 
A sample size of approximately 24 subjects is proposed for this study. For a two-period, two-treatment, two-
sequence crossover design (2x2x2), this study size when all subjects treated with P-321 are analyzed, will provide 
98% power to detect a LTMH difference vs placebo of 60 μm at 1 hour or a power of 99% if the average increase 
in LTMH over the six hours is 60 μm (assuming within-subject SD of 71). In this study it is expected that the study 
medication will reach its peak effect at 1 hour post dose and that the effect diminishes at 4 and 6 hours post dose 
(to values still above pre-dose values).  
 
Disposition, Demographic, and Background Characteristics 
Subject disposition, demographic, and background characteristics will be summarized using descriptive statistics.  
Baseline homogeneity with respect to demographic and background characteristics will be assessed via an overall 
F-test from analysis of variance (ANOVA).  For categorical variables, treatment differences will be assessed using 
the chi-square test or Cochran Mantel Haenszel (CMH) test with modified ridit scores for ordered categorical 
variables. 
 
Pharmacodynamic Analysis 
Treatment group differences for tear volume assessments will be conducted via comparisons of tear meniscus 
height, and if applicable, tear meniscus volume (TMV).  These parameters will be compared between each dose of 
P-321 Ophthalmic Solution and Placebo using a t-test for each eye separately and for the within-subject average.  
Analaysis of covariance (ANCOVA) models will be used to adjust for the baseline TMH and TMV for each eye 
separately and for the average of the two eyes.  Generalized estimation equations (GEE) will also be used to 
account for the correlation between eyes.  For the GEE analysis, an exchangeable correlation matrix will be 
assumed.   
 
Safety 
All safety analyses will be included for all subjects who were randomized and received at least one dose of study 
medication.   
 
The incidence of AEs will be tabulated by treatment group, by treatment sequence, by severity, and by relationship 
to study medication.   
 
 

Parion Sciences, Inc. 
 
P-321 Ophthalmic Solution 
Protocol P-321-201 Version 2.0 
CONFIDENTIAL 
Page 7 
 
TABLE OF CONTENTS 
1 
PROTOCOL SYNOPSIS .............................................................................. 3 
2 
BACKGROUND INFORMATION ........................................................... 12 
2.1 
Description of Study Medication ...................................................................................... 12 
2.2 
Non-Clinical Studies for P-321 Ophthalmic Solution ...................................................... 13 
2.2.1  Pharmacology ....................................................................................................................13 
2.2.2  Absorption, Distribution, Metabolism, and Excretion .......................................................14 
2.2.3  Toxicology .........................................................................................................................15 
2.3 
Clinical Experience with P-321 Ophthalmic Solution ...................................................... 16 
2.4 
Justification for Route of Administration and Dose Selection ......................................... 16 
2.5 
GCP Compliance .............................................................................................................. 16 
2.6 
Population to be Studied ................................................................................................... 17 
3 
TRIAL OBJECTIVES AND PURPOSE ................................................... 18 
4 
INVESTIGATIONAL PLAN ..................................................................... 19 
4.1 
Overall Study Design ........................................................................................................ 19 
4.2 
Endpoints .......................................................................................................................... 20 
4.2.1  Primary Endpoint ...............................................................................................................20 
4.2.2  Secondary Endpoints .........................................................................................................20 
4.2.3  Safety and Tolerability Endpoints .....................................................................................21 
4.3 
Duration of Participation................................................................................................... 21 
5 
SELECTION AND WITHDRAWAL OF SUBJECTS ............................ 22 
5.1 
Subject Inclusion Criteria ................................................................................................. 22 
5.2 
Subject Exclusion Criteria ................................................................................................ 22 
5.3 
Randomization Criteria ..................................................................................................... 23 
5.4 
Subject Withdrawal Criteria and Stopping Rules ............................................................. 24 
6 
PROCEDURES ............................................................................................ 25 
6.1 
Visit 1: Screening (3 to 9 days prior to Visit 2 – Randomization) ................................... 25 
6.2 
Visit 2:  First Treatment Visit (3 -9 days after Visit 1) ..................................................... 26 
6.3 
Visit 3:  Second Treatment Visit (7-14 days after Visit 2) ............................................... 26 
6.4 
Early Termination Visit .................................................................................................... 27 
6.5 
Selecting Dosage Strength in Phase 2 ............................................................................... 28 
6.6 
Potential Toxicity Management ........................................................................................ 28 

Parion Sciences, Inc. 
 
P-321 Ophthalmic Solution 
Protocol P-321-201 Version 2.0 
CONFIDENTIAL 
Page 8 
 
6.7 
Collection of Data ............................................................................................................. 29 
7 
TREATMENT OF SUBJECTS .................................................................. 30 
7.1 
Treatment Administration ................................................................................................. 30 
7.2 
Trial Treatments ................................................................................................................ 30 
7.3 
Methods to Minimize Bias ................................................................................................ 30 
7.4 
Concomitant Medications ................................................................................................. 31 
7.4.1  Medications Permitted .......................................................................................................31 
7.4.2  Medications Not Permitted ................................................................................................31 
7.5 
Treatment Compliance ...................................................................................................... 32 
7.6 
Drug Accountability.......................................................................................................... 32 
7.7 
Maintenance of Randomization and Procedure for Breaking the Code ........................... 32 
8 
STATISTICS ................................................................................................ 34 
8.1 
Statistical Methods ............................................................................................................ 34 
8.1.1  Subject Disposition, Demographic and Background Characteristics ................................34 
8.1.2  Pharmacodynamic parameters ...........................................................................................34 
8.1.3  Analysis of Efficacy ...........................................................................................................34 
8.1.4  Analysis of Safety ..............................................................................................................34 
8.1.5  Interim Reviews of Data ....................................................................................................35 
8.2 
Sample Size Estimation .................................................................................................... 35 
8.3 
Level of Significance ........................................................................................................ 35 
8.4 
Criteria for Termination of an Individual Subject ............................................................ 35 
8.5 
Criteria for Termination of the Trial ................................................................................. 35 
8.6 
Procedure for Accounting for Missing, Unused, or Spurious Data .................................. 36 
8.7 
Procedure for Reporting Deviations from the Statistical Plan .......................................... 36 
8.8 
Subjects to be Included in the Analysis ............................................................................ 36 
9 
ASSESSMENT OF PHARMACODYNAMICS ....................................... 37 
10 
ASSESSMENT OF SAFETY ..................................................................... 38 
10.1 
Safety Parameters .............................................................................................................. 38 
10.2 
Procedures for Adverse Events Reporting ........................................................................ 38 
10.3 
Serious Adverse Event Reporting ..................................................................................... 38 
10.4 
Procedures for Reporting Pregnancy ................................................................................ 39 
11 
DIRECT ACCESS TO SOURCE DATA AND DOCUMENTS ............. 40 

Parion Sciences, Inc. 
 
P-321 Ophthalmic Solution 
Protocol P-321-201 Version 2.0 
CONFIDENTIAL 
Page 9 
 
12 
QUALITY CONTROL AND QUALITY ASSURANCE ........................ 41 
13 
ETHICS ........................................................................................................ 42 
13.1 
Institutional Review Board ............................................................................................... 42 
13.2 
Informed Consent Requirements ...................................................................................... 42 
13.3 
Data Handling and Record Keeping ................................................................................. 43 
13.4 
Data Quality Control and Reporting ................................................................................. 43 
13.5 
Records Retention ............................................................................................................. 43 
13.6 
Publication Policy ............................................................................................................. 43 
14 
REFERENCES ............................................................................................ 44 
APPENDIX I: SCHEDULE OF VISITS AND PROCEDURES. ...................... 46 
APPENDIX II: ADVERSE EVENT REPORTING ........................................... 48 
APPENDIX III: VISUAL ACUITY ASSESSMENT ......................................... 51 
APPENDIX IV: BIOMICROSCOPY/EXTERNAL EYE EXAMINATION .. 52 
APPENDIX V: FLUROSCEIN TEAR BREAK-UP TIME (TBUT) ................ 54 
APPENDIX VI: FLUORESCEIN CORNEAL STAINING .............................. 55 
APPENDIX VII: LISSAMINE GREEN CONJUNCTIVAL STAINING ....... 56 
APPENDIX VIII: INSTILLATION OF MEDICATION .................................. 57 
APPENDIX IX: DRY EYE SYMPTOM QUESTIONNAIRES ........................ 58 
APPENDIX X: TEAR VOLUME ASSESSMENTS: ......................................... 62 
APPENDIX XI: POST INSTILLATION QUESTIONNAIRES ....................... 70 
APPENDIX XII:  MEIBOGRAPHY ASSESSMENT ........................................ 71 
APPENDIX XIII:  SERUM CHEMISTRY AND HEMATOLOGY 
ANALYTES ............................................................................................ 72 
APPENDIX XIV:  DOSE SELECTION FOR PHASE 2 AND DATA 
REVIEW DURING STUDY .................................................................. 73 

Parion Sciences, Inc. 
 
P-321 Ophthalmic Solution 
Protocol P-321-201 Version 2.0 
CONFIDENTIAL 
Page 10 
 
ABBREVIATIONS 
AE 
Adverse event 
ANCOVA 
Analysis of covariance 
AUC 
Area under the curve analysis 
BID 
Two times daily 
C 
Celsius 
CMH 
Cochran Mantel Haenszel (test) 
CRF 
Case report form 
ECG 
Electrocardiogram 
ENaC 
Epithelial sodium channel 
F 
Fahrenheit 
FDA 
Food and Drug Administration 
GEE 
Generalized estimation equations 
GLP 
Good Laboratory Practices 
ICH 
International Conference on Harmonization  
IOP 
Intraocular pressure 
IRB 
Institutional Review Board 
Isc 
Short-circuit current 
IV 
Intravenous 
LTMH 
Lower tear meniscus height 
LTMV 
Lower tear meniscus volume 
NOAEL 
No-observed-adverse-effect level 
OSDI 
Ocular symptom disease index 
PD 
Potential difference 
PI 
Principal investigator 
QID 
Four times daily 
SAE 
Serious adverse event 
SANDE 
Symptom Assessment in Dry Eye questionnaire 
SPEED 
Standard Patient Evaluation of Eye Dryness questionnaire 
SS 
Sjögren’s syndrome 
TBUT 
Tear break-up time 
TMH 
Tear meniscus height 
TTMV 
Total tear meniscus volume calculated as UTMV + LTMV 

Parion Sciences, Inc. 
 
P-321 Ophthalmic Solution 
Protocol P-321-201 Version 2.0 
CONFIDENTIAL 
Page 11 
 
UHR-OCT 
Ultra high resolution optical coherence tomography 
UTMH 
Upper tear meniscus height 
UTMV 
Upper tear meniscus volume 

Parion Sciences, Inc. 
 
P-321 Ophthalmic Solution 
Protocol P-321-201 Version 2.0 
CONFIDENTIAL 
Page 12 
 
2 BACKGROUND INFORMATION 
2.1 Description of Study Medication 
Parion Sciences, Inc. is developing P-321 Ophthalmic Solution for the treatment of subjects with 
dry eye disease.  P-321 is a novel potent inhibitor of the epithelial sodium channel (ENaC) and a 
structural analog of amiloride with unique pharmacokinetic (PK) and pharmacodynamic 
characteristics designed for ocular topical administration, metabolic stability and limited 
systemic exposure. The formulation being studied is a sterile non-preserved aqueous solution of 
P-321.   
ENaC is a transmembrane sodium channel important in the regulation of epithelial sodium 
absorption that is present in the eye and other tissues such as lung, kidney, colon, and sweat 
glands.  ENaC has been extensively characterized in the lung where it plays a major role in the 
regulation of the composition of the airway surface liquid and is tightly linked to the 
maintenance of airway surface hydration and mucocilliary clearance (Barker, 1998).  The 
absorption of sodium from the epithelial surface liquid via ENaC osmotically entrains water into 
the epithelium, decreasing the level of hydration of the mucosal surface.   
The dynamics of the ocular tear film are maintained through an integrated system known as the 
lacrimal functional unit that consists of the ocular surface epithelium (cornea and conjunctiva), 
the lacrimal glands, the meibomian glands, and their neural and immunological components 
(Stern, 2004).  
ENaC is a key ion channel in this process, mediating the absorption of sodium (and hence water) 
from the tear fluid through the ocular surface epithelium (cornea and conjunctiva) where ENaC 
is expressed (Levin, 2006; Thelin, 2012; Krueger. 2012; Yu, 2012a; Yu, 2012b).  Therefore, 
ENaC provides an absorptive pathway for tear fluid loss, which regulates the composition and 
volume of tears under non-stimulated or “basal” conditions.  The inhibition of ENaC with highly 
potent, small molecule channel blockers represents a unique ocular hydration strategy, working 
by preventing the absorption of tear fluid and thereby maintaining the protective and lubricating 
actions of tears on the ocular surface. 
 

Parion Sciences, Inc. 
 
P-321 Ophthalmic Solution 
Protocol P-321-201 Version 2.0 
CONFIDENTIAL 
Page 13 
 
2.2   Non‐Clinical Studies for P‐321 Ophthalmic Solution 
2.2.1   Pharmacology 
In vitro studies: 
The inhibitory effect of P-321 on ENaC was studied in human and canine primary cultures of 
bronchial epithelial cells.  Apical administration of P-321 produced a concentration-dependent 
inhibition of ENaC-mediated short-circuit currents (Isc) with a potency of 3.247 ± 1.231 nM 
(n=12) and 1.901 ± 0.7543 nM (n=3) for canine and human airway epithelial cells, respectively. 
Primary cultures of human conjunctival epithelia grown on a permeable support at an air-liquid 
interface were used to assess the effect of P-321 on the absorption of fluid by the conjunctiva.  
Addition of fluid to the apical surface of these cells resulted in rapid absorption of fluid into the 
tissue.  The presence of P-321 on the apical surface inhibited the “tear” fluid absorption of the 
conjunctiva, suggesting that ENaC-mediated sodium absorption plays an important role on fluid 
absorption and tear dynamics. 
Among the unique characteristics built in the design of P-321 are the low systemic exposure 
following administration on the ocular surface, and the retention of the drug on the ocular surface 
to increase the duration of action.  The penetration of P-321 into the corneal epithelium was 
measured by confocal microscopy imaging, taking advantage of the intrinsic fluorescence of 
P-321.  Ex vivo imaging of mouse corneas treated with P-321 or amiloride indicated that in 
corneas treated with P-321, the drug remained associated with the mucosal surface of the cornea, 
whereas under identical conditions, amiloride had fully penetrated the epithelium, the stroma, 
and the endothelium, suggesting that P-321 is selectively retained by the epithelium of the ocular 
surface. 
In vivo Studies 
The effect of P-321 on the activity of ENaC in the ocular surface was studied in C57BL/6 mice 
by in vivo measurements of the transepithelial potential difference (PD) driven by sodium 
movement through ENaC.  Topical ocular instillation of P-321 produced a concentration-
dependent inhibition of the ocular PD measurements with a potency of 57.2 nM, (95% 
Confidence Interval: 35.2 to 93.0 nM).  These studies are consistent with in vitro results obtained 
in airway cells and suggest that P-321 is a potent inhibitor of the ocular ENaC-mediated 
epithelial sodium transport in vivo. 
The ability of P-321 to increase tear volume was studied in the ExLac dry eye animal model in 
rats in which the main lacrimal glands have been surgically removed (Fujihara, 2001).  ExLac 
rats exhibit approximately 50 to 60% reduction in the basal tear volume compared to normal 
animals.  A single ocular instillation of P-321 produced a concentration-dependent increase of 
tear volume that reached tear volumes similar to those observed in normal animals and at 
maximally effective concentrations.  The increase in tear levels was maintained for several hours 
following a single administration of P-321.   
The effect of repeat dosing of P-321 on tear volume was also studied in the ExLac rat animal 
model.   

Parion Sciences, Inc. 
 
P-321 Ophthalmic Solution 
Protocol P-321-201 Version 2.0 
CONFIDENTIAL 
Page 14 
 
Animals were treated with repeated administrations of 0.001% P-321 or vehicle control for five 
consecutive days at two dosing frequencies, twice daily (BID) and four times daily (QID).  
Animals treated with vehicle control showed no significant changes in tear volume throughout 
the five days of dosing. In contrast, in the group of animals treated with P-321 administered BID 
or QID, a gradual increase in tear volume was observed on each day of treatment reaching by the 
fifth day of treatment a steady state level similar to the tear volume of normal rats. On the first 
day of treatment, the animals receiving P-321 QID had a larger increase in tear volume than the 
animals treated BID, however, both groups had similar levels of tear volume by the end of 
treatment on Day 5.  These results show that a maximum effect on tear volume can be achieved 
with low concentrations of P-321 (0.001%) when administered either BID or QID over five 
consecutive days. 
In vivo pharmacology studies have shown that epithelial sodium channel inhibitors, including P-
321 have a stimulatory effect on tear volume in an animal model of dry eye disease (Thelin, 
2012).   
These in vivo and in vitro pharmacological actions together with the PK properties of P-321 
provide a strong scientific rationale for the use of P-321 Ophthalmic Solution for the treatment of 
diseases of impaired ocular hydration such as dry eye.  
2.2.2 Absorption, Distribution, Metabolism, and Excretion 
The absorption, distribution, metabolism, and excretion profile of P-321 was characterized in 
in vitro and in vivo studies.  P-321 was not metabolized in plasma from different species (rat, 
rabbit, dog and human) or by incubation with rat and dog hepatocytes.   
Oral administration of P-321 to rats did not produce measurable plasma drug concentrations, 
suggesting that P-321 is not orally available.   
The PK and systemic clearance of P-321 was characterized in rats following intravenous (IV) 
administration.  P-321 displayed biphasic elimination from plasma with a long terminal half-life 
and a high volume of distribution.  The PK of P-321 in plasma showed no difference among sex, 
and no accumulation was observed after multiple days of IV administration. 
The renal elimination of P-321 and its potential for inhibition of ENaC in the kidney was studied 
in rats treated with P-321 by topical ocular administration or by IV infusion.  The amount of 
P-321 recovered in urine over 24 hours following IV and ocular administration accounted for 
only a small fraction of the total dose administered corresponding to 0.57-1.3% and 0.19%, 
respectively.  Ocular administration of P-321 Ophthalmic Solution in dogs given four times per 
day over multiple days also indicated that very low amounts of P-321 were excreted in the urine 
and these concentrations of drug were not associated with changes in urine electrolyte excretion, 
the most sensitive measurement of the effect of ENaC blockers in the kidney.  
The ocular distribution and PK following topical ocular administration of P-321 was assessed in 
Dutch Belted rabbits following a single dose of 0.1% P-321 Ophthalmic Solution or during QID 
administration for 14 days. The ocular distribution of P-321 was limited only to the external 
surface of the eye. P-321 had a long terminal half-life in tears of approximately 24 hours.  
Sustained drug levels were also observed in the palpebral and bulbar conjunctiva and eyelids for 
up to 48 hours following a single administration.  After multiple days of QID dosing, P-321 

Parion Sciences, Inc. 
 
P-321 Ophthalmic Solution 
Protocol P-321-201 Version 2.0 
CONFIDENTIAL 
Page 15 
 
concentrations in these tissues, increased relative to the levels observed following a single 
administration, and reached a steady-state level after approximately 5 days of dosing.  P-321 had 
minimal or no penetration into internal regions of the eye such as the retina and aqueous humor, 
or the main lacrimal glands.  Furthermore, the systemic exposure of P-321 following ocular 
instillation was low, as evidenced by low or non-detectable drug levels in the plasma following a 
single dose or during 14 days of QID administration. 
The toxicokinetics of P-321 were estimated in Good Laboratory Practices (GLP) studies 
conducted in rabbits and dogs following ocular administration four times per day for 28 days.  
The systemic exposure of P-321 in rabbits was low with only the highest dose tested 
(0.5% P-321, QID) exhibiting quantifiable plasma drug levels.  P-321 was rapidly absorbed 
following ocular administration and rapidly cleared from plasma, with mean t1/2 values ranging 
from 0.183 to 0.254 hours on Days 1 and 28, respectively.  No accumulation was observed over 
28 days of dosing based on plasma drug concentrations. Note, the nominal ocular dose that 
produced systemic exposure in rabbits is 120-fold larger than the initial dose to be given to the 
subjects in this study, and 40-fold larger than the high dose planned for this study (0.05%).  The 
systemic exposure in dogs was also low, and only observed with the highest dose tested (0.05% 
QID) on Day 28.  P-321 was rapidly absorbed following ocular administration and rapidly 
cleared from plasma, with mean t1/2 values ranging from 2.28 to 2.68 hours. Note, the nominal 
ocular dose that produced systemic exposure in dogs is 12-fold larger than the initial dose to be 
given to the subjects in this study, and 4-fold larger than the high dose planned for this study 
(0.05%).   
In summary, P-321 is metabolically stable.  Following IV administration P-321 is rapidly cleared 
primarily via non-renal mechanisms, and is not orally available.  The ocular tissue distribution of 
P-321 following ocular instillation is essentially limited to its site of action on the ocular surface 
(tears, palpebral conjunctiva, bulbar conjunctiva, and cornea) with no penetration to internal 
structures of the eye (aqueous humor, retina) or the main lacrimal glands.  Topical ocular 
administration of P-321 Ophthalmic Solution at pharmacologically active concentrations results 
in minimal to no systemic exposure and also failed to produce any renal effect.  Furthermore, in 
subjects with dry eye disease treated with 0.01% P-321 BID for 28 days, we were not able to 
detect any drug present in plasma or urine from these subjects.    
2.2.3 Toxicology  
Multiple toxicology studies have been conducted using P-321Ophthalmic Solution.  Systemic 
administration of P-321 via IV, oral and ocular routes of administration, in both acute and repeat-
dose nonclinical studies, demonstrated that P-321 Ophthalmic Solution at pharmacologically 
active concentrations is well tolerated.  Extensive ocular toxicology studies for up to 28 days of 
administration at higher frequencies than those used in this study have been conducted in rabbits 
and dogs, with the dog being the most sensitive species.  The primary finding associated with 
ocular administration of P-321 was a dose-dependent increase of ocular irritation, described as 
minimal or slight, that reversed upon discontinuation of treatment.  No significant effects of 
P-321 Ophthalmic Solution were observed at any dose level for both species on 
electroretinograms, corneal thickness, and corneal endothelial cell density.  For the dose limiting 
factor of ocular irritation, the no-observed-adverse-effect levels (NOAEL) of 0.8 mg/eye/day in 
rabbits and 0.024 mg/eye/day in dogs exceeds the human doses planned for of this study. The 
NOAEL of 0.05 mg/kg/day in rats administered P-321 IV exceeds the potential exposure from 

Parion Sciences, Inc. 
 
P-321 Ophthalmic Solution 
Protocol P-321-201 Version 2.0 
CONFIDENTIAL 
Page 16 
 
the proposed initial ocular dose of 2.2661x10-4 mg/kg/day (assuming bilateral dosing of 0.017% 
P-321, QD with a 40 µl drop size in a 60 kg person) by 225-fold on a Human Equivalent Dose 
basis. For the high dose planned in this study, the dose of 6.666x10-4 mg/Kg/day (assuming 
bilateral dose of 0.05% P-321 QD in a 60 Kg person, the systemic safety margin is 75-fold on a 
Human Equivalent Dose basis. 
No systemic effects at any dose level in dogs or rabbits were observed following ocular 
administration of P-321 Ophthalmic Solution. 
In a battery of genotoxicity studies, P-321 did not cause mutations in the Ames or mouse 
lymphoma assay in vitro with or without S9 metabolic activation.  Additionally, the compound 
was negative in a rat micronucleus study.  Thus, P-321 can be considered to be non-mutagenic 
and non-clastogenic, with no evidence of disruption of the mitotic apparatus.   
2.3 Clinical Experience with P‐321 Ophthalmic Solution 
There has been one study completed with P-321 Ophthalmic Solution in which 40 subjects with 
mild to moderate dry eye disease were treated with P-321 Ophthalmic Solution.  In this study, P-
321 Ophthalmic Solution was well-tolerated at concentrations of 0.0005%, 0.0015%, 0.005% 
instilled twice daily for up to 15 days and 0.01% instilled twice daily for up to 28 days.  There 
were no clinically relevant adverse drug-related, dose-related or time of treatment-related effects 
on any safety measure.  No serious adverse events (SAEs) were reported.  No evidence of 
systemic exposure of P-321 was observed.  
Although this study was not powered for effects on efficacy measurements, improvements in the 
frequency and severity of symptoms of dry eye disease that approached statistical significance 
compared with placebo were observed.  In addition, consistent with the proposed mechanism of 
action of P-321, the treatment difference relative to placebo favored P-321 for the measurements 
of tear meniscus height (TMH) observed in this study.   
2.4 Justification for Route of Administration and Dose Selection 
P-321 Ophthalmic Solution is expected to exert its biological activity through direct interaction 
with ENaC on the corneal and conjunctival surface of the eye.  Since the intended route of 
administration for P-321 is topical ocular, this route of administration will be used in this study.  
The dose planned for this study was selected based upon results of the first clinical study and 
preclinical safety studies.   
This study is a single day crossover comparing P-321 Ophthalmic Solution and Placebo on the 
pharmacodynamic measure, tear volume.  During Phase 1, a single dose of 0.017% will be 
administered and during Phase 2 and based on the recommendation of the Data Review Group, a 
single dose of either 0.05%, 0.017% or 0.01% will be administered.  These doses on a single 
instillation frequency and are covered by the safety profile obtained in the most sensitive species 
(dog) with safety margins that range from 6-fold to 1.2-fold.  
2.5 GCP Compliance 
This clinical trial will be conducted in compliance with the protocol, International Conference on 
Harmonization (ICH) Good Clinical Practice guidelines, and other applicable regulatory 
requirements. 

Parion Sciences, Inc. 
 
P-321 Ophthalmic Solution 
Protocol P-321-201 Version 2.0 
CONFIDENTIAL 
Page 17 
 
2.6 Population to be Studied 
Dry eye disease is a multifactorial debilitating disease of the ocular surface characterized by 
ocular signs of corneal and conjunctival impairment and damage of the protective epithelial 
surface, as well as, decreased tear volume, decreased tear break-up time, and symptoms of 
discomfort that can range from mild to severe such as, burning, pain, stinging, itching, swelling, 
foreign body sensation, photophobia, and ocular fatigue.  Frequent instillation of artificial tears is 
currently the most commonly used treatment for mild to moderate dry eye signs and symptoms.   
According to recent prevalence estimates, dry eye disease can affect up to 20 million people in 
the US, with a disproportionate number of women and elderly being afflicted.  However, with 
the spread use of digital technologies in recent years, increased incidence of dry eye in younger 
adults is being observed.  There is a heterogeneous collection of diseases with many shared 
characteristics that can precipitate dry eye disease.  Dry eye disease is one of the hallmarks of the 
Sjögren's syndrome (SS); however, they represent only a fraction of subjects who experience dry 
eye symptoms.  Dry eye is also observed in approximately 40 to 60% of subjects who have 
undergone hematopoietic stem cell transplantation and develop graft versus host disease (Saboo, 
2015).  One core abnormality of the disease is the decrease in tear volume that can be originated 
by a deficiency of tear secretion or composition which in turn triggers the loss of volume and 
compromises the protective barrier of the ocular film.  Additionally, dry eye symptoms can be 
the side effect of many commonly used medications such as anticholinergics, antidepressants, 
and environmental factors such as air conditioning and focusing on video displays for prolonged 
periods of time.  These symptoms of dry eye can vary from mild to severe and in the most severe 
cases, can result in significant vision impairment and permanent damage of the ocular surface.  
In this study, subjects with tear deficient dry eye disease will be recruited for participation. 
Approximately 24 subjects with tear deficient dry eye disease documented by low tear volume as 
measured by UHR-OCT will be completed in this single-center, randomized,  cross-over, 
placebo controlled study to evaluate the changes in tear volume by P-321 Ophthalmic Solution or 
Placebo.  The study consists of two Phases.  Approximately 8 subjects participating in Phase 1 
will receive 0.017% P-321 Ophthalmic Solution or Placebo, and the remainder of the 24 subjects 
participating in Phase 2 will receive either 0.05%, 0.017% or 0.01%.  The decision on the dose 
administered in Phase 2 will be made following unmasked data review from subjects in Phase 1.  
In each Phase, subjects will receive sequentially two treatments: P-321 Ophthalmic Solution 
(Treatment A) and Placebo (Treatment B).  Subjects will be randomly assigned to receive 
treatment sequence AB or BA, with each subject in Phase 1 and Phase 2 being treated with P-321 
Ophthalmic Solution and placebo  The Principal Investigator, Medical Monitor and Parion 
Sciences representatives not involved in the day to day conduct of the study will review 
unmasked data as part of the Data Review Group, which will decide the dose to be used in Phase 
2 of the study.  The treatment assignments will remain masked to subjects in the study, the 
clinical monitor, and other site and Parion Sciences personnel involved in the conduct of the 
study and not involved in the Data Review Group.  Additional unmasked reviews of subject data 
may occur during the study to make recommendations on further dose adjustments and for 
planning purposes.  These reviews will follow the procedures outlined above. 
 

Parion Sciences, Inc. 
 
P-321 Ophthalmic Solution 
Protocol P-321-201 Version 2.0 
CONFIDENTIAL 
Page 18 
 
3 TRIAL OBJECTIVES AND PURPOSE 
The primary objective of this trial is to assess changes in tear volume by the non-invasive 
techniques Ultra High Resolution Optical Coherence Tomography (UHR-OCT) following the 
administration of P-321 Ophthalmic Solution or Placebo in subjects with tear deficient dry eye 
disease.   
The secondary objectives are to: 
 assess changes in lower tear meniscus height by Keratograph 5M  
 compare lower tear meniscus height measurements between UHR-OCT and Keratograph 
5M 
 assess the duration of action of P-321 Ophthalmic Solution 
 compare the pharmacodynamic activity of different strengths of P-321 in subjects with 
tear-deficient dry eye 
 monitor safety and tolerability of P-321 Ophthalmic Solution 

Parion Sciences, Inc. 
 
P-321 Ophthalmic Solution 
Protocol P-321-201 Version 2.0 
CONFIDENTIAL 
Page 19 
 
4 INVESTIGATIONAL PLAN 
4.1 Overall Study Design 
This is a single-center, randomized,  cross-over, placebo-controlled, Phase 2a trial designed to 
evaluate the pharmacodynamic effects of tear volume of P-321 Ophthalmic Solution in tear-
deficient dry eye subjects.  Approximately 24 eligible subjects will complete the study which 
consists of two Phases: Approximately 8 subjects participating in Phase 1 will receive 0.017% P-
321 ophthalmic Solution and Placebo, and the remainder of the 24 subjects participating in Phase 
2 will receive either 0.05%, 0.017% or 0.01% P-321 and placebo.  The decision on the dose 
administered in Phase 2 will be made following unmasked data review from subjects in Phase 1.  
In each Phase, subjects will receive sequentially two treatments: P-321 Ophthalmic Solution 
(Treatment A) and Placebo (Treatment B).  Subjects will be randomly assigned to receive 
treatment sequence AB or BA, in a 1:1 ratio.  
The pharmacodynamic measures of tear volume will be assessed by two methods: UHR-OCT 
and Keratograph 5M.  Optical coherence tomography (OCT) has been used to image the anterior 
segment of the eye including tears on the ocular surface. The method is non-invasive and non-
contact which is suitable for imaging the tear meniscus around both upper and lower lids. The 
system at Bascom Palmer Eye Institute is a custom made OCT system (UHR-OCT) with an ultra-
high resolution (3 µm). Many previous studies have been done using UHR-OCT and its clinical 
application has been well documented. With the wide scan of the UHR-OCT, cross-sectional 
images of the tear menisci can be imaged and tear meniscus volume can be calculated.  The 
Keratograph 5M is a corneal topographer with a built in camera optimized for external imaging. 
The Keratograph 5M has a feature that enables the non-invasive assessment of the tear meniscus 
height of the inferior eyelid from high resolution images obtained under infrared light.  With the 
use of a built in measurement tool the height of the tear meniscus is obtained. 
The study will consist of three study visits: a Screening Visit (Visit 1), and two treatment visits 
(Visit 2 and Visit 3).  The duration of the study may be up to 23 days. 
At Visit 1, three tear volume measurements will be conducted over 1 hour with measurements 
taken approximately 30 minutes apart (initial timepoint, and at 30 and 60 minutes later) and prior 
to any invasive ocular assessments.  The average of these three measurements will be obtained 
and used as baseline tear volume and meniscus height and to determine the eligibility of the 
subject to participate in the study.   
At Visits 2 and 3, tear volume will be assessed serially over 6 hours: Before administration of 
assigned study medication (time =  0, pretreatment),  and at 15 minutes, 30 minutes, 1 hour, 2 
hours, 4 hours and 6 hours after study medication administration.  Subjects will be asked to 
arrive to the clinic for Visit 2 and Visit 3 between 8:00AM and 11:00AM and at approximately 
the same time as Visit 1.   
Safety assessments including adverse events (AEs), biomicroscopy and external eye examination 
and an assessment of comfort immediately after taking the medication will be conducted 
following each in-clinic dose.  Changes in medical conditions and medication, abbreviated 
physical exam changes and vital signs will be recorded periodically throughout the study. A post 

Parion Sciences, Inc. 
 
P-321 Ophthalmic Solution 
Protocol P-321-201 Version 2.0 
CONFIDENTIAL 
Page 20 
 
instillation dry eye symptom assessment will be conducted at Visits 2 and 3 immediately prior to 
the 2 hour post dose time point.  
Subjects may be asked to stop or withhold certain medications, and on visit days and for at least 
6 hours after dosing with study medication, withhold certain medications and not wear contact 
lenses on visit days.  After the assessments of  Visit 3 are completed, the subject will be 
discharged from the study. 
A detailed schedule of the time and events for the study is provided in Appendix I. 
A schematic of the study design is shown in Figure 1. 
Figure 1: P-321-201 Study Schematic 
 
 
4.2 Endpoints 
4.2.1 Primary Endpoint 
The primary endpoint for this study is the change in measurements of tear volume over time as 
measured by the UHR-OCT following the administration of P-321 Ophthalmic Solution and 
Placebo in subjects with tear deficient dry eye disease.   
4.2.2  Secondary Endpoints 
The secondary endpoints are to: 
 assess changes in lower tear meniscus height by Keratograph 5M  
 compare lower tear meniscus height measurements between UHR-OCT and Keratograph 
5M 

Parion Sciences, Inc. 
 
P-321 Ophthalmic Solution 
Protocol P-321-201 Version 2.0 
CONFIDENTIAL 
Page 21 
 
 assess the duration of action of P-321 Ophthalmic Solution 
 compare the pharmacodynamic activity of different strengths of P-321 in subjects with 
tear-deficient dry eye 
 monitor safety and tolerability of P-321 Ophthalmic Solution 
4.2.3 Safety and Tolerability Endpoints 
Safety endpoints include: AEs, biomicroscopy and external eye examination and comfort 
assessment (after each in-clinic dose).   
4.3 Duration of Participation 
The study will consist of three study visits: A Screening Visit (Visit 1), and two Treatment Visits 
(Visit 2 and Visit 3).  The duration of the study may be up to 23 days. The start of each visit will 
take place between 8:00AM and 11:00 AM and at approximately the same time as Visit 1. 
Visit 1 is expected to last approximately 2 hours and Visits 2 and 3 are expected to last 
approximately 7 hours.  
 

Parion Sciences, Inc. 
 
P-321 Ophthalmic Solution 
Protocol P-321-201 Version 2.0 
CONFIDENTIAL 
Page 22 
 
5 SELECTION AND WITHDRAWAL OF SUBJECTS 
5.1 Subject Inclusion Criteria  
Subjects must meet the following criteria at Screening to be enrolled in the study: 
1. Provide written informed consent 
2. Male or female subjects aged 18 to 80 years 
3. Are willing and able to follow instructions and can be present for the required study visits 
for the duration of the study 
4. Have a history of predominantly tear-deficient dry eye of mild to moderate severity, 
supported by a previous clinical diagnosis  
5. Subjects must have in both eyes an average tear meniscus height (TMH) of the lower eye lid 
of less than 175µm as assessed by UHR-OCT 
6. Have a Schirmer’s test >1mm and <10 mm 
7. Have normal lid anatomy 
8. Female subjects of child bearing potential must have a negative serum pregnancy test at 
Screening and agree to use a medically acceptable form of birth control (e.g., intrauterine 
device, birth control pill, patch or subcutaneous implant, condoms, diaphragm, or 
abstinence) throughout the duration of the study.  Females who are breast feeding an infant 
are not eligible to participate in the study. 
9. Subjects must: 
a. Remain on current medications for the duration of the study 
b. Be on the current medication regimen at least during the past 28 days 
c. Be able to withhold ocular topical medications, including artificial tears, topical 
steroids, Restasis, autologous serum, and lid wipes and scrubs on visit days while 
in the clinic, and for at least 6 hours after dosing with study medication 
d. If they are contact lens wearers, be able to withhold wearing contact lenses on 
visit days, while in the clinic, and for at least 6 hours after dosing  
5.2 Subject Exclusion Criteria  
Subjects who meet any of the following criteria at Screening or during the study will be excluded 
from the study. 
1. Have an identifiable or suspected dry eye caused by pharmacologic, post-traumatic, or post-
surgical condition 
2. Have undergone refractive eye surgery (e.g., LASIK) in either eye during the past 12 months  
3. Have undergone uncomplicated cataract surgery in either eye during the past 3 months  
4. Have undergone previous eyelid surgery in either eye (e.g., blepharoplasty, ptosis repair)  
5. Have lid irregularities or deformities  
6. Have severe corneal surface irregularities  
7. Have undergone botulinum toxin (Botox™ or equivalent) injection in the periocular area 
within 3 months prior to Visit 1  

Parion Sciences, Inc. 
 
P-321 Ophthalmic Solution 
Protocol P-321-201 Version 2.0 
CONFIDENTIAL 
Page 23 
 
8. Have a history of glaucoma or IOP > 25 mmHg at the Screening Visit (Visit 1) or a history 
of elevated IOP within the past year 
9. Subjects that have a systemic, multi-organ disease with the exception of subjects with SS or 
GVHD requiring active medical or surgical treatment are excluded, except if the following 
conditions are met: 
a. the condition is chronic (> 1 years' duration), stable, of mild severity and 
adequately controlled 
b. the condition does not or is unlikely to have ocular manifestations 
c. the condition is one of the following: 
i. essential hypertension 
ii. coronary artery disease 
iii. Type II diabetes mellitus without diabetic retinopathy 
iv. thyroid dysfunction without thyroid eye disease 
v. non-morbid obesity 
vi. remote history of cancer (> 5 years from diagnosis) 
10. Have punctal plugs, punctal occlusion, or history of nasolacrimal duct obstruction  
11. Stevens-Johnson syndrome, ocular cicatricial pemphigoid, or other ocular cicatrizing 
disorders 
12. Past or present exposure keratopathy, neurotrophic keratopathy, lagophthalmos, or trichiasis 
13. Subjects taking the following medications within 14 days of Visit 1 or during the study are 
excluded 
a. Oral, nasal and ocular antihistamines 
b. Oral or topical secretagogues such as pilocarpine and Evoxac 
c. Topical anti-glaucoma medications 
14. History of allergies to any of the components of the study medication 
15. Are pregnant or breast feeding an infant.  
16. Have any significant illness that, in the opinion of the Principal Investigator (PI), could 
interfere with the study parameters 
17. Use of any investigational product or device within 28 days prior to the Screening Visit or 
during the study 
18. Are unable in the opinion of the PI to comply fully with the study requirements or to 
complete the study 
 
5.3 Randomization Criteria 
At Visit 2 (First Treatment Visit) and Visit 3 (Second Treatment Visit), an eligible subject must: 
1. 
Continue to meet all clinical inclusion/exclusion criteria as defined in Section 5.1 and 
Section 5.2, with the exception of the inclusion criteria #5 (UHR-OCT measurement) 
and #6 (Schirmer’s test measurement) which will not be reassessed for continuation at 
these visits.   

Parion Sciences, Inc. 
 
P-321 Ophthalmic Solution 
Protocol P-321-201 Version 2.0 
CONFIDENTIAL 
Page 24 
 
A log will be maintained at the sites for those subjects that do not meet eligibility criteria. 
Minimally this log will include the subject’s age, sex and race and the reason that they were not 
eligible.  Screen failure data will not be collected in the clinical database.   
5.4 Subject Withdrawal Criteria and Stopping Rules 
Treatment may be discontinued and the subject withdrawn at any time during the study at the 
discretion of the investigator, Medical Monitor or Parion Sciences for any reason including but 
not limited to occurrence of an AE which precludes subsequent participation, withdrawal of 
Informed Consent, or requirement of an ocular surgery or intervention.  Also in the event that a 
woman becomes pregnant while participating on the study, she will be withdrawn from the 
study.  In the event that discontinuation of treatment is necessary, the investigator will make 
every attempt to complete all subsequent safety assessments and the Early Termination Visit.  
The reason for premature discontinuation should be entered onto the paper case report form 
(CRF).  Subjects who withdraw from the study will be replaced.   
Additionally, the trial or parts of the trial may be discontinued by Parion Sciences, Inc. or at the 
recommendation of the Investigator or Medical Monitor after consultation with Parion.  This 
may be based on a significant number of AEs of a similar nature that warrant such action or at 
the request of Parion Sciences, Inc.   

Parion Sciences, Inc. 
 
P-321 Ophthalmic Solution 
Protocol P-321-201 Version 2.0 
CONFIDENTIAL 
Page 25 
 
6 PROCEDURES 
The procedures performed for this study are listed below.  The times indicated in the following 
sections and Appendices are based on the visit starting in the AM with each visit starting at a 
consistent timeframe relative to Visit 1.   
6.1 Visit 1: Screening (3 to 9 days prior to Visit 2 – Randomization)  
The following procedures will be completed at Visit 1 which will start between 8:00AM and 
11:00AM: 
 Obtain written informed consent 
 Review eligbility criteria 
 Review of the medical history  
 Review concomitant medication history in the past 28 days  
 Administer ocular symptom questionnaires (SPEED, OSDI, and SANDE Part 1 only) 
before other procedures 
 Biomicroscopy and external eye examination 
 Visual acuity  
 Abbreviated physical exam (including respiratory, cardiovascular, musculoskeletal, 
gastrointestinal, dermatological) 
 Vital signs (pulse, blood pressure, temperature and respiration rate) and height and 
weight 
 Conduct pretreatment measurements in both eyes by UHR-OCT and Keratograph 5M 
three times in one hour (at 0 minutes, 30 ± 10 minutes and 60 ± 20 minutes).   NOTE: 
throughout the study, UHR-OCT will be conducted first, immediately followed by 
Keratograph 5M. 
 Tear osmolarity 
 TBUT 
 Assessment of meibomian glands 
 Corneal staining 
 Conjunctival staining 
 Schirmer’s test   
 IOP  
 Collect blood for hematology, chemistry and pregnancy tests 
 
Monitoring of adverse events will begin from the time the Informed consent is signed 
 
Eligible subjects will be instructed to return to the clinic between 3 and 9 days for the first 
treatment (Visit 2, First Treatment Visit) with the visit occurring in the AM, at approximately 
the same time of day as Visit 1.  Subjects will be reminded not to use ocular medications or 
wear contact lenses on the day of Visit 2. 
 

Parion Sciences, Inc. 
 
P-321 Ophthalmic Solution 
Protocol P-321-201 Version 2.0 
CONFIDENTIAL 
Page 26 
 
6.2 Visit 2:  First Treatment Visit (3 ‐9 days after Visit 1) 
The following procedures will be completed at Visit 2 which will take place between 8:00AM 
and 11:00 AM and at approximately the same time as Visit 1: 
 Subjects will be asked to remain on site through this visit and limit use of devices with 
video display screens. 
 Confirm continued eligibility through review of inclusion and exclusion criteria as 
outlined in Sections 5.1 and 5.2 of the protocol with the exception of the inclusion 
criteria #5 (UHR-OCT dry eye) and #6 (Schirmer’s test measurement) which will not be 
reassessed for continuation at this visit. 
 Review of concomitant medications and medical changes since last visit 
 Administer symptom questionnaires (SPEED, OSDI, and SANDE Part 1 and Part 2) 
before other procedures and before dosing 
 Assess adverse events since the last visit and during this visit 
 Collect vital signs (pulse, blood pressure, temperature and respiration rate) pre-treatment 
 Conduct pretreatment  measurements in both eyes by UHR-OCT and Keratograph 5M  
(at approximately the same time as conducted at Visit 1) immediately prior the 
administration of study medication.  UHR-OCT will be conducted first, immediately 
followed by Keratograph 5M. 
 Subjects will be assigned a treatment number at this visit. 
 Administer one drop of assigned study medication in each eye immediately after the 
pretreatment assessment (the drug administration will be conducted by the PI or clinical 
site personnel). NOTE:  Remove study medication from refrigerator at least 15 minutes 
prior to administration.   
 At approximately 5 minutes after drug administration, administer drop instillation 
comfort assessment  
 Repeat assessments by UHR-OCT and Keratograph 5M post dose at 15 ± 5 minutes, 30 
± 10 minutes minutes, 1 hour ± 20 minutes, 2 hours ± 30 minutes, 4 hours ± 30 minutes, 
and 6 hours ± 30 minutes. 
 Immediately prior to the 2 hour time point for tear volume measurement, a post 
instillation dry eye symptom assessment will be completed 
 After the 6-hour tear volume assessment, conduct a biomicroscopy and external 
examination  
 At the end of the visit, the subject will be instructed to return to the clinic between 7 and 
14 days for the second treatment (Visit 3, Second Treatment Visit) with the visit 
occurring in the AM, at approximately the same time of day as Visit 1 
 The subjects will be instructed to maintain the same medications and study restrictions 
between visits to continue being eligible to remain in the study. Subjects will be 
reminded not to use ocular medications or wear contact lenses on the day of Visit 3 
 
6.3 Visit 3:  Second Treatment Visit (7‐14 days after Visit 2) 
 Subjects will be asked to remain on site through this visit and limit use of devices with 
video display screens. 

Parion Sciences, Inc. 
 
P-321 Ophthalmic Solution 
Protocol P-321-201 Version 2.0 
CONFIDENTIAL 
Page 27 
 
 Confirm continued eligibility through review of inclusion and exclusion criteria as 
outlined in Sections 5.1 and 5.2 of the protocol with the exception of the inclusion 
criteria #5 (UHR-OCT dry eye) and #6 (Schirmer’s test measurement) which will not be 
reassessed for continuation at this visit. 
 Review of concomitant medications and medical changes since last visit 
 Administer symptom questionnaires (SPEED, OSDI, and SANDE Part 1 and Part 2) 
before other procedures and before dosing   
 Assess adverse events since the last visit and during this visit 
 Collect vital signs pre-treatment (pulse, blood pressure, temperature and respiration rate) 
 Conduct pretreatment measurements in both eyes by UHR-OCT and Keratograph 5M in 
the AM (at approximately the same time as conducted at Visit 1) immediately prior the 
administration of study medication.  NOTE: throughout the study, UHR-OCT will be 
conducted first, immediately followed by Keratograph 5M. 
 Administer one drop of assigned study medication in each eye immediately after the 
pretreatment assessment (the drug administration will be conducted by the PI or clinical 
site personnel). NOTE:   Remove study medication from refrigerator at least 15 minutes 
prior to administration.   
 At approximately 5 minutes after drug administration, administer drop instillation 
comfort assessment 
 Repeat assessments by UHR-OCT and Keratograph 5M post dose at 15 ± 5 minutes, 30 
± 10 minutes minutes, 1 hour ± 20 minutes, 2 hours ± 30 minutes, 4 hours ± 30 minutes, 
and 6 hours ± 30 minutes. 
 Immediately prior to the 2 hour time point for tear volume measurement, a post 
instillation dry eye symptoms assessment will be completed 
 After the 6-hour tear volume assessment, conduct a biomicroscopy and external eye 
examination 
 At this point, the subject will be discharged from the study. 
 Subjects may resume previously used ocular medications when discharged from the 
study. 
 
6.4 Early Termination Visit 
The following assessments will be performed at the Early Termination Visit for randomized 
subjects who are withdrawn from the study prematurely:  
 
 Assess adverse events since the last visit and during this visit 
 Assess concomitant medications and medical changes since last visit  
 Collect vital signs (pulse, blood pressure, temperature and respiration rate) and height 
and weight 
 Conduct an abbreviated physical examination (including respiratory, cardiovascular, 
musculoskeletal, gastrointestinal, and dermatological) 
 Conduct a biomicroscopy and external eye examination 
 
   

Parion Sciences, Inc. 
 
P-321 Ophthalmic Solution 
Protocol P-321-201 Version 2.0 
CONFIDENTIAL 
Page 28 
 
6.5 Selecting Dosage Strength in Phase 2 
The decision of dose strength for P-321 Opthalmic Solution in Phase 2 of the study will be the 
responsibility of the Data Review Group constituted by the Prinicipal Investigator (or a designee 
not directly involved in the conduct of the study), the Medical Monitor and representatives of 
Parion Sciences.  Decision on the dose level to be given in Phase 2 will be made based on 
unmasked review of the study data from the first 8 subjects by the review committee.  Data to be 
considered will include safety and efficacy measures.  A detailed criterion for Dose selection for 
Phase 2 is described in Appendix XIV and outlined below. 
The dose level may be increased to 0.05% in Phase 2 in the event that: 
1) No cases of serious, suspected related, unexpected events are noted in Phase 1 OR 
2) No cases of serious ocular safety events are noted in Phase 1 
3) Lack of evidence that P-321 produced an increase in tear volume based on OCT and/or 
Keratograph 5M, or evidence that additional improvements in tear volume (or the 
duration of effect) may be obtained with a higher dose. 
The dose level may be decreased to 0.01% in Phase 2 in the event that: 
1) No cases of serious, suspected related, unexpected events are noted in Phase 1  
2) No cases of serious ocular safety events are noted in Phase 1  
3) There is evidence of a significant increase in tear volume and the duration of effect based 
on OCT and/or Keratograph 5M 
 
The dose level may remain at 0.017% (the same as in Phase 1) in the event: 
1) No cases of serious, suspected related, unexpected events are noted in Phase 1  
2) No cases of serious ocular safety events are noted in Phase 1  
3) There is not compelling data to either increase or decrease the strength for Phase 2.  
 
The Data Review Group will make a recommendation to the Parion Sciences to increase the 
dose, decrease the dose or maintain the dose.  
Additional unmasked reviews of subject data may occur throughout the study to make 
recommendations on further dose adjustments and for planning purposes.  These reviews will 
follow the procedures outlined above. 
6.6 Potential Toxicity Management 
All preclinical evidence indicates that systemic exposure of P-321 via ocular topical 
administration is none or negligible at concentrations up to 10-fold higher than the concentration 
planned in this study (the estimated systemic safety margins for the doses anticipated in this 
study range from 75- to 375-fold).  However, since P-321 is an ENaC inhibitor, a previous 
potential safety signal of concern following the administration of P-321, was drug-induced 
hyperkalemia.  This possibility was carefully investigated in Study P-321-101.  No changes in 
plasma or serum potassium were noted in this study in subjects administered 0.01% P-321 
Ophthalmic Solution BID for up to 28 days.  

Parion Sciences, Inc. 
 
P-321 Ophthalmic Solution 
Protocol P-321-201 Version 2.0 
CONFIDENTIAL 
Page 29 
 
No concerns for systemic toxicity in this single-dose administration study are based on the lack 
of safety findings from the P-321-101 study when treatment with P-321 was administered BID 
for up to 28 days.  In addition, in the same study, the pharmacokinetic results demonstrated a 
lack of systemic availability of 0.01% P-321 Ophthalmic Solution given twice daily for 28 days.  
In this study, treatment with P-321 Ophthalmic Solution at doses up to 0.05% will be given only 
once to each participating subject.  Thus, no post dose monitoring of serum potassium is planned 
for this trial. 
Any additional questions regarding toxicity management should be managed by appropriate 
medical professional at the clinical site and directed to Parion Sciences Medical Monitor. 
6.7 Collection of Data 
Source documentation for data collected in the study will be maintained at the investigative site.  
In cases where no source documents will be used (i.e., data will be recorded directly onto the 
CRF without first being recorded on another document, such as the subject symptom 
questionnaires, for which data will be recorded directly on the CRF pages by the subject), the 
original data will be included in the CRF and this will be noted in the investigator files. 

Parion Sciences, Inc. 
 
P-321 Ophthalmic Solution 
Protocol P-321-201 Version 2.0 
CONFIDENTIAL 
Page 30 
 
7 TREATMENT OF SUBJECTS 
7.1 Treatment Administration 
Study medication will be administered by the PI or clinical site personnel at Visits 2 and 3.  At 
Visit 2, eligible subjects will be randomized (1:1 ratio) to receive one of two treatment 
sequences: P-321 Ophthalmic Solution at Visit 2, and Placebo at Visit 3, or Placebo at Visit 2 
and P-321 at Visit 3.  The order of the treatment is randomized, neither the subjects nor site 
personnel will know which treatment the subject receives at which visit.  Assessments will be 
conducted before and at the indicated times after study medication administration in the 
indicated order in Section 6.   
7.2 Trial Treatments 
Subjects will receive P-321 Opthalmic Solution or Placebo in random order at Visit 2 and 3.  The 
study treatment order will be determined by the assignment of the randomization code.  P-321 
Ophthalmic Solution and Placebo.   
P-321 Ophthalmic Solution is a sterile, aqueous, non-preserved solution of approximately pH 5, 
and tonicity of approximately 290 mOsm/kg.  Placebo solution has identical composition without 
the active ingredient.  Both solutions are packaged in low density, polyethylene dropper bottles.  
Each bottle of study medication will contain sufficient volume of ophthalmic solution for the 
intended dosing (1 drop in each eye).  Only one drop should be instilled in each eye.   
For Phase 1, one pouch of study medication will be used at each clinical visit, the label on the 
pouch will indicate the visit number at which the drug will be administered (Visit 2 or Visit 3).  
The labels on the kit and the pouches will minimally contain the following information:  Study 
ID, kit number, storage temperature, and “Caution: New Drug – Limited by Federal Law to 
Investigational use”.  The study medications will be stored at approximately 2-8C in a secure 
area with limited access to study personnel. 
For Phase 2, the dose selected of P-321 Ophthalmic Solution and Placebo will be provided by a 
compounding pharmacy in identical individual vials as those of the Phase1  based on a 
randomization code.No medication kits will be prepared for Phase 2.  The pharmacy will be 
unmasked to distribute according to the randomization scheme.  The study medications will be 
stored at approximately 2-8C in a secure area with limited access to study personnel and should 
be labeled and “Caution: New Drug – Limited by Federal Law to Investigational use”.  
Pharmacy records should include Study ID, randomization number, visit number, date, and 
subject identifiers. 
The medication will be administered by the PI or clinical site personnel at each of Visit 2 and 
Visit 3.  There will be no study medication administered at an Early Termination Visit. 
7.3 Methods to Minimize Bias 
To minimize bias, the treatment regimen will be randomized and masked.  The randomization 
code will be generated by an independent designee of Parion Sciences, Inc. who is not involved 
in the day-to-day conduct of the clinical study.  The randomization code will be provided to the 
designee of Parion Sciences, Inc. who is responsible for the manufacture, packaging and labeling 

Parion Sciences, Inc. 
 
P-321 Ophthalmic Solution 
Protocol P-321-201 Version 2.0 
CONFIDENTIAL 
Page 31 
 
of the clinical supplies; further the randomization code will be maintained in a secure location 
separate from the clinical study site personnel.   
The Medical Monitor and Principal Investigator and members of the Parion team not involved in 
the conduct of the study will be unmasked as part of the Data Review Group for decision making 
on the strength of P-321 Opthalmic Solution to be used in Phase 2 of the study.  The treatment 
assignments will remain masked to subjects in the study, the clinical monitor, and other site and 
Parion Sciences personnel involved in the conduct of the study and not involved in the Data 
Review Group.  Additional unmasked reviews of subject data may occur throughout the study to 
make recommendations on further dose adjustments and for planning purposes.  These reviews 
will follow the procedures outlined in Section 6.5. 
Subjects will be assigned the next available treatment number upon qualifying to be randomized.   
7.4 Concomitant Medications 
7.4.1 Medications Permitted 
All medications including prescription, over-the-counter, and natural remedies, that the subject 
has taken within 28 days prior to Visit 1 or during the study will be recorded in the CRF and in 
the subjects’ source documents.  The name of the drug, dose, route of administration, duration of 
treatment (including start and stop dates), frequency, and indication will be recorded for each 
medication.  The use of fluorescein and lissamine green do not need to be recorded on the 
concomitant medications page.   
Subjects should use medications consistently throughout the study and for 28 days prior to Visit 
1 with the exceptions outlined in Section 7.4.2.   
7.4.2 Medications Not Permitted 
Use of the following products on visit days, while in the clinic, and for at least 6 hours after 
dosing will not be allowed (use of these all other times during the study is permitted): 
 Topical ocular medications including artificial tears, topical steroids, Restasis®, 
autologous serum, and lid wipes and scrubs. 
 Contact lens wear 
Use of the following medications during the study will NOT be allowed within 14 days of Visit 1 
or during the study: 
 Oral, nasal and ocular antihistamines 
 Oral or topical secretagogues such as pilocarpine or Evoxac 
 Topical anti-glaucoma medications 
 
Use of the following medications during the study or within 28 days prior to Visit 1 will NOT be 
allowed: 
 Investigational product or device 

Parion Sciences, Inc. 
 
P-321 Ophthalmic Solution 
Protocol P-321-201 Version 2.0 
CONFIDENTIAL 
Page 32 
 
Use of the following medications during the study or within 3 months prior to Visit 1 will NOT 
be allowed: 
 Botulinum toxin (Botox® or equivalent) injection in the periocular region 
7.5 Treatment Compliance 
Because this is a single day crossover, with study medication administered by the PI or clinical 
site personnel, treatment compliance will not be calculated.  Time of administration of study 
medication and kit number will be captured in the CRF. 
7.6 Drug Accountability 
Study medication accountability will occur during monitoring visits by Parion Sciences, Inc, or 
its designee.  Accountability will be ascertained by performing reconciliation between numbers 
of Kits/bottles of study medication received on site/compounded for distribution, number of 
bottles dispensed to subjects according to the protocol-specified dosing regimen, and the 
remaining unused study medication at the time of reconciliation.   
Clinical trial materials and bulk supplies will be shipped to the investigational site/pharmacy 
under sealed conditions.  Study medication shipment records will be verified by comparing 
actual quantity of drug received against the shipment inventory sheet accompanying the drug 
received at the site.  Accurate records of receipt and disposition of the study medications (e.g., 
dates, quantity, subject number, dose dispensed, returned, etc.) must be maintained by the 
investigator or his/her designee.  Study medication will be stored at the site in an area free of 
environmental extremes, at controlled temperatures between 2 – 8°C (36 - 46°F).  This area 
should be limited and have controlled access.   
At the end of the study, all study materials, including unused study medication bottles and bulk 
supplies will be returned to Parion Sciences, Inc. (or its designee) for disposal.  The study 
monitor or designee should verify drug accountability at routine monitoring visits.   
7.7 Maintenance of Randomization and Procedure for Breaking the Code 
The treatment assignments will be masked to the investigator, medical monitor, study site 
personnel, subjects in the study and those involved in the conduct of the study. 
Only in the case of a medical emergency, or occurrence of a suspected related, unexpected, SAE, 
may the randomization code be unmasked and made available to the investigator, medical 
monitor, subject, and/or other personnel involved in the monitoring or conduct of this study.  In 
the absence of medical need, the randomization code will not be available to the above personnel 
until after the study is completed and the database is locked.  
The Data Review Group will review unmasked data.  The Medical Monitor and Principal 
Investigator (or designee) and members of the Parion team not involved in the conduct of the 
study will be unmasked as part of the Data Review Group for decision making on the strength of 
P-321 Opthalmic Solution to be used in Phase 2 of the study.  The treatment assignments will 
remain masked to subjects in the study, the clinical monitor, and other site and Parion Sciences 
personnel involved in the conduct of the study and not involved in the Data Review 
Group.  Additional unmasked reviews of subject data may occur throughout the study to make 

Parion Sciences, Inc. 
 
P-321 Ophthalmic Solution 
Protocol P-321-201 Version 2.0 
CONFIDENTIAL 
Page 33 
 
recommendations on further dose adjustments and for planning purposes.  These reviews will 
follow the procedures outlined in Section 6.5. 
For Phase 1, a a randomization list will be generated and the kits will be labeled in a masked 
fashion.  The randomization assignments will be kept in a secure area at Parion Sciences, Inc. or 
designee.  For Phase 2, a randomization list will be provided to the pharmacy and the pharmacy 
will distribute the assigned drug according to the randomization schedule with subjects 
remaining masked.  
In case of a medical need, the investigator will treat the subject as needed regardless of 
randomized treatment.  Since there is no specific antidote to P-321 Ophthalmic Solution, 
immediate emergency unmasking is not necessary.  If the investigator feels it is necessary to 
unmask a subject’s treatment assignment after an emergency situation, the investigator must call 
the medical monitor and notify Parion Sciences, Inc.  The treatment assignment will be revealed 
on a subject-by-subject basis, leaving the masking of the remaining subjects intact. 

Parion Sciences, Inc. 
 
P-321 Ophthalmic Solution 
Protocol P-321-201 Version 2.0 
CONFIDENTIAL 
Page 34 
 
8 STATISTICS 
8.1 Statistical Methods 
8.1.1 Subject Disposition, Demographic and Background Characteristics 
Subject disposition, demographic, and background characteristics will be summarized by using 
descriptive statistics.  Baseline homogeneity with respect to demographic and background 
characteristics will be assessed via an overall F-test from analysis of variance (ANOVA).  For 
categorical variables, treatment differences will be assessed using the chi-square test or Cochran 
Mantel Haenszel (CMH) test with modified ridit scores for ordered categorical variables. 
Background characteristics include:  demographics, tear volume measurements by UHR-OCT 
and Keratograph 5M, visual acuity,  symptoms upon entry, medical history, concomitant 
medication use, tear osmolarity, tear break up time, meibomian gland assessments, corneal and 
conjunctival staining, Schirmer and IOP. 
8.1.2 Pharmacodynamic parameters 
UHR-OCT will assess the following parameters in both eyes: UTMH, LTMH, UTMV, LTMV, 
and TTMV (UTMV + LTMV).  These assessments, as appropriate, will be compared between 
each dose of P-321 Ophthalmic Solution and Placebo using a t-test for each eye separately and 
for the within-subject average.  Analysis of covariance (ANCOVA) models will be used to adjust 
for the baseline tear volume and tear meniscus height for each eye separately and for the average 
of the two eyes.  Generalized estimation equations (GEE) will also be used to account for the 
correlation between eyes.  For the GEE analysis, an exchangeable correlation matrix will be 
assumed.  Area under the curve (AUC) analysis will also be performed as an exploratory analysis 
to compare OCT assessments and  Keratograph 5M LTMH for Placebo vs each dose of P-321.  
8.1.3 Analysis of Efficacy 
This is a pharmacodynamic and tolerability study of a single administration of P-321 Ophthalmic 
Solution or Placebo, and therefore, no primary or secondary efficacy endpoints will be formally 
assessed.  
8.1.4 Analysis of Safety 
All safety data collected on or after the date that study medication was first dispensed up through 
the date of the final post dose assessment will be summarized. 
The objective of the statistical analysis of the safety parameters is to investigate the data for any 
effects of study medication on clinical tolerability.  All such parameters will be summarized by 
treatment group and time point as indicated below. Because this study, is a cross over design 
and, at the cross over treatment, the subjects may no longer be treatment naive, analysis will 
check for sequence/period effects.  If sequence/period effects are detected, the analysis of safety 
will use just the first period results.  Provided that no sequence/period effects are seen, analysis 
will use the most-recent treatment received as the treatment group. 
In the absence of any predefined hypotheses, the general strategy of the safety analysis will be to 
examine the data summaries for any trends amongst the treatment groups.  No formal hypothesis 
testing will be carried out.  

Parion Sciences, Inc. 
 
P-321 Ophthalmic Solution 
Protocol P-321-201 Version 2.0 
CONFIDENTIAL 
Page 35 
 
The incidence of AEs will be tabulated by treatment group overall, by treatment sequence, by 
severity, and relationship to study medication.   
Change from baseline values (or shifts from baseline, if more appropriate) will be presented for 
other safety measures for the visits at which they are assessed. 
8.1.5 Interim Reviews of Data  
A Data Review Group will review unmasked data when approximately 8 subjects have 
completed Phase 1.  The Data Review Group will include the Prinicpal Investigator (or 
designee), the Medical Monitor and representative of Parion Sciences not involved in the 
conduct of the study.  Other study site personnel, subjects in the study and those involved in the 
conduct of the study will remain masked.  Additional unmasked reviews of subject data may 
occur throughout the study to make recommendations on further dose adjustments and for 
planning purposes.  These reviews will follow the procedures outlined in Section 6.5. 
8.2 Sample Size Estimation 
An initial sample size of approximately 24 subjects is proposed for this study. The study design 
includes OCT measurements at time 0 (pretreatment) and post dose at 15 minutes, 30 minutes, 1 
hour, 2 hours, 4 hours and 6 hours. Shen et al. (Shen, 2009) reported that among the measures of 
tear volume and tear film thickness obtainable through OCT, the most sensitive and specific 
measure of dry eye is the low tear meniscus height (LTMH). Power estimations for a two-period, 
two-treatment, two-sequence crossover design (2x2x2),this study size when all subjects treated 
with P-321are analyzed, will provide 98% power to detect a difference of 60 μm at 1 hour or a 
power of 99% if the average increase in LTMH over the six hours is 60 μm (assuming within-
subject SD of 71). In this study it is expected that the drug will reach its peak effect at 1 hour 
post dose and that the effect diminishes at hours 4 and 6 (to values still above pre-dose values).   
 
8.3 Level of Significance 
Each hypothesis will be tested at a significance level of 0.05.   
8.4 Criteria for Termination of an Individual Subject 
An individual subject may be terminated from the trial for any reason including, but not limited 
to the following: 
 Subject withdrawing consent to continue in the trial  
 Occurrence of an AE which precludes subsequent participation  
 Requirement of an ocular surgery or intervention that is exclusionary for the trial 
 Physician discretion based on the ability of the subject to continue schedule or treatment 
regimens according to protocol, or for the safety of the subject  
 In the event that a woman becomes pregnant while participating on the study, she will be 
withdrawn from the study 
8.5 Criteria for Termination of the Trial 
The trial may be discontinued by Parion Sciences, Inc. or at the recommendation of the principal 
investigator after consultation with Parion.  This may be based on a significant number of AEs of 

Parion Sciences, Inc. 
 
P-321 Ophthalmic Solution 
Protocol P-321-201 Version 2.0 
CONFIDENTIAL 
Page 36 
 
a similar nature that warrant such action, or at the request of Parion Sciences, Inc.  Should this be 
necessary, both parties will arrange discontinuation procedures and notify the appropriate 
regulatory authority(ies) and Institutional Review Board (IRB). In terminating the study, Parion 
Sciences and the investigator will assure that adequate consideration is given to the protection of 
the subjects’ interests.   
8.6 Procedure for Accounting for Missing, Unused, or Spurious Data 
All analyses will be based on observed data only.  No attempts will be made to impute or 
estimate missing data. 
8.7 Procedure for Reporting Deviations from the Statistical Plan 
Any deviations from the statistical plan will be described and a justification given in the final 
clinical report. 
8.8 Subjects to be Included in the Analysis 
All safety analyses will include all subjects who were randomized and received at least one dose 
of study medication.   

Parion Sciences, Inc. 
 
P-321 Ophthalmic Solution 
Protocol P-321-201 Version 2.0 
CONFIDENTIAL 
Page 37 
 
9 ASSESSMENT OF PHARMACODYNAMICS 
Detailed measurements of tear volume before and after dose administration will be obtained 
using UHR-OCT (tear volume and tear meniscus height) and Keratograph 5M (tear meniscus 
height).  Procedures for these measurements are located in Appendix X. 

Parion Sciences, Inc. 
 
P-321 Ophthalmic Solution 
Protocol P-321-201 Version 2.0 
CONFIDENTIAL 
Page 38 
 
10 ASSESSMENT OF SAFETY 
10.1 Safety Parameters 
Subject safety will be evaluated by a medical professional during the study.  Tolerance of study 
medication as well as general subject well-being will be assessed.  Subjects may be discontinued 
from the study at any time by the investigator if this action is considered in the subject's best 
interest. 
Post dose safety parameters are measured as described in Appendix I and include: 
 Assessment of adverse events (Appendix II) 
 Biomicroscopy and external eye examination (Appendix IV) 
 Assessment of comfort in taking the medication will be conducted (Appendix XI) 
10.2 Procedures for Adverse Events Reporting  
An AE is any untoward medical occurrence in a subject or clinical investigation subject 
administered a pharmaceutical product, which does not necessarily have to have a causal 
relationship with this treatment.  AEs will be documented upon signing the informed consent.  A 
treatment emergent AE (TEAE) is an AE that either commenced following initiation of study 
treatment or was present prior to study treatment but increased in frequency or severity following 
initiation of study treatment.   
A non-serious AE is any AE that does not meet the definitions for SAEs as described in 
Section 10.3.   
AEs that occur prior to subject randomization at Visit 2 will be documented in source 
documents. TEAEs will be monitored throughout the study and will be recorded on the CRF with 
the date and time of onset, date and time of resolution, intensity, seriousness, causality 
(relationship to study medication), treatment required and the outcome.   
If an AE occurs, the investigator will institute support and/or treatment as deemed appropriate.  
If a non-serious AE is unresolved at the time of the last visit, a reasonable effort will be made to 
follow up until the AE is resolved or stabilized, the subject is lost to follow-up, or there is some 
other resolution of the event.   
To elicit AEs simple questions with minimal connotations should be used as the initial questions 
at all evaluation points during the trial.  For example: 
 How have you felt since your last assessment? 
 Have you had any health problems since your last assessment? 
10.3 Serious Adverse Event Reporting 
An SAE is any untoward medical occurrence occurring on this trial that results in any of the 
following outcomes: 
 Death  

Parion Sciences, Inc. 
 
P-321 Ophthalmic Solution 
Protocol P-321-201 Version 2.0 
CONFIDENTIAL 
Page 39 
 
 A life-threatening adverse drug experience (i.e., the subject is at immediate risk of death 
at the time of the event)  
 In-patient hospitalization or prolongation of existing hospitalization  
 A persistent or significant incapacity or substantial disruption of the ability to conduct 
normal life functions 
 
A congenital anomaly/birth defect   
 
Important medical events that may not result in death, be life-threatening, or require 
hospitalization may be considered serious when, based upon appropriate medical 
judgment, they may jeopardize the subject and may require medical or surgical 
intervention to prevent one of the outcomes listed in this definition 
The Investigator or other study personnel must immediately inform Parion Sciences or designee 
by phone or email of any AE considered serious or otherwise significant, as described above.  In 
addition, a completed SAE report form must be submitted to Parion within 24 hours of 
initial awareness of the event. 
 
SAE Reporting 
Dedicated Safety Email Address:   safety@parion.com 
 
It is the responsibility of the investigator or their designee to report any event of this nature to 
Parion Sciences, Inc. within 24 hours of the event being brought to the investigator’s or their 
staffs' attention.  It is also the responsibility of the investigator to report all SAEs to their IRB 
according to their requirements and provide a copy of this notification to Parion Sciences.  The 
investigator should make every attempt to follow all SAEs to resolution. 
Information to submit when reporting an SAE to Parion Sciences, Inc. is located in Appendix II. 
10.4 Procedures for Reporting Pregnancy 
Any subject found to be pregnant at any time during the study will be withdrawn from the study 
immediately.  Any pregnancy outcome that meets the criteria for an SAE will be reported as an 
SAE.  All pregnancies will be reported to Parion Sciences within 24 hours of the event being 
brought to the investigator’s or their staffs' attention.  It is also the responsibility of the 
investigator to report all pregnanciess to their IRB according to their requirements and provide a 
copy of this notification to Parion Sciences.  The investigator should make every attempt to 
follow all pregnancies to resolution (i.e., birth or voluntary or spontaneous termination of the 
pregnancy).   
 

Parion Sciences, Inc. 
 
P-321 Ophthalmic Solution 
Protocol P-321-201 Version 2.0 
CONFIDENTIAL 
Page 40 
 
11 DIRECT ACCESS TO SOURCE DATA and DOCUMENTS 
The principal investigator will permit trial-related monitoring, audits, IRB review, and regulatory 
inspection(s) by providing direct access to source data and documents.   

Parion Sciences, Inc. 
 
P-321 Ophthalmic Solution 
Protocol P-321-201 Version 2.0 
CONFIDENTIAL 
Page 41 
 
12 QUALITY CONTROL AND QUALITY ASSURANCE 
The progress of the study will be monitored by on-site, written, e-mail and telephone 
communications between personnel at the study center and Parion Sciences, Inc. (or designated 
monitor).  The investigator will allow Parion Sciences, Inc. clinical monitors, designees, 
auditors, and regulatory authorities to inspect all CRFs; subject records (source documents), 
signed informed consent forms; records of study medication receipt, storage, and dispensation; 
and regulatory files related to this study. 
At the time of database lock, the clinical database will be audited in order to ensure accuracy of 
all data as well as to provide an estimated error rate for the final, locked database.  The results of 
the audit will be provided in the final study report.  The audit will involve a comparison of CRF 
values with values from data listings generated from the clinical database.  Values of all 
variables will be confirmed for the five randomly selected subjects.  If the database fails to meet 
an accuracy rate of 99.5% (less than 1 error / 200 fields), a second set of 5 subjects will be 
selected, If a combined sample fails to meet an accuracy rate of 99.5%, the remainder of the 
database will be rechecked or take other action taken agreed with by Parion. 

Parion Sciences, Inc. 
 
P-321 Ophthalmic Solution 
Protocol P-321-201 Version 2.0 
CONFIDENTIAL 
Page 42 
 
13 ETHICS 
This protocol is written in accordance with the principles established by the 18th World Medical 
Assembly General Assembly (Helsinki, 1964) and amendments and clarifications adopted by 
subsequent General Assemblies.  The investigator will make sure that the study described in this 
protocol is conducted in full conformance with those principles, the protocol, current FDA 
regulations, ICH Good Clinical Practices (GCP) guidelines, Good Laboratory Practices (GLP) 
guidelines, local ethical and regulatory requirements, including the Federal Food, Drug and 
Cosmetic Act, U.S. applicable Code of Federal Regulations (CFR) (title 21), any Ethics 
Committee (EC) requirements relative to clinical studies.  As required by the US FDA, the study 
drug may not be shipped to any participating investigator until the requisite study documentation 
has been submitted to the IND. 
13.1 Institutional Review Board 
The EC/IRB must be a properly constituted board or committee operating in accordance with 21 
CFR Part 56, “Institutional Review Boards.”  This protocol, any protocol amendments and the 
associated informed consent forms and translations must be submitted to the EC/IRB for review 
and approved before the enrollment of any subject into the trial. 
All subject recruitment materials and advertising information, including translated versions of 
these documents, must be submitted to Parion or its designee and to the EC/IRB for review and 
approval prior to implementation.  EC/IRB approval of any protocol amendments must be 
received before any of the changes outlined in the amendments are put into effect, except when 
the amendment has been enacted to eliminate a potential hazard to study subjects.  In such cases, 
the chair of the EC/IRB should be notified immediately and the amendment forwarded to the 
EC/IRB for review and approval. 
In addition, the Clinical Investigator Brochure should be submitted to the IRB.   
Written IRB approval must adequately identify the materials approved.  Copies of all approved 
materials, all correspondence with the IRB, and written approval from the IRB must be made 
available to Parion Sciences, Inc. (or designated monitor) prior to shipment of study medication 
and the start of subject enrollment into the study. 
SAEs will be reported to the IRB by the principal investigator as required by the IRB.   
13.2 Informed Consent Requirements 
Written informed consent will be obtained from each subject prior to any study related 
procedures being performed.  A copy of the signed and dated consent document will be given to 
each subject.  The original signed and dated informed consent document must be maintained in 
the study files at the investigative site and be available for Parion Sciences, Inc. or designee, and 
regulatory authorities for review. 
Each informed consent form will contain contact information with a telephone number the 
subject should contact if they have medical concerns 24-hours a day.   

Parion Sciences, Inc. 
 
P-321 Ophthalmic Solution 
Protocol P-321-201 Version 2.0 
CONFIDENTIAL 
Page 43 
 
13.3 Data Handling and Record Keeping 
All procedures for the handling and analysis of data will be conducted using good clinical 
practices meeting ICH and U.S. Food and Drug Administration (FDA) guidelines for the 
handling and analysis of data for clinical trials. 
13.4 Data Quality Control and Reporting 
After data have been entered into the study database, a system of computerized data validation 
checks and manual data reviews will be implemented and applied to the database.  Query reports 
pertaining to data omissions and discrepancies will be forwarded to the clinical investigator and 
monitor(s) for resolution.  The study database will be updated in accordance with the resolved 
query reports.  All changes to the study database will be documented. 
CRFs will be provided by Parion Sciences, Inc.  All data relating to the trial must be recorded in 
the CRFs.  The Investigator must verify that all data entries in the CRFs are accurate and 
complete. The CRF must be signed and dated by the Investigator upon subject withdrawal or 
completion of the study. 
During monitoring visits, CRFs will be reviewed by study monitor(s) for completeness, 
accuracy, and legibility. CRFs will be compared with the source documents to ensure that there 
are no discrepancies. All CRF entries, corrections, and alterations must be made by an 
Investigator or his/her designee. Corrections must be made in such a way that the original entry 
is not obliterated. Correction fluid must NOT be used. The correct data must be inserted, dated 
and initialed by the Investigator or his/her designee. The study monitor is not allowed to make 
entries on the CRF pages. 
The original CRF page will be retrieved by the monitor and returned to Parion Sciences, Inc. 
after complete review of the case.  A copy must be maintained by the Investigator.  If 
documented corrections to a CRF are needed after removal of the original CRF copy from the 
center, a Data Correction Form (DCF) will be used. The Investigator or a staff member must 
verify, sign, and date each DCF. 
A log will be maintained at the sites for those subjects that do not meet eligibility criteria. 
Minimally this log will include the subject’s age, sex and race and the reason that they were not 
eligible.  Screen failure data will not be collected in the clinical database.   
13.5 Records Retention 
The study center will retain all records related to the study in compliance with ICH Good 
Clinical Practices Guidelines. 
13.6 Publication Policy 
The institution and investigators participating in this trial shall have no rights to publish, disclose 
or present the results of this study without prior written consent of Parion Sciences, Inc. 

Parion Sciences, Inc. 
 
P-321 Ophthalmic Solution 
Protocol P-321-201 Version 2.0 
CONFIDENTIAL 
Page 44 
 
14 REFERENCES 
Arita R, Itoh K, Inoue K, Amano S. Noncontact infrared meibography to document age-related 
changes of the Meibomian glands in a normal population. Ophthalmology. 2008;115:911–915. 
Barker, P. M., Nguyen, M. S., Gatzy, J. T., Grubb, B., Norman, H., Hummler, E., Koller, B. 
(1998). Role of gammaENaC subunit in lung liquid clearance and electrolyte balance in newborn 
mice. Insights into perinatal adaptation and pseudohypoaldosteronism. The Journal of Clinical 
Investigation, 102(8), 1634–40. doi:10.1172/JCI3971. 
Foulks G, Bron AJ. A clinical description of meibomian gland dysfunction. Ocul Surf. 
2003;1:107–126. 
Fujihara, T., Murakami, T., Fujita, H., Nakamura, M., Nakata, K. (2001). Improvement of 
corneal barrier function by the P2Y(2) agonist INS365 in a rat dry eye model. Investigative 
Ophthalmology & Visual Science, 42(1), 96–100. 
Korb D.R., Herman J.P., Greiner J.V., Scaffidi R.C., Finnemore V.M., Exford J.M., Blackie 
C.A., Douglass T. (2005) Lid Wiper Epitheliopathy and Dry Eye Symptoms.  Eye and Contact 
Lens, 31(1), 2-8. 
Krueger, B., Schlötzer-Schrehardt, U., Haerteis, S., Zenkel, M., Chankiewitz, V. E., Amann, K. 
U., Korbmacher, C. (2012). Four subunits (αβγδ) of the epithelial sodium channel (ENaC) are 
expressed in the human eye in various locations. Investigative Ophthalmology & Visual Science, 
53(2), 596–604. doi:10.1167/iovs.11-8581. 
Lemp, M. A. (1995). Report of the National Eye Institute/Industry workshop on Clinical Trials in 
Dry Eyes. The CLAO Journal : Official Publication of the Contact Lens Association of 
Ophthalmologists, Inc, 21(4), 221–32. 
Levin, M. H., Kim, J. K., Hu, J., & Verkman, A. S. (2006). Potential difference measurements of 
ocular surface Na+ absorption analyzed using an electrokinetic model. Investigative 
Ophthalmology & Visual Science, 47(1), 306–16. doi:10.1167/iovs.05-1082. 
Ngo W., Situ P., Keir N., Korb D., Blackie C., Simpson T., (2013). Psychometric Properties and 
Validation of the Standard Patient Evaluation of Eye Dryness Questionnaire. Cornea, (32):1204–
1210. 
Saboo, U., Amparo, F., Abud, T., Schaumberg, D., Dana, R., (2015). Vision-Related Quality of 
Life in Patients with Graft-versus-Host Disease. Ophthalmology, 122 (8), 1669-1674. 
Schaumberg, D. A., Gulati, A., Mathers, W. D., Clinch, T., Lemp, M. A., Nelson, J. D., Dana, R. 
(2007). Development and validation of a short global dry eye symptom index. The Ocular 
Surface, 5(1), 50–7. 

Parion Sciences, Inc. 
 
P-321 Ophthalmic Solution 
Protocol P-321-201 Version 2.0 
CONFIDENTIAL 
Page 45 
 
Schiffman R.M., Christianson M.D., Jacobsen G., Hirsch J.D., Reis B.L. (2000). Reliability and 
validity of the Ocular Surface Disease Index. Arch Ophthalmol., 118:615-621. 
 
Shen M., Li J., Wang J., Ma H., Cai C., Tao A., Yuan Y., Lu F (2009). Upper and lower tear 
menisci in the diagnosis of dry eye. Invest. Ophthalmol. Vis. Sci., 50:2722-2726 
Stern, M. E., Gao, J., Siemasko, K. F., Beuerman, R. W., & Pflugfelder, S. C. (2004). The role of 
the lacrimal functional unit in the pathophysiology of dry eye. Experimental Eye Research, 
78(3), 409–16. 
Thelin, W. R., Johnson, M. R., Hirsh, A. J., Kublin, C. L., & Zoukhri, D. (2012). Effect of 
topically applied epithelial sodium channel inhibitors on tear production in normal mice and in 
mice with induced aqueous tear deficiency. Journal of Ocular Pharmacology and Therapeutics : 
The Official Journal of the Association for Ocular Pharmacology and Therapeutics, 28(4), 433–
8. doi:10.1089/jop.2011.0157. 
Yu, D., Thelin, W. R., Randell, S. H., & Boucher, R. C. (2012a). Expression profiles of 
aquaporins in rat conjunctiva, cornea, lacrimal gland and Meibomian gland. Exp Eye Res. (103), 
22–32.  
Yu, D., Thelin, W. R., Rogers, T. D., Stutts, M. J., Randell, S. H., Grubb, B. R., & Boucher, R. 
C. (2012b). Regional differences in rat conjunctival ion transport activities. Am J Physiol Cell 
Physiol., 303(7), C767–780. 
 

Parion Sciences, Inc. 
 
P-321 
Protocol P-321-201  
 
CONFIDENTIAL 
Page 46 
 
APPENDIX I: SCHEDULE OF VISITS AND PROCEDURES. 
Table 1 
Schedule of Visits and Procedures  
Event 
Visit 1 
Visit 2 
 
Visit 3 
ET 
Screening Visit 
First Treatment Visit 
(3 to 9 days after Visit 1) 
Wash-out  
(7 to 14 Days) 
Second Treatment Visit 
(7 to 14 days after Visit 2) 
Early Termination Visit 
Informed Consent 
X 
 
 
 
 
Eligibility Criteria Reviewed 
X 
X 
 
X 
 
Medical History/Changes 
X 
X 
 
X 
X 
Concomitant 
Medication/Changes  
Xa 
X 
 
X 
X 
Abbreviated Physical Exam 
X 
 
 
 
X 
Vital Signs 
X 
Xb 
 
Xb 
X 
Tear Osmolarity 
X 
 
 
 
 
Assessment of Meibomian 
Glandsc 
X 
 
 
 
 
Pregnancy Test 
X 
 
 
 
 
Serum Chemistry 
X 
 
 
 
 
Hematology 
X 
 
 
 
 
Dry Eye Symptomsd 
X 
X 
 
X 
 
Study Medication 
Administration 
N/A 
One drop per eye in AMe 
 
One drop per eye in AMe 
 
UHR-OCT Assessmentsf 
Xg 
Xh 
 
Xh 
 
Keratograph 5M 
Xg 
Xh 
 
Xh 
 
Drop Instillation Comfort 
Assessmenti 
 
X 
 
X 
 

Parion Sciences, Inc. 
 
P-321 
Protocol P-321-201  
 
CONFIDENTIAL 
Page 47 
 
Event 
Visit 1 
Visit 2 
 
Visit 3 
ET 
Screening Visit 
First Treatment Visit 
(3 to 9 days after Visit 1) 
Wash-out  
(7 to 14 Days) 
Second Treatment Visit 
(7 to 14 days after Visit 2) 
Early Termination Visit 
Post Instillation Dry Eye 
Symptoms Assessment  
 
Xj 
 
Xj 
 
Visual Acuity 
X 
 
 
 
 
Biomicroscopy and External 
Eye Examination 
X 
Xk 
 
Xk 
X 
Corneal Staining 
X 
 
 
 
 
Conjunctival Staining 
X 
 
 
 
 
TBUT 
X 
 
 
 
 
Intraocular Pressure  
X 
 
 
 
 
Schirmer’s Test 
X 
 
 
 
 
Adverse Event Monitoring 
X 
X 
 
X 
X 
a. 
Concomitant medications taken within 28 days of screening will be reviewed 
b. 
To be completed pre-treatment 
c. 
Meibomian gland assessment to include clinical exam and meibography 
d. 
Dry eye symptom questionnaires (OSDI, SPEED, and SANDE with SANDE part 1 at visit 1, 2 and 3 and Part 2 at Visit 2 and Visit 3 only) will be administered pre-
dose and before other procedures. 
e. 
Remove study medication from refrigerator at least 15 minutes before administration 
f. 
Measurementes include: UTMH, LTMH, UTMV, LTMV, and TTMV (UTMV + LTMV) 
g. 
To be measured three times in one hour (at 0 minutes, 30 minutes, and 60 minute interval) 
h. 
Timepoints: Pre dose and post dose at 15±5 minutes, 30±10 minutes, 1 hour±20 minutes, 2 hours±30 minutes, 4 hours±30 minutes, and 6 hours±30 minutes 
i. 
To be completed approximately 5 minutes after dosing 
j. 
To be completed immediately prior to the 2 hour post dose tear volume measurements 
k. 
To be completed after 6 hour tear volume assessment 
 
 

Parion Sciences, Inc. 
 
P-321 Ophthalmic Solution 
Protocol P-321-201  
CONFIDENTIAL 
Page 48 
 
APPENDIX II: ADVERSE EVENT REPORTING 
Adverse Event Definitions 
Adverse Event (AE):  Any untoward medical occurrence in a subject or clinical investigation 
subject administered a pharmaceutical product; which does not necessarily have a causal 
relationship with this treatment.  
Treatment Emergent Adverse Event (TEAE): A treatment emergent AE (TEAE) is an AE that 
either commenced following initiation of study treatment or was present prior to study treatment 
but increased in frequency or severity following initiation of study treatment.   
A SERIOUS ADVERSE EVENT (SAE) is any adverse drug experience occurring at any dose 
that results in any of the following outcomes:  
 Death 
 A life-threatening adverse drug experience (i.e., the subject is at immediate risk of death 
at the time of the event) 
 In-patient hospitalization or prolongation of existing hospitalization 
 A persistent or significant incapacity or substantial disruption of the ability to conduct 
normal life functions 
 A congenital anomaly/birth defect 
 Important medical events that may not result in death, be life-threatening, or require 
hospitalization may be considered serious when, based upon appropriate medical 
judgment, they may jeopardize the subject and may require medical or surgical 
intervention to prevent one of the outcomes listed in this definition 
A NON-SERIOUS ADVERSE EVENT is any adverse event that does not meet the definitions 
for serious adverse events as described above.  
Adverse Event Classification 
Each Adverse Event will be classified as SERIOUS or NONSERIOUS using the definitions 
provided above. 
The INTENSITY of each Adverse Event will be classified as MILD, MODERATE, or 
SEVERE.   
The CAUSALITY of the Adverse Event will be classified as NOT RELATED to study 
medication, POSSIBLY RELATED to study medication, or RELATED to study 
medication defined as follows: 
Not related: 
An event that does not follow a reasonable temporal sequence from 
administration to the suspected drug, is not a known response pattern to 
the suspect drug or due wholly to the subject’s clinical state or other 
factors.  

Parion Sciences, Inc. 
 
P-321 Ophthalmic Solution 
Protocol P-321-201  
CONFIDENTIAL 
Page 49 
 
Possibly related: 
An event that follows a reasonable temporal sequence form administration 
of the study medication, follows a known or expected response pattern to 
the suspected drug, but that could be explained by the subject’s clinical 
state or other factors. 
Related: 
An event that follows a distinct temporal sequence from administration of 
the study medication, follows a known or expected response pattern to the 
suspected drug, and cannot be explained by subject’s clinical state or other 
factors  
Serious Adverse Event Reporting 
The following information should be provided when an SAE is reported to Parion Sciences: 
1. Protocol Number 
2. Site ID 
3. Subject Initials 
4. Subject Number 
5. Subject Demographic information, including: 
a. Date of Birth 
b. Sex 
c. Race 
6. Start date of study medication administration 
7. Date of last dose of study product  
9. SAE information, including: 
a. SAE Term (diagnosis only; if known or serious signs/symptoms) 
b.  Description of SAE/narrative 
c. Date of onset 
d. Outcome 
e. Date of resolution or death 
f. Duration of SAE if less than 24 hours 
g. Relationship to study medication 
h.  Action taken with Study medication 
i. If ocular, which eye(s) were affected 
10. Criteria for classifying the event as serious, including whether the SAE resulted in any of 
the following:   
a. Death 

Parion Sciences, Inc. 
 
P-321 Ophthalmic Solution 
Protocol P-321-201  
CONFIDENTIAL 
Page 50 
 
b. Life-threatening 
 
c. In-patient hospitalization or prolongation of existing hospitalization 
 
d. A persistent or significant incapacity or substantial disruption of the ability to conduct 
normal life functions 
 
e. Congenital anomaly/birth defect 
 
f. Important medical events that may not result in death, be life-threatening, or require 
hospitalization may be considered serious when, based upon appropriate medical 
judgment, they may jeopardize the subject and may require medical or surgical 
intervention to prevent one of the outcomes listed in this definition. Examples of such 
medical events include allergic bronchospasm requiring intensive treatment in an 
emergency room or at home, blood dyscrasias or convulsions that do not result in in-
patient hospitalization, or the development of drug dependency or drug abuse. 
11. Concomitant medications 
12. Relevant history 
13. Possible causes of SAE other than study medication 
14. Copy of the Adverse Event page from the Case Report Form if the subject has been 
randomized 
15. Signed copy of the SAE form  
 
 

Parion Sciences, Inc. 
 
P-321 Ophthalmic Solution 
Protocol P-321-201  
CONFIDENTIAL 
Page 51 
 
APPENDIX III: VISUAL ACUITY ASSESSMENT 
Visual acuity will be measured by the M&S Technologies Smart System II (Park Ridge, IL).  
This is a  computer generated visual acuity test.  The Smart System II comprises a computer 
processor, using a flat LCD screen monitor, and an interactive keypad controller. The LCD 
screen monitor is wall-mounted and manufactured to M&S Technologies’ specifications, with 
high resolution and a 450:1 nominal contrast ratio.  The examiner uses the keypad to access 
directly each primary acuity test, specific optotypes, randomization options, and to increase or 
decrease the size of the optotype on demand.  The system allows the examiner to present random 
letter sequences to preclude subjects from memorizing the sequence to pass each line. The Smart 
System II can be calibrated for lane lengths of 6 to 22 feet. 
  
 

Parion Sciences, Inc. 
 
P-321 Ophthalmic Solution 
Protocol P-321-201  
CONFIDENTIAL 
Page 52 
 
APPENDIX IV: BIOMICROSCOPY/EXTERNAL EYE EXAMINATION 
Slit lamp biomicroscopy will be performed and the observations will be graded as described 
below: 
Lashes 
 
0= Normal 
 
1= Abnormal 
 
Eyelid 
 
Erythema  
 0 = Normal, without any redness 
 
 
+1 = A low grade flushed reddish color 
 
 
+2 = Diffused redness encompassing the entire lid margin 
+3 = Deep diffused reddish color of lid margins and superior or inferior eyelid 
Edema 
 
 
    
0 = Normal, no swelling of the lid tissue 
 
 
+1 = Slight diffuse swelling above normal 
 
 
+2 = General swelling 
 
+3 = Swelling sufficient to close the lid 
 
Conjunctiva 
Erythema 
0 = Normal 
+1 = A flush, pink color predominantly confined to the palpebral or bulbar     
conjunctiva; slight localized injection 
+2 = More prominent red color of the palpebral or bulbar conjunctiva 
+3 = Marked redness of the palpebral or bulbar conjunctiva 
 
Edema 
  
 0 = Normal, no swelling of the conjunctiva 
+1 = Slight diffuse or regional swelling of the conjunctiva 
+2 = General swelling of the conjunctiva 
+3 = Extensive swelling of the conjunctiva 
 
Tear Film Debris 
 
 
  0 = None; absence of debris 
 
 
+1 = Mild; presence of debris in inferior tear meniscus 
+2 = Moderate; presence of debris in inferior tear meniscus and in tear film overlying 
 
cornea 
+3 = Severe; presence of debris in inferior tear meniscus and in tear film overlying 
cornea  
presence of mucus strands in inferior fornix or on bulbar conjunctiva 
+4 = Very Severe; presence of debris in inferior tear meniscus and in tear film overlying 
cornea;  
presence of numerous AND/OR adherent mucus strands in inferior fornix and on 
bulbar conjunctiva or filamentary keratitis 

Parion Sciences, Inc. 
 
P-321 Ophthalmic Solution 
Protocol P-321-201  
CONFIDENTIAL 
Page 53 
 
 
 
Cornea 
Endothelial Changes 
 
 
  0 = Normal 
 
 
+1 = Slight pigment, keratoprecipitates, guttata 
 
 
+2 = Moderate pigment, keratoprecipitates, guttata 
 
 
+3 = Dense pigment, keratoprecipitates, guttata    
 
Edema 
    
0 = None, transparent and clear 
 
 
+1 = Mild, dull glassy appearance 
 
 
+2 = Moderate, dull glassy appearance of epithelium with large number of vacuoles 
 
+3 = Severe, epithelial bullae and/or stromal edema, localized or diffuse, with or without 
stromal striae.    
 
Anterior Chamber 
 
Cells 
 
 
  0 = No cells seen 
 
 
+1 = + cells 
 
 
+2 = ++ cells 
 
 
+3 = +++ cells 
 
 
+4 = ++++ cells, Hypopyon formation 
 
Flare 
 
 
  0 = No Tyndall effect 
+1 = Tyndall beam in the anterior chamber has a mild intensity 
 
+2 = Tyndall beam in the anterior chamber is of strong intensity 
+3 = Tyndall beam is very intense; the aqueous has a white, milky appearance 
 
 
Lens Pathology 
 
0 = Normal; no opacity in the lens 
1 = Abnormal; existing opacity in the lens; aphakic or pseudophakic eyes or other 
abnormal findings. 
 

Parion Sciences, Inc. 
 
P-321 Ophthalmic Solution 
Protocol P-321-201  
CONFIDENTIAL 
Page 54 
 
APPENDIX V: FLUROSCEIN TEAR BREAK‐UP TIME (TBUT) 
Non-preserved fluorescein will be used to conduct this assessment.  When conducting all 
assessments room temperature and humidity should be relatively consistent throughout each visit 
and throughout the study. 
TBUT should be conducted as specified in Appendix I:  Schedule of Visits and Procedures. 
Fluorescein Tear Break-Up Time 
 Perform the examination with the slit lamp at 10X magnification and cobalt blue 
illumination. 
 Draw 5 L of 2% sodium fluorescein into the micropipette, allowing a drop to form. 
 Gently touch the drop at the tip of the delivery dropper to the lower palpebral conjunctiva 
of the right eye.   
 In order to thoroughly mix the fluorescein with the tear film, ask the subject to blink 
several times and move his/her eye around. 
 Using a stop watch, measure the time it takes for the appearance of the first dry spot after 
blinking. 
 Ask the subject to blink again and repeat the measurement of the time it takes for the 
appearance of the first dry spot after blinking.  Repeat this procedure once more for a 
total of three measurements.  
NOTE:  If this procedure is completed within two minutes, proceed to measure corneal staining 
in the same eye as described in Appendix VI without applying more fluorescein. 
 Repeat these steps for the left eye. 
 Using these three assessments calculate the mean time in seconds for each eye and record 
this time in the subject’s chart as well as the case report form. 
 
 
 

Parion Sciences, Inc. 
 
P-321 Ophthalmic Solution 
Protocol P-321-201  
CONFIDENTIAL 
Page 55 
 
APPENDIX VI: FLUORESCEIN CORNEAL STAINING  
The cornea will be stained with non-preserved, 2% fluorescein as described by Lemp et al. 
(Lemp, 1995).  When conducting all assessments room temperature and humidity should be 
relatively consistent throughout each visit and throughout the study. 
Corneal Staining should be conducted as specified in Appendix I: Schedule of Visits and 
Procedures. 
Corneal Staining 
 Using a yellow barrier filter (Wratten or Tiffen #11 or #12) and the slit lamp with cobalt 
blue illumination, with a 3 mm slit width and 10X or 16X magnification. 
 Draw a 5 L drop of fluorescein in the right eye. 
 In order to thoroughly mix the fluorescein with the tear film, ask the subject to blink 
several times and move his/her eye around. 
 Wait two minutes. 
 Evaluate the cornea for staining referencing the diagram below.   
 Punctate staining is recorded using a standard grading system of 0-3 for each of the five 
areas shown below. 
 Repeat this procedure for the left eye. 
 

Parion Sciences, Inc. 
 
P-321 Ophthalmic Solution 
Protocol P-321-201  
CONFIDENTIAL 
Page 56 
 
APPENDIX VII: LISSAMINE GREEN CONJUNCTIVAL STAINING 
The conjunctiva will be stained with non-preserved, 1% lissamine green as described by Lemp et 
al. (Lemp, 1995).  When conducting all assessments room temperature and humidity should be 
relatively consistent throughout each visit and throughout the study. 
Conjunctival Staining should be conducted as specified in Appendix I:  Schedule of Visits and 
Procedures. 
 Without flushing the eye from the previous assessment, instill a 20 l drop of lissamine 
green to the right eye using a micropipette, allowing a drop to form. 
 Gently touch the drop at the tip of the delivery dropper to the lower palpebral conjunctiva 
of the right eye.    
 In order to thoroughly coat the ocular surface with the lissamine, ask the subject to blink 
several times and move his/her eye around. 
 After 1 minute and before 4 minutes have elapsed, using white light of moderate 
intensity, grade the areas of the conjunctiva of the right eye with the 0-3 scale shown 
below. 
 Repeat this procedure for the left eye. 
 
 
 

Parion Sciences, Inc. 
 
P-321 Ophthalmic Solution 
Protocol P-321-201  
CONFIDENTIAL 
Page 57 
 
APPENDIX VIII: INSTILLATION OF MEDICATION 
Study personnel will instill medication at Visit 2 (First Treatment Visit) and Visit 3 (Second 
Treatment Visit). 
Instilling the Medication 
 The study personnel will remove the study medication from the refrigerator at least 15 
minutes prior to planned administration. 
 The study personnel will record the kit number in the subject’s records and the Subject 
ID  number on the labels of the kit and vial pouches before proceeding with dosing the 
subject: 
 Confirm that the visit number on the pouch corresponds to the subject’s visit  
 Open the pouch  
 Instruct subject to slightly tilt his/her head back and look upward 
 The study personnel should gently squeeze the bottle allowing one drop to coat the ocular 
surface.  
 Repeat procedure for left eye using the same bottle. 
 The subject should gently close his or her eyes for a few seconds. 
 Use one pouch of assigned study medication for Visit 2 and one pouch for Visit 3.   
 The used bottle should be returned to its pouch and the pouch returned to its kit box. 
 After dose administration at Visit 2, return the kit containing one used, and one unused 
bottle to the refrigerator. 
 After dosing at Visit 3, return the bottle into the pouch and place the pouch in the kit box.  
At this time, the kit containing two used bottles can be stored at room temperature before 
returning to the sponsor for disposal. 

Parion Sciences, Inc. 
 
P-321 Ophthalmic Solution 
Protocol P-321-201  
CONFIDENTIAL 
Page 58 
 
APPENDIX IX: DRY EYE SYMPTOM QUESTIONNAIRES 
The following subject reported outcomes measurements will be collected as noted in Appendix I: 
 SANDE 
 SPEED 
 OSDI 
 
SYMPTOM ASSESSMENT IN DRY EYE QUESTIONNAIRE (SANDE) (Schaumberg, 
2007) 
Part 1 (administer at Visits 1, 2, and 3) 
 
PLEASE COMPLETE THE FOLLOWING QUESTIONS REGARDING THE 
FREQUENCY AND SEVERITY OF YOUR DRY EYE SYMPTOMS 
1.   Frequency of symptoms:
Please place an ‘I’ on the line to indicate how often, on average, your eyes 
felt dry and/or irritated in the past day:
Rarely 
All the time
2.   Severity of symptoms: 
Please place an ‘I’ on the line to indicate how severe, on average, you feel your 
symptoms of dryness and /or irritation were in the past day:
Very Mild 
Very Severe

Parion Sciences, Inc. 
 
P-321 Ophthalmic Solution 
Protocol P-321-201  
CONFIDENTIAL 
Page 59 
 
Part 2 (administer at only Visits 2 and 3) 
 
 
 
 
PLEASE COMPLETE THE FOLLOWING QUESTIONS REGARDING THE 
FREQUENCY AND SEVERITY OF YOUR DRY EYE SYMPTOMS 
1.   Frequency of symptoms:
Please place an ‘I’ on the line to indicate how often, on average, your eyes feel 
dry or irritated now compared to at your last visit
2.   Severity of symptoms: 
Please place an ‘I’ on the line to indicate how severe, on average, you feel 
your symptoms of dryness and irritation are now compared to at your last visit
Last Visit
Much less 
Frequent 
Much more 
frequent
Last Visit
Much more 
severe 
Much less 
severe 

Parion Sciences, Inc. 
 
P-321 Ophthalmic Solution 
Protocol P-321-201  
CONFIDENTIAL 
Page 60 
 
SPEED QUESTIONNAIRE (Ngo, 2013 and Korb, 2005)   
 
 
1. Report the type of SYMPTOMS you experience and when they occur: 
 
 
At this Visit 
Within the 
past 72 hours 
Within past 3 
months
Symptoms 
Yes
No
Yes
No 
Yes 
No
Dryness 
 
Grittiness or Scratchiness 
 
Soreness or Irritation 
 
Burning or Watering
 
Fatigue 
 
 
 
 
2. Report the FREQUENCY of your symptoms using the rating list below: 
 
Symptoms 
0
1
2 
3
Dryness 
 
Grittiness or Scratchiness 
 
Soreness or Irritation 
 
Burning or Watering
 
Fatigue 
 
 
0 = Never 
1 = Sometimes 
2 = Often 
3 = Constant 
 
 
 
3. Report the FREQUENCY of your symptoms using the rating list below: 
Symptoms 
0
1
2
3 
4
Dryness 
 
 
Grittiness or Scratchiness 
 
 
Soreness or Irritation 
 
 
Burning or Watering
 
 
Fatigue 
 
 
 
0 = No problems 
1 =Tolerable; not perfect, but not uncomfortable 
2 = Uncomfortable; irritating, but does not interfere with my day 
3 = Bothersome; irritating and interferes with my day 
4 = Intolerable; unable to perform my daily tasks 
 
 
 

Parion Sciences, Inc. 
 
P-321 Ophthalmic Solution 
Protocol P-321-201  
CONFIDENTIAL 
Page 61 
 
OCULAR SYMPTOM DISEASE INDEX (Schiffman, 2000) 
Ocular Surface Disease Index (OSDI) Questionnaire 
Please answer the questions by checking the box that best represents your answer 
 
HAVE YOU EXPERIENCED ANY OF THE FOLLOWING DURING THE LAST WEEK: 
 
 
HAVE PROBLEMS WITH YOUR EYES LIMITED YOU IN PERFORMING ANY OF THE 
FOLLOWING DURING THE LAST WEEK: 
 
 
HAVE YOUR EYES FELT UNCOMFORTABLE IN ANY OF THE FOLLOWING 
SITUATIONS DURING THE LAST WEEK: 
 
 
All of the 
time
Most of the 
time
Half of the 
time
Some of 
the time 
None of the 
time
1. Eyes that are sensitive to light? 
4 
3 
2 
1 
0 
2. Eyes that feel gritty? 
4 
3 
2 
1 
0 
3. Painful or sore eyes? 
4 
3 
2 
1 
0 
4. Blurred vision? 
4 
3 
2 
1 
0 
5. Poor vision? 
4 
3 
2 
1 
0 
 
All of the 
time 
Most of 
the time 
Half of the 
time 
Some of 
the time 
None of 
the time 
N/A 
6. Reading? 
4 
3 
2 
1 
0 
N/A 
7. Driving at night? 
4 
3 
2 
1 
0 
N/A 
8. Working with a computer 
or bank machine (ATM)? 
4 
3 
2 
1 
0 
N/A 
9. Watching TV? 
4 
3 
2 
1 
0 
N/A 
 
All of the 
time 
Most of 
the time 
Half of the 
time 
Some of 
the time 
None of 
the time 
N/A 
10. Windy conditions? 
4 
3 
2 
1 
0 
N/A 
11. Places or areas with low 
humidity (very dry)? 
4 
3 
2 
1 
0 
N/A 
12. Areas that are air 
conditioned? 
4 
3 
2 
1 
0 
N/A 
 

Parion Sciences, Inc. 
 
P-321 Ophthalmic Solution 
Protocol P-321-201  
CONFIDENTIAL 
Page 62 
 
APPENDIX X: TEAR VOLUME ASSESSMENTS: 
Three assessments of tear volume are used in the study:  Ultra high resolution optical coherence 
tomography (UHR-OCT) measuring tear volume and tear meniscus height, lower tear meniscus 
height measured by Keratograph 5M, and Schirmer test.  The sections below briefly describe 
procedures for each. 
Tear meniscus imaged Ultra High Resolution Optical Coherence Tomography (UHR-OCT) 
The custom-built ultra-high resolution (3 microns axial resolution) spectral domain OCT can 
image a full 15mm width scan at up to 48 images per second.  The tear meniscus around the 
upper and lower eyelids can be  imaged and measured with the OCT, a unique capability. The 
OCT images obtained with this system show the tear menisci around both eyelids (Figure 1).   
Figure 1: Tear menisci imaged with UHR-OCT 
 
 
Figure 1: Upper and lower tear menisci imaged with ultra-high resolution optical coherence 
tomography. A custom built 3 µm resolution ultra-high resolution optical coherence tomography was 
used to image both upper and lower tear menisci. The boundaries of the tear meniscus were clearly 
visualized. The bars denote to 500 µm. 
 

Parion Sciences, Inc. 
 
P-321 Ophthalmic Solution 
Protocol P-321-201  
CONFIDENTIAL 
Page 63 
 
OCT imaging 
Each subject will be asked to sit in front of a slit-lamp, on which an OCT probe is mounted. 
An internal fixation target will be provided to facilitate the subject to keep the eye on a 
straight forward direction. The central OCT beam as indicated as a green line on the OCT 
monitor is set to be on the corneal apex (Figure 1), which a specular reflection is normally 
detected. Immediately after eye opening, corneal images with the OCT will be recorded. A 
vertical OCT scan with a scan width of up to 13 mm will be used so that the entire cornea and 
both upper and lower eyelids will be imaged. The measurements will be acquired in one scan 
with 3 images in the same fashion. The first image will be processed for the measurement. If 
the first image is not good, the second or third image will be used.  The measurements of the 
image analyzed  will be collected in the CRF. 
 
Image process to yield the results.  
All meniscus variables of upper (A) and lower (B) tear menisci are measured with a custom 
software program with operator inputs (TDanalyer, ver. 1.0) (Figure 2). Touch points (pink 
dots) between two elements (eyelid, cornea, and tear meniscus) and a middle point (green dot) 
of the front edge of the tear meniscus are marked. After that, the software process the image, 
to yield the results. The three-point method is used to fit a circle to yield tear the meniscus 
height and area. Tear meniscus height and area of both upper and lower tear menisci will be 
used. In addition, the eye lid length will be photographied and measured to calculate tear 
meniscus volumes in both upper and lower tear menisci. 

Parion Sciences, Inc. 
 
P-321 Ophthalmic Solution 
Protocol P-321-201  
CONFIDENTIAL 
Page 64 
 
Figure 2:  Measuring menisci variables with UHR-OCT 
 
 
 
Tear Meniscus Height measured by Keratograph 5M  
Evaluation of tear film volume will be assessed via tear meniscus height measurements using the 
Keratograph 5M.  High resolution images of the lower tear meniscus from both eyes are obtained 
under infrared light as indicated in the Keratograph 5M user manual.  Using integrated 
magnification and measurement tools, the tear meniscus height of the lower lid margin are 
estimated.  Detailed description of the operation of the instrument and software is described in 
Keratograph 5M user manual provided by Oculus.   
Instructions: 
 
 Turn on the computer.  After turning on the computer the operating system loads the 
Keratograph 5M program.  If necessary click on the Keratograph 5M icon  
. 
 Turn on the Keratograph 5M 
 
 
 Enter Subject information in the Patient Data Management Page. 

Parion Sciences, Inc. 
 
P-321 Ophthalmic Solution 
Protocol P-321-201  
CONFIDENTIAL 
Page 65 
 
 
 
 In the "Patient" box on the top left, select [New]. The following screen will appear: 
 
 Enter the patient’s last name, first name, and date of birth and click [Save]. 
 Click [Keratograph] in the “Functions” box to transition from the Patient Data 
Management  to the Keratograph Overview. 
 In the “Examination” menu click [New] and the following screen will appear: 

Parion Sciences, Inc. 
 
P-321 Ophthalmic Solution 
Protocol P-321-201  
CONFIDENTIAL 
Page 66 
 
 
 
 Activate the [Tear Meniscus Height] function button on the “TF Scan” Box on the left. 
 In the illumination box on the right-hand side of the screen, select [IR] lighting. 
 If necessary, adjust the camera for optimal focusing on the tear meniscus as seen on the 
example in the image below (i.e. at approximately the 6:00 position). 
 
 
 
 After a blink, focus the camera on the central part of the tear meniscus of the lower eyelid 
as indicated in the red circle above. 
 Click on the [Image] button to record the image. 
 The magnification changer and camera settings located at the right-hand side of the 
screen are set to optimal settings. No adjustments should be needed. 
 Confirm that the image is in focus at the central area of the eyelid (below the center of the 
iris), if not, repeat the image. 
Note: This procedure is repeated to obtain 3 quality images per eye 

Parion Sciences, Inc. 
 
P-321 Ophthalmic Solution 
Protocol P-321-201  
CONFIDENTIAL 
Page 67 
 
 
Repeat the procedure for the other eye. 
 Select [Close] after the three images have been taken.  
 
Measurement of the Tear Meniscus Height (TMH) 
 
 From the three images from each eye obtained above, the tear meniscus height is 
measured with a software-integrated ruler.  The evaluations can be made at different 
magnification levels.  Select a higher magnification if necessary. 
 
If the TMH is not measured at the time the image is captured, select the patient and the 
assessment from the Patient Data Management Page by double clicking on the assessment on the 
right of the screen for the selected patient on the left. 
 
The following screen will be displayed: 
 
 
 
 
 Measure the tear meniscus height with the ruler option.  
 Select the following button  
from the left of the screen with the left mouse button. 

Parion Sciences, Inc. 
 
P-321 Ophthalmic Solution 
Protocol P-321-201  
CONFIDENTIAL 
Page 68 
 
 The button will be highlighted in blue. 
 Click once with the left mouse button on the edge of the lower eyelid to position one of 
the edges of the measurement. 
 Move the cursor vertically from this edge to the upper tear meniscus margin and 
 click the left mouse button again. 
 
 The measurement length will appear on the image (in millimeters) as indicated below: 
 
 
 
 The system will display the real measurement regardless of the magnification used for the 
measurement. 
 If the selection of the tear meniscus height is not accurate, delete the measurement and 
repeat the procedure. 
 Record the distance of the TMH. 
 Repeat the procedure for the all three images of each eye. 
 Click [Close] and the image with the measurement will be saved in the patient file.  
 
 
Schirmer Test 
Schirmer strips will be supplied to the clinical site.  When conducting assessments room 
temperature and humidity should be relatively consistent throughout each visit and throughout 
the study.  
Schirmer Test without Anesthesia 
 While still in the plastic sheath, fold the notched end of the Schirmer at the apex of 
“v”.  Additionally, fold a partial second fold at the halfway point of the strip so that 
the strip does not lie directly in the subject’s line of sight. 
 Remove the right eye strip from the sheath. 

Parion Sciences, Inc. 
 
P-321 Ophthalmic Solution 
Protocol P-321-201  
CONFIDENTIAL 
Page 69 
 
 Ask the subject to look up and gently draw the right lower lid in a downward and 
temporal direction.  
 Place the rounded end of the strip toward the temporal one-third of the lower eyelid.  
 Repeat this procedure in the left eye. 
 Darken slightly the room, and instruct the subject to relax and look at an object in the 
room while blinking normally or have subjects gently close eyes. 
 Strips are removed after five minutes. 
 After removing the strips, with a sharp pencil draw a horizontal line across the 
leading edge of moisture and a second horizontal line across the lowest point of 
moisture. 
 Using a ruler and/or the millimeters recorded on the strips, measure a point halfway 
between the two lines and record this as the amount of wetting. 
 
 
 

Parion Sciences, Inc. 
 
P-321 Ophthalmic Solution 
Protocol P-321-201  
CONFIDENTIAL 
Page 70 
 
APPENDIX XI: POST INSTILLATION QUESTIONNAIRES 
DROP INSTILLATION COMFORT MEASUREMENT  
Evaluation of the comfort of the eye drop will be conducted approximately 5 minutes following 
initial dosing at Visits 2 and 3 for subjects.   
 
The subject will respond to the following question upon instillation of the study medication: 
 
“Did you experience any discomfort when the drop was placed in your eyes?" 
 
The response to the question will be graded using the following scale: 
 
1 = None 
2 – Mild 
3 = Moderate 
4 = Severe 
 
Note:  The drop instillation comfort response is NOT considered an AE regardless of severity 
unless it results in discontinuation of the subject from the study.  
If the subject experiences discomfort symptoms within 15 minutes after the drop instillation 
comfort assessment is completed, then the site should record these symptoms as AEs. 
 
POST INSTILLATION DRY EYE SYMPTOMS ASSESSMENT 
 
The subject will respond to the following question immediately prior to the 2 hour post dose tear 
volume measurements at Visits 2 and 3: 
Did you experience any change in your dry eye symptoms after instillation of the eye drop? 
 
-1 = Worsening 
 0 = No change 
+1 = Improvement 
 
 
 

Parion Sciences, Inc. 
 
P-321 Ophthalmic Solution 
Protocol P-321-201  
CONFIDENTIAL 
Page 71 
 
APPENDIX XII:  MEIBOGRAPHY ASSESSMENT 
Meibomian gland evaluation will be conducted in both eyes using the clinical grading scores 
indicated below for plugging, character of secretions, and ease of expression (modified from 
Foulks, 2003). In addition, meibomian gland loss as determined by non-contact Meibography as 
described by Arita (Arita, 2008). 
 
Plugging  (nasal third of lower lid) 
0 no glands plugged 
1 1-2 glands plugged 
2 3- 4 glands plugged 
3 5 glands plugged 
 
Character of secretion 
0 clear 
1 turbid 
2 turbid with clumps or granular 
3 thick or paste-like 
 
Ease of expression 
0 easily expressed 
1 light pressure 
2 moderate pressure 
3 heavy pressure 
 
Noncontact meiboscopy (Arita et al2): Scored for LL and UL0  
no gland loss 
1 gland loss 33% of total area  
2 gland loss, 33%–67% of total area 
3 gland loss  >67% of total area 
 
Scores of upper and lower lid summed  
Scale range: 0 – 6 
 

Parion Sciences, Inc. 
 
P-321 Ophthalmic Solution 
Protocol P-321-201  
CONFIDENTIAL 
Page 72 
 
APPENDIX XIII:  SERUM CHEMISTRY AND HEMATOLOGY ANALYTES 
 
Serum Chemistry Panel includes the following analytes: 
 
 Sodium 
 Potassium 
 BUN/Urea 
 Creatinine 
 Glucose 
 Calcium 
 Phosphorus 
 Total Protein 
 Albumin 
 AST(SGOT) 
 ALT(SGPT) 
 Alkaline Phosphatase 
 
Hematology Panel includes: 
 WBC 
 Haemoglobin 
 Haematocrit 
 RBC 
 MCV 
 MCH 
 MCHC 
 RDW 
 Platelet Count 
 Differential (% and absolute) 
Serum pregnancy test in women of child bearing potential. 
 

Parion Sciences, Inc. 
 
P-321 Ophthalmic Solution 
Protocol P-321-201  
CONFIDENTIAL 
Page 73 
 
APPENDIX XIV:  DOSE SELECTION FOR PHASE 2 AND DATA REVIEW 
DURING STUDY 
The decision on dosage strength to be used in Phase 2 will be the responsibility of the Data 
Review Group constituted by the Prinicipal Investigator (or designee), Medical Monitor and 
representative(s) of Parion Sciences not involved in the conduct of the study. The Data Review 
Group may request the participation of an independent statistician to assest in the assessment of 
the safety of the study medication and the dosage strength selection for Phase 2.  
The Data Review Group will review unmasked data in order to make a decision on the dose to be 
administered in Phase 2.  The Data Review Group will convene when approximately 8 subjects 
have completed the study,or earlier if needed.  The trial will continue enrolling during the time 
the review by the Data Review Group is being prepared and being held.  The Data Review Group 
will review the following to assist in making their recommendation for dose selection in Phase 2: 
 Adverse events 
 Biomicroscopy and external eye examination  
 Drop instillation comfort assessments 
 Abnormal alert laboratory results 
 Tear volume via OCT 
 Tear volume via Keratograph 5M 
Recommendations by the Data Review Group may include: 
1) The dose level may be increased to 0.05% in Phase 2 in the event that: 
a) No cases of serious, suspected related, unexpected events are noted in Phase 1 AND 
b) No cases of serious ocular safety events are noted in Phase 1 
c) Lack of evidence that P-321 produced an increase in tear volume based on OCT 
and/or Keratograph 5M, or evidence that additional improvements in tear volume (or 
the duration of effect) may be obtained with a higher dose 
2) The dose level may be decreased to 0.01% in Phase 2 in the event that: 
a) There is evidence of a significant increase in tear volume and duration of effect in 
Phase 1 based on OCT and/or Keratograph 5M 
b) No cases of serious, suspected related, unexpected events are noted in Phase 1  
c) No cases of serious ocular safety events are noted in Phase 1 
3) The dose level may remain at 0.017% (the same as in Phase 1) in the event that: 
a) There is no compelling data to either increase or decrease the strength for Phase 2.  
b) No cases of serious, suspected related, unexpected events are noted in Phase 1  
c) No cases of serious ocular safety events are noted in Phase 1 
4) Discontinue the study. 
5) Amend the protocol 
 
The Data Review Group will make a recommendation to the Parion Sciences following the 
meeting and review of data and via a written memo.  If additional data is required, the Data 
Review Group may request additional data for their review.  If the Data Review Group requires 

Parion Sciences, Inc. 
 
P-321 Ophthalmic Solution 
Protocol P-321-201  
CONFIDENTIAL 
Page 74 
 
additional unmasked data in order to safeguard the safety of the study subjects, this data will be 
provided.   
 
The Data Review Group will make every effort to arrive to a decision by consensus. 
Upon receipt fo theData Review Group recommendation, Parion representatives will make a 
decision that is consistent with the safeguard of the interests of study subjects. 
Additional Data Reviews 
Additional unmasked reviews of subject data may occur throughout the study to make 
recommendations on further dose adjustments and for planning purposes.  These reviews will 
follow the procedures outlined above. 
Unmasking the study 
In the event of a medical emergency where breaking the mask of the study is being considered, 
the Principal Investigator may request unmasking by contacting the Medical Monitor and the 
Parion Representative.  If the Medical Monitor and Parion Representative grant the unmasking, 
the unmasking will be clearly documented with the date the code is broken indicated, who 
authorized the unmasking and other details regarding the unmasking.  A copy of this unmasking 
memo will be  provided to the sponsor for their records and a copy should remain in the source.